WO2023143576A1 - 一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式 - Google Patents

一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式 Download PDF

Info

Publication number
WO2023143576A1
WO2023143576A1 PCT/CN2023/073719 CN2023073719W WO2023143576A1 WO 2023143576 A1 WO2023143576 A1 WO 2023143576A1 CN 2023073719 W CN2023073719 W CN 2023073719W WO 2023143576 A1 WO2023143576 A1 WO 2023143576A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
crystal form
ray powder
powder diffraction
Prior art date
Application number
PCT/CN2023/073719
Other languages
English (en)
French (fr)
Inventor
林艳琼
温剑锋
冯建鹏
李卫东
王传申
李宗斌
Original Assignee
苏州亚盛药业有限公司
亚盛医药集团(香港)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州亚盛药业有限公司, 亚盛医药集团(香港)有限公司 filed Critical 苏州亚盛药业有限公司
Publication of WO2023143576A1 publication Critical patent/WO2023143576A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention belongs to the field of medicinal chemistry, and in particular relates to a macrocyclic compound or a crystal form or an amorphous form of a salt or a solvate thereof and a preparation method and application thereof.
  • Polycomb family (PcG) proteins are a class of chromatin modifying enzymes that are dysregulated in many human cancers.
  • Polycomb Repressive Complex (PRC2, Polycomb Repressive Complex2) includes SUZ12 (repressor factor of zeste 12), EED and catalytic subunit EZH2 (enhancer factor of zeste homologue 2), through methylation of the target gene promoter region and It surrounds core histone H3 lysine 27 (H3K27me3) to repress genes.
  • PRC2 is an important part of the cellular machinery involved in the epigenetic regulation of gene transcription and plays a key role in development, tissue differentiation and regeneration (Moritz and Trievel, J.Biol.Chem 293(36):13805-13814(2018); Fiskus et al., Mol Cancer Ther 5(12):3096-3014(2006)).
  • EED, SUZ12 and EZH2 are overexpressed in many cancers including but not limited to breast, prostate and hepatocellular carcinoma. There is a need in the art for small molecules that inhibit EED activity for the treatment of cancer and other diseases.
  • the compound of formula I is disclosed in WO2021011713A1.
  • the compound of formula I is an effective EED inhibitor, which can be used to treat or prevent one or more diseases mediated by EED overexpression.
  • the low purity, low solubility and poor stability of medicinal active ingredients will affect their absorption in the body, resulting in low bioavailability, which is not conducive to further drug development.
  • the structure of the salt form, solvate or its crystal form of the medicinal active ingredient often affects the its physical and chemical properties.
  • the technical problem to be solved by the present invention is to provide a crystalline form of a macrocyclic compound or its salt, solvate or Amorphous form.
  • the crystalline form or amorphous form of the macrocyclic compound or its salt, solvate of the present invention has the following one or more advantages: high crystallinity, good stability, low hygroscopicity, easy to form solvate and relatively difficult to prepare .
  • the present invention solves the above-mentioned technical problems through the following technical solutions.
  • the present invention provides a crystal form A of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five, at least six or at least seven characteristic peaks at the following 2 ⁇ angles : 5.181° ⁇ 0.2°, 6.254° ⁇ 0.2°, 8.708° ⁇ 0.2°, 11.496° ⁇ 0.2°, 11.743° ⁇ 0.2°, 16.538° ⁇ 0.2° and 20.361° ⁇ 0.2°;
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern of the crystalline form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.181° ⁇ 0.2°, 16.538° ⁇ 0.2° and 20.361° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.181° ⁇ 0.2°, 11.743° ⁇ 0.2°, 16.538° ⁇ 0.2° and 20.361° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.181° ⁇ 0.2°, 6.254° ⁇ 0.2°, 11.743° ⁇ 0.2°, 16.538° ⁇ 0.2° and 20.361° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.181° ⁇ 0.2°, 6.254° ⁇ 0.2°, 11.496° ⁇ 0.2°, 11.743° ⁇ 0.2° and 16.538° ⁇ 0.2°, 20.361° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.181° ⁇ 0.2°, 6.254° ⁇ 0.2°, 8.708° ⁇ 0.2°, 11.496° ⁇ 0.2°, 11.743° ⁇ 0.2°, 16.538° ⁇ 0.2°, and 20.361° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.181° ⁇ 0.2°, 6.254° ⁇ 0.2°, 8.708° ⁇ 0.2°, 10.304° ⁇ 0.2°, 11.496° ⁇ 0.2°, 11.743° ⁇ 0.2°, 16.538° ⁇ 0.2°, 18.275° ⁇ 0.2°, 18.58° ⁇ 0.2°, 20.361° ⁇ 0.2°, 21.113° ⁇ 0.2°, 23.495° ⁇ 0.2 °, 24.232° ⁇ 0.2°, 26.337° ⁇ 0.2°, and 26.767° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.181° ⁇ 0.2°, 6.254° ⁇ 0.2°, 7.052° ⁇ 0.2°, 8.708° ⁇ 0.2°, 10.304° ⁇ 0.2°, 10.633° ⁇ 0.2°, 11.496° ⁇ 0.2°, 11.743° ⁇ 0.2°, 12.466° ⁇ 0.2°, 12.849° ⁇ 0.2°, 13.224° ⁇ 0.2°, 14.047° ⁇ 0.2 °, 14.784° ⁇ 0.2°, 15.004° ⁇ 0.2°, 15.917° ⁇ 0.2°, 16.538° ⁇ 0.2°, 17.529° ⁇ 0.2°, 17.726° ⁇ 0.2°, 18.275° ⁇ 0.2°, 18.58° ⁇ 0.2°, 19.083° ⁇ 0.2°, 19.291° ⁇ 0.2°, 19.848° ⁇ 0.2°, 20.361° ⁇ 0.2°, 21.113° ⁇ 0.2°, 22.221° ⁇ 0.2°, 22.458° ⁇ 0.2°, 23.066
  • the X-ray powder diffraction pattern analysis data of the crystal form A of the compound of formula I are basically as shown in Table 1:
  • the X-ray powder diffraction pattern of the crystal form A of the compound of formula I is substantially as shown in FIG. 4 .
  • thermogravimetric analysis curve (TGA) of the crystalline form A of the compound of formula I shows a weight loss of 0.1264% ⁇ 0.2% during heating from 29.6°C ⁇ 3°C to 150.14°C ⁇ 3°C.
  • thermogravimetric analysis curve of the crystalline form A of the compound of formula I shows a weight loss of 0.1264% during heating from 29.6°C to 150.14°C.
  • thermogravimetric analysis curve of the crystal form A is substantially as shown in FIG. 5 .
  • the differential scanning calorimetry (DSC) curve (DSC) of the crystalline form A of the compound of formula I has endothermic peaks with onset temperatures of 327.1°C ⁇ 3°C and 334.5°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form A of the compound of formula I has endothermic peaks with onset temperatures of 327.1°C and 334.5°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form A of the compound of formula I has endothermic peaks with peak temperatures of 330.45°C ⁇ 3°C and 336.58°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form A of the compound of formula I has endothermic peaks with peak temperatures of 330.45°C and 336.58°C, respectively.
  • the differential scanning calorimetry curve of Form A of the compound of formula I is substantially as shown in FIG. 6 .
  • the dynamic vapor sorption curve (DVS) of the crystalline form A of the compound of formula I shows that at 25° C. and 80% RH The lower moisture absorption weight gain is 0.44% ⁇ 0.2%.
  • the dynamic vapor sorption curve of Form A of the compound of formula I shows a hygroscopic weight gain of 0.44% at 25°C and 80% RH.
  • the dynamic vapor adsorption curve of Form A of the compound of formula I is shown in FIG. 7 .
  • the present invention also provides a preparation method of the crystal form A of the compound of formula I, preferably any of the following methods:
  • Method 1 comprises the following steps: the crystal form B of the compound of formula I is stirred in a solvent to precipitate a solid, and the crystal form A of the compound of formula I is obtained after separation and drying;
  • the solvent is an organic solvent or a mixed solvent of an organic solvent and water;
  • the organic solvent is selected from one or more of methanol, ethanol, dichloromethane and acetonitrile; the stirring is preferably carried out at a temperature of 20-60°C; the stirring time is preferably 1.5-2.5 days;
  • the mass volume ratio of the crystal form B of the compound of formula I to the solvent is preferably (250mg ⁇ 350mg): 1mL; when the solvent is a mixed solvent of an organic solvent and water, the volume ratio of the organic solvent to water is preferably It is (0.5 ⁇ 3.5): 1; Wherein, when described organic solvent is ethanol, described stirring is carried out at 40 ⁇ 60 °C of temperature; When described solvent is methyl alcohol and water volume ratio is (2.5 ⁇ 3.5): 1 When the mixed solvent is
  • Method 2 comprises the following steps: stirring the crystal form B of the compound of formula I in dichloromethane to obtain a mixed solution, adding an anti-solvent and stirring to precipitate a solid, and obtaining the crystal form A of the compound of formula I after separation and drying; the anti-solvent One or more selected from ethanol, tetrahydrofuran and ethyl acetate; the stirring is preferably carried out at a temperature of 20-60°C; the stirring time is preferably 1.5-2.5 days; the crystal form of the compound of formula I
  • the mass volume ratio of B to the dichloromethane is preferably (50 mg-200 mg): 1 mL; the volume ratio of the dichloromethane to the anti-solvent is preferably (0.5-2.5): 1;
  • the third method comprises the following steps: the amorphous compound of formula I is stirred in a solvent to precipitate solids, and the crystal form A of the compound of formula I is obtained after separation and drying;
  • the solvent is an organic solvent or a mixed solvent of an organic solvent and water;
  • the organic solvent is selected from one or more of methanol, ethanol, acetonitrile, isopropanol and methylene chloride; the stirring is preferably carried out at a temperature of 20-60°C; the stirring time is preferably 1.5-2.5 days;
  • the mass volume ratio of the amorphous form of the compound of formula I to the solvent is preferably (200mg ⁇ 350mg): 1mL; when the solvent is a mixed solvent of an organic solvent and water, the volume ratio of the organic solvent to water is preferably It is (0.5 ⁇ 3.5): 1; Wherein, when described solvent is the mixed solvent of methanol and water, the volume ratio of described methanol and water is (2.5 ⁇ 3.5): 1; When described solvent is ethanol or
  • Method 4 comprises the following steps: the hydrochloride crystal form A of the compound of formula I is stirred in a mixed solvent of organic solvent and water to precipitate a solid, and the crystal form A of the compound of formula I is obtained after separation and drying; the organic solvent is selected from methanol and one or both of ethanol; the stirring is preferably carried out at a temperature of 35 to 45°C; the stirring time is preferably 2.5 to 3.5 days; the mass of the compound of formula I hydrochloride and the mixed solvent
  • the volume ratio is preferably (100mg-200mg): 1 mL; the volume ratio of the organic solvent to water is preferably (2.5-3.5): 1;
  • Method 5 comprises the following steps: the sulfate crystal form A of the compound of formula I is stirred in a solvent to precipitate a solid, and the crystal form A of the compound of formula I is obtained after separation and drying;
  • the solvent is a mixed solvent of methanol, an organic solvent and water or A mixed solvent of methanol and dichloromethane;
  • the organic solvent is selected from one or more of methanol, ethanol and acetonitrile;
  • the stirring is preferably carried out at a temperature of 35 to 45°C;
  • the stirring time is preferably 2.5 to 3.5 days;
  • the mass volume ratio of the sulfate crystal form A of the compound of formula I to the solvent is preferably (100 mg-200 mg): 1 mL;
  • the volume ratio of the organic solvent to water is preferably (0.5-3.5): 1;
  • Method 6 includes the following steps: mixing the crystal form A of the sulfate salt of the compound of formula I with methanol, adding heptane until the solid is precipitated and stirring, and obtaining the crystal form A of the compound of formula I after separation and drying; the stirring is preferably at 20-30°C temperature; the stirring time is preferably 0.5 to 1.5 days; the mass volume ratio of the sulfate crystal form A of the compound of formula I to the methanol is preferably (30 mg to 40 mg): 1 mL;
  • Method 7 comprises the following steps: the mesylate salt crystal form A of the compound of formula I is stirred in a solvent to precipitate a solid, and the crystal form A of the compound of formula I is obtained after separation and drying;
  • the solvent is a mixture of water or an organic solvent and water Solvent;
  • the organic solvent is selected from one or both of methanol and acetonitrile;
  • the stirring is preferably carried out at a temperature of 35 to 45°C;
  • the stirring time is preferably 2.5 to 3.5 days;
  • the formula I compound A The mass volume ratio of the sulfonate salt form A to the solvent is preferably (100mg-200mg): 1mL;
  • Method 8 includes the following steps: mixing the mesylate salt crystal form A of the compound of formula I with DMF, adding acetonitrile until the solid is precipitated and stirring, and obtaining the crystal form A of the compound of formula I after separation and drying; the stirring is preferably at 20 to 30 °C; the stirring time is preferably 12 to 16 hours; the mass volume ratio of the compound mesylate of formula I to the DMF is preferably (30 mg to 70 mg): 1 mL;
  • Method 9 comprises the following steps: the mesylate crystal form A of the compound of formula I is stirred in a solvent until clear, and the crystal form A of the compound of formula I is obtained after volatilization and drying; the solvent is methanol, or ethanol and methyl acetate Mixed solvent; the organic solvent is selected from one or both of methanol and acetonitrile; the volatilization and drying are preferably carried out at a temperature of 20-30°C; the volume ratio of the ethanol and methyl acetate is preferably (1.5- 2.5):1.
  • the stirring is preferably performed at a temperature of 25°C or 50°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the crystal form B of the compound of formula I to the solvent is preferably 300mg: 1mL.
  • the volume ratio of the organic solvent to water is preferably 1:1 or 3:1.
  • the stirring is preferably performed at a temperature of 50°C.
  • the solvent is a mixed solvent of methanol and water with a volume ratio of 3:1
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring is preferably performed at a temperature of 50°C.
  • the stirring is preferably performed at a temperature of 25°C or 50°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the crystal form B of the compound of formula I to the dichloromethane is preferably 100mg: 1mL or 180mg: 1mL.
  • the volume ratio of the dichloromethane to the anti-solvent is preferably 1:1 or 2:1.
  • the stirring is preferably performed at a temperature of 25°C or 50°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the amorphous compound of the formula I to the solvent is preferably 250 mg: 1 mL or 300 mg: 1 mL.
  • the volume ratio of the organic solvent to water is preferably 1:1 or 3:1.
  • the volume ratio of methanol and water is preferably 3:1.
  • the stirring is preferably performed at a temperature of 50°C.
  • the stirring is preferably performed at a temperature of 40°C.
  • the stirring time is preferably 3 days.
  • the mass volume ratio of the hydrochloride of the compound of formula I to the mixed solvent is preferably 150mg: 1mL.
  • the volume ratio of the organic solvent to water is preferably 3:1.
  • the stirring is preferably performed at a temperature of 40°C.
  • the stirring time is preferably 3 days.
  • the mass volume ratio of the sulfate salt of the compound of formula I to the solvent is preferably 150mg: 1mL.
  • the volume ratio of the organic solvent and water Preferably it is 1:1 or 3:1.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 1 day.
  • the mass volume ratio of the sulfate salt of the compound of formula I to the methanol is preferably 35.71 mg: 1 mL.
  • the stirring is preferably performed at a temperature of 40°C.
  • the stirring time is preferably 3 days.
  • the mass volume ratio of the compound mesylate of formula I to the solvent is preferably 150mg: 1mL.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 14 hours.
  • the mass volume ratio of the compound mesylate of formula I to the DMF is preferably 50mg: 1mL.
  • the volatilization and drying are preferably performed at a temperature of 25°C.
  • the volume ratio of the ethanol and methyl acetate is preferably 2:1.
  • the present invention provides a crystal form B of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five, at least six or at least seven characteristic peaks at the following 2 ⁇ angles : 5.884° ⁇ 0.2°, 14.747° ⁇ 0.2°, 16.575° ⁇ 0.2°, 18.116° ⁇ 0.2°, 19.987° ⁇ 0.2°, 22.225° ⁇ 0.2° and 26.884° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.884° ⁇ 0.2°, 14.747° ⁇ 0.2° and 16.575° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.884° ⁇ 0.2°, 14.747° ⁇ 0.2°, 16.575° ⁇ 0.2° and 18.116° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.884° ⁇ 0.2°, 14.747° ⁇ 0.2°, 16.575° ⁇ 0.2°, 18.116° ⁇ 0.2° and 26.884° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.884° ⁇ 0.2°, 14.747° ⁇ 0.2°, 16.575° ⁇ 0.2°, 18.116° ⁇ 0.2°, 19.987° ⁇ 0.2°, and 26.884° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.884° ⁇ 0.2°, 14.747° ⁇ 0.2°, 16.575° ⁇ 0.2°, 18.116° ⁇ 0.2°, 19.987° ⁇ 0.2°, 22.225° ⁇ 0.2°, and 26.884° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.884° ⁇ 0.2°, 13.263° ⁇ 0.2°, 14.747° ⁇ 0.2°, 16.575° ⁇ 0.2°, 17.259° ⁇ 0.2°, 18.116° ⁇ 0.2°, 19.558° ⁇ 0.2°, 19.987° ⁇ 0.2°, 21.566° ⁇ 0.2°, 22.225° ⁇ 0.2°, 23.456° ⁇ 0.2°, 23.999° ⁇ 0.2 ° and 26.884° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.884° ⁇ 0.2°, 13.263° ⁇ 0.2°, 13.868° ⁇ 0.2°, 14.299° ⁇ 0.2°, 14.747° ⁇ 0.2°, 15.622° ⁇ 0.2°, 16.575° ⁇ 0.2°, 17.259° ⁇ 0.2°, 18.116° ⁇ 0.2°, 19.558° ⁇ 0.2°, 19.987° ⁇ 0.2°, 21.566° ⁇ 0.2°, 22.225° ⁇ 0.2°, 23.258° ⁇ 0.2°, 23.456° ⁇ 0.2°, 23.999° ⁇ 0.2°, 24.894° ⁇ 0.2 °, 26.884° ⁇ 0.2°, 29.551° ⁇ 0.2°, 31.442° ⁇ 0.2°, and 31.695° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.884° ⁇ 0.2°, 10.54° ⁇ 0.2°, 11.629° ⁇ 0.2°, 12.427° ⁇ 0.2°, 13.263° ⁇ 0.2°, 13.868° ⁇ 0.2°, 14.299° ⁇ 0.2°, 14.747° ⁇ 0.2°, 15.622° ⁇ 0.2°, 16.575° ⁇ 0.2°, 17.259° ⁇ 0.2°, 18.116° ⁇ 0.2 °, 19.558° ⁇ 0.2°, 19.987° ⁇ 0.2°, 21.566° ⁇ 0.2°, 22.225° ⁇ 0.2°, 23.258° ⁇ 0.2°, 23.456° ⁇ 0.2°, 23.999° ⁇ 0.2°, 24.894° ⁇ 0.2°, 25.501° ⁇ 0.2°, 26.884° ⁇ 0.2°, 27.328° ⁇ 0.2°, 27.7° ⁇ 0.2°, 28.048° ⁇ 0.2°, 28.557° ⁇ 0.2°, 29.551° ⁇ 0.2°, 3
  • the X-ray powder diffraction pattern analysis data of the crystal form B of the compound of formula I are basically as shown in Table 2:
  • the X-ray powder diffraction pattern of the crystal form B of the compound of formula I is substantially as shown in FIG. 8 .
  • thermogravimetric analysis curve (TGA) of the crystal form B of the compound of formula I shows a weight loss of 0.1817% ⁇ 0.2% during heating from 28.73°C ⁇ 3°C to 149.63°C ⁇ 3°C.
  • thermogravimetric analysis curve of the crystal form B of the compound of formula I shows a weight loss of 0.1817% during heating from 28.73°C to 149.63°C.
  • thermogravimetric analysis curve of the crystal form B of the compound of formula I is substantially as shown in FIG. 9 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form B of the compound of formula I has endothermic peaks with onset temperatures of 249.1°C ⁇ 3°C and 336.8°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystal form B of the compound of formula I has endothermic peaks with onset temperatures of 249.1°C and 336.8°C, respectively.
  • the differential scanning calorimetry curve of the crystal form B of the compound of formula I has endothermic peaks with peak temperatures of 252.54°C ⁇ 3°C and 337.59°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form B of the compound of formula I has endothermic peaks with peak temperatures of 252.54°C and 337.59°C, respectively.
  • the differential scanning calorimetry curve of the crystal form B of the compound of formula I has a peak temperature of 255.28°C ⁇ 3°C exothermic peak.
  • the differential scanning calorimetry curve of the crystalline form B of the compound of formula I has an exothermic peak with a peak temperature of 255.28°C.
  • the differential scanning calorimetry curve of Form B of the compound of formula I is substantially as shown in FIG. 10 .
  • the dynamic vapor sorption curve (DVS) of the crystalline form B of the compound of formula I shows a hygroscopic weight gain of 0.84% ⁇ 0.2% at 25° C. and 80% RH.
  • the dynamic vapor sorption curve of Form B of the compound of formula I shows a hygroscopic weight gain of 0.84% at 25°C and 80% RH.
  • the dynamic vapor adsorption curve of Form B of the compound of formula I is shown in FIG. 11 .
  • the present invention also provides a preparation method of the crystal form B of the compound of formula I, preferably any of the following methods:
  • Method 1 comprises the following steps: the crystal form A of the compound of formula I is stirred in an organic solvent to precipitate a solid, and after separation and drying, the crystal form B of the compound of formula I is obtained, and the organic solvent is selected from ethyl acetate, acetone, 88% acetone and one or more of tetrahydrofuran; the stirring is preferably carried out at 20-60°C; the stirring time is preferably 1.5-2.5 days; the mass volume ratio of the crystal form A of the compound of formula I to the organic solvent Preferably (80mg: 1mL-250mg): 1mL; wherein, when the organic solvent is tetrahydrofuran, the stirring is carried out at a temperature of 35-45°C;
  • Method 2 comprises the following steps: the amorphous compound of formula I is stirred in a solvent to precipitate solids, and the crystal form B of the compound of formula I is obtained after separation and drying;
  • the solvent is an organic solvent or the volume ratio of acetone and water is (0.25 ⁇ 0.75): a mixed solvent of 1;
  • the organic solvent is selected from one or more of ethanol, ethyl acetate, acetone, methyl isobutyl ketone and methyl tert-butyl ether;
  • the stirring is preferably at 20 Carried out at a temperature of ⁇ 60°C; the stirring time is preferably 1.5 to 2.5 days;
  • the mass volume ratio of the amorphous compound of the formula I to the solvent is preferably (250 mg ⁇ 350 mg): 1 mL; wherein, when the When the organic solvent is ethyl acetate or methyl tert-butyl ether, the stirring is carried out at a temperature of 40-60°C; when the organic solvent is
  • the third method comprises the following steps: the hydrochloride crystal form A of the compound of formula I or the sulfate crystal form A of the compound of formula I are stirred in 88% acetone to precipitate a solid, and the crystal form B of the compound of formula I is obtained after separation and drying; Stirring is preferably carried out at a temperature of 35-45°C; the stirring time is preferably 2.5-3.5 days; the formula I compound hydrochloride crystal form A or the formula I compound sulfate crystal form A and the 88% acetone
  • the mass volume ratio is preferably (100mg ⁇ 200mg): 1mL;
  • Method 4 includes the following steps: mixing the crystal form A of the sulfate salt of the compound of formula I with methanol, adding acetone until the solid is precipitated and stirring, and obtaining the crystal form A of the compound of formula I after separation and drying; the stirring is preferably at a temperature of 20 to 30°C The stirring time is preferably 0.5 to 1.5 days; the mass volume ratio of the compound sulfate crystal form A of the formula I to the methanol is preferably (30 mg to 40 mg): 1 mL;
  • Method five comprises the following steps: stirring the crystal form A of the mesylate salt of the compound of formula I in a solvent until clear, volatilizing and drying to obtain the crystal form A of the compound of formula I;
  • the solvent is ethanol, or a mixture of methanol and an organic solvent Solvent;
  • the organic solvent is selected from one or both of methyl acetate and dichloromethane;
  • the volatilization and drying are preferably carried out at a temperature of 20 to 30°C; the volume ratio of ethanol and methyl acetate is preferably (1.5 ⁇ 2.5):1.
  • the stirring is preferably performed at a temperature of 25°C, 40°C or 50°C.
  • the stirred The time is preferably 2 days.
  • the mass volume ratio of the crystal form A of the compound of formula I to the organic solvent is preferably 100mg: 1mL, 150mg: 1mL or 200mg: 1mL.
  • the stirring is preferably performed at a temperature of 40°C.
  • the volume ratio of the acetone and water is preferably 1:2.
  • the stirring is preferably performed at a temperature of 25°C or 50°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the amorphous compound of the formula I to the solvent is preferably 300mg: 1mL.
  • the stirring is preferably performed at a temperature of 50°C.
  • the organic solvent is ethanol or methyl isobutyl ketone
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring is preferably performed at a temperature of 40°C.
  • the stirring time is preferably 3 days.
  • the mass volume ratio of the hydrochloride salt form A of the compound of formula I or the sulfate salt form A of the compound of formula I to the 88% acetone is preferably 150mg: 1mL.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 1 day.
  • the mass volume ratio of the sulfate crystal form A of the compound of formula I to the methanol is preferably 35.71 mg: 1 mL.
  • the volatilization and drying are preferably performed at a temperature of 25°C.
  • the volume ratio of the methanol and the organic solvent is preferably 2:1.
  • the present invention provides a crystal form C of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five, at least six, at least seven or at least Eight characteristic peaks: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2°, 10.012° ⁇ 0.2°, 10.95° ⁇ 0.2°, 15.058° ⁇ 0.2°, 18.077° ⁇ 0.2°, 19.423° ⁇ 0.2° and 22.479° ⁇ 0.2°;
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern of the crystalline form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2° and 22.479° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2°, 18.077° ⁇ 0.2° and 22.479° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2°, 15.058° ⁇ 0.2°, 18.077° ⁇ 0.2° and 22.479° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2°, 10.95° ⁇ 0.2°, 15.058° ⁇ 0.2° and 18.077° ⁇ 0.2°, 22.479° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2°, 10.012° ⁇ 0.2°, 10.95° ⁇ 0.2°, 15.058° ⁇ 0.2°, 18.077° ⁇ 0.2°, and 22.479° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2°, 10.012° ⁇ 0.2°, 10.95° ⁇ 0.2°, 15.058° ⁇ 0.2°, 18.077° ⁇ 0.2°, 19.423° ⁇ 0.2°, and 22.479° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2°, 10.012° ⁇ 0.2°, 10.637° ⁇ 0.2°, 10.95° ⁇ 0.2°, 13.558° ⁇ 0.2°, 14.065° ⁇ 0.2°, 15.058° ⁇ 0.2°, 17.435° ⁇ 0.2°, 18.077° ⁇ 0.2°, 19.129° ⁇ 0.2°, 19.423° ⁇ 0.2 °, 19.947° ⁇ 0.2°, 20.709° ⁇ 0.2°, 22.147° ⁇ 0.2°, 22.479° ⁇ 0.2°, 23.435° ⁇ 0.2°, 24.781° ⁇ 0.2°, 26.883° ⁇ 0.2°, 29.492° ⁇ 0.2° and 31.713° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.085° ⁇ 0.2°, 9.623° ⁇ 0.2°, 10.012° ⁇ 0.2°, 10.637° ⁇ 0.2°, 10.95° ⁇ 0.2°, 11.707° ⁇ 0.2°, 13.558° ⁇ 0.2°, 14.065° ⁇ 0.2°, 15.058° ⁇ 0.2°, 17.435° ⁇ 0.2°, 18.077° ⁇ 0.2°, 19.129° ⁇ 0.2 °, 19.423° ⁇ 0.2°, 19.947° ⁇ 0.2°, 20.709° ⁇ 0.2°, 22.147° ⁇ 0.2°, 22.479° ⁇ 0.2°, 23.435° ⁇ 0.2°, 24.781° ⁇ 0.2°, 25.439° ⁇ 0.2°, 26.548° ⁇ 0.2°, 26.883° ⁇ 0.2°, 28.552° ⁇ 0.2°, 28.853° ⁇ 0.2°, 29.492° ⁇ 0.2°, 31.713° ⁇ 0.2°, 32.514° ⁇ 0.2°
  • the X-ray powder diffraction pattern analysis data of the crystal form C of the compound of formula I are basically as shown in Table 3:
  • the X-ray powder diffraction pattern of Form C of the compound of formula I is substantially as shown in FIG. 12 .
  • the present invention also provides a method for preparing crystal form C of the compound of formula I, preferably comprising the following steps: stirring the crystal form A of the compound of formula I in tetrahydrofuran to precipitate a solid, separating and drying to obtain the crystal form of the compound of formula I C; the stirring is carried out at a temperature of 20 to 30°C; the stirring time is preferably 0.5 to 1.5 days; the mass volume ratio of the crystal form A of the compound of formula I to the tetrahydrofuran is preferably 20 mg: 1 mL to 50 mg : 1 mL.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 1 day.
  • the mass volume ratio of the crystal form A of the compound of formula I to the tetrahydrofuran is preferably 33.33 mg: 1 mL.
  • the present invention provides a crystal form of toluene solvate of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four or at least five characteristic peaks at the following 2 ⁇ angles: 5.298° ⁇ 0.2 °, 14.611° ⁇ 0.2°, 18.098° ⁇ 0.2°, 20.024° ⁇ 0.2° and 20.9° ⁇ 0.2°;
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern of the crystalline form of the toluene solvate of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.298° ⁇ 0.2°, 14.611° ⁇ 0.2° and 20.9° ⁇ 0.2° .
  • the X-ray powder diffraction pattern of the crystal form of the toluene solvate of the compound of formula I has the following 2 ⁇ angles: There are characteristic peaks: 5.298° ⁇ 0.2°, 14.611° ⁇ 0.2°, 18.098° ⁇ 0.2° and 20.9° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the toluene solvate of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.298° ⁇ 0.2°, 14.611° ⁇ 0.2°, 18.098° ⁇ 0.2° , 20.024° ⁇ 0.2° and 20.9° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the toluene solvate of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.298° ⁇ 0.2°, 10.439° ⁇ 0.2°, 11.496° ⁇ 0.2° , 13.324° ⁇ 0.2°, 14.611° ⁇ 0.2°, 18.098° ⁇ 0.2°, 20.024° ⁇ 0.2°, 20.9° ⁇ 0.2°, 21.837° ⁇ 0.2°, 22.303° ⁇ 0.2°, 23.122° ⁇ 0.2°, 24.506 ° ⁇ 0.2°, 25.886° ⁇ 0.2°, and 27.506° ⁇ 0.2°.
  • the X-ray powder diffraction pattern analysis data of the crystal form of the toluene solvate of the compound of formula I are basically as shown in Table 4: 5.298° ⁇ 0.2°, 5.745° ⁇ 0.2°, 9.662° ⁇ 0.2° , 10.439° ⁇ 0.2°, 11.496° ⁇ 0.2°, 13.324° ⁇ 0.2°, 14.101° ⁇ 0.2°, 14.611° ⁇ 0.2°, 14.98° ⁇ 0.2°, 15.64° ⁇ 0.2°, 16.769° ⁇ 0.2°, 17.628 ° ⁇ 0.2°, 18.098° ⁇ 0.2°, 19.258° ⁇ 0.2°, 20.024° ⁇ 0.2°, 20.9° ⁇ 0.2°, 21.232° ⁇ 0.2°, 21.837° ⁇ 0.2°, 22.303° ⁇ 0.2°, 22.698° ⁇ 0.2°, 23.122° ⁇ 0.2°, 24.506° ⁇ 0.2°, 25.128° ⁇ 0.2°, 25.886° ⁇ 0.2°, 26.977° ⁇ 0.2°, 27.506° ⁇ 0.2°, 28
  • the X-ray powder diffraction pattern of the crystalline form of the toluene solvate of the compound of formula I is substantially as shown in FIG. 13 .
  • thermogravimetric analysis curve (TGA) of the crystalline form of the toluene solvate of the compound of formula I shows that during heating from 34.82°C ⁇ 3°C to 147.13°C ⁇ 3°C, there is 5.19% ⁇ 0.5% weightlessness.
  • thermogravimetric analysis curve of the crystalline form of the toluene solvate of the compound of formula I shows a weight loss of 5.19% during heating from 34.82°C to 147.13°C.
  • thermogravimetric analysis curve of the crystalline form of the toluene solvate of the compound of formula I is substantially as shown in FIG. 14 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form of the toluene solvate of the compound of formula I has endothermic peaks with onset temperatures of 120.68°C ⁇ 3°C and 334.15°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystal form of the toluene solvate of the compound of formula I has endothermic peaks with onset temperatures of 120.68°C and 334.15°C, respectively.
  • the differential scanning calorimetry curve of the crystal form of the toluene solvate of the compound of formula I has endothermic peaks with peak temperatures of 151.28°C ⁇ 3°C and 336.25°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystal form of the toluene solvate of the compound of formula I has endothermic peaks with peak temperatures of 151.28°C and 336.25°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the toluene solvate of the compound of formula I has an exothermic peak with a peak temperature of 238.88°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form of the toluene solvate of the compound of formula I has a peak temperature of Exothermic peak at 238.88°C.
  • the differential scanning calorimetry curve of the crystalline form of the toluene solvate of the compound of formula I is substantially as shown in FIG. 15 .
  • the hydrogen nuclear magnetic resonance spectrum ( 1 H-NMR) of the crystalline form of the toluene solvate of the compound of formula I shows that the weight percentage is 3.27% ⁇ 0.5% toluene.
  • the proton nuclear magnetic resonance spectrum of the crystalline form of the toluene solvate of the compound of formula I shows 3.27% by weight of toluene.
  • the H NMR spectrum of the crystalline form of the toluene solvate of the compound of formula I is substantially as shown in FIG. 16 .
  • the present invention also provides a method for preparing the crystal form of the toluene solvate of the compound of formula I, preferably comprising the following steps: stirring the crystal form B of the compound of formula I in toluene to precipitate a solid, separating and drying to obtain the compound of formula I
  • the crystal form of toluene solvate ; the stirring is carried out at a temperature of 20-30°C; the stirring time is preferably 1.5-2.5 days; the mass volume ratio of the crystal form B of the compound of formula I to the toluene Preferably (250mg-350mg): 1mL.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the crystal form B of the compound of formula I to the toluene is preferably 300mg: 1mL.
  • the present invention provides a crystal form E of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five, at least six or at least seven characteristic peaks at the following 2 ⁇ angles : 6.001° ⁇ 0.2°, 10.676° ⁇ 0.2°, 11.203° ⁇ 0.2°, 12.526° ⁇ 0.2°, 13.09° ⁇ 0.2°, 16.891° ⁇ 0.2° and 21.179° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the crystal form E of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.001° ⁇ 0.2°, 10.676° ⁇ 0.2° and 11.203° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form E of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.001° ⁇ 0.2°, 10.676° ⁇ 0.2°, 11.203° ⁇ 0.2° and 12.526° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form E of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.001° ⁇ 0.2°, 10.676° ⁇ 0.2°, 11.203° ⁇ 0.2°, 12.526° ⁇ 0.2° and 16.891° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form E of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.001° ⁇ 0.2°, 10.676° ⁇ 0.2°, 11.203° ⁇ 0.2°, 12.526° ⁇ 0.2°, 16.891° ⁇ 0.2°, and 21.179° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form E of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.001° ⁇ 0.2°, 10.676° ⁇ 0.2°, 11.203° ⁇ 0.2°, 12.526° ⁇ 0.2°, 13.09° ⁇ 0.2°, 16.891° ⁇ 0.2°, and 21.179° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form E of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.001° ⁇ 0.2°, 6.484° ⁇ 0.2°, 8.32° ⁇ 0.2°, 10.676° ⁇ 0.2°, 11.203° ⁇ 0.2°, 12.526° ⁇ 0.2°, 13.09° ⁇ 0.2°, 13.771° ⁇ 0.2°, 14.61° ⁇ 0.2°, 14.982° ⁇ 0.2°, 15.429° ⁇ 0.2°, 16.423° ⁇ 0.2 °, 16.891° ⁇ 0.2°, 18.034° ⁇ 0.2°, 18.757° ⁇ 0.2°, 20.239° ⁇ 0.2°, 20.864° ⁇ 0.2°, 21.179° ⁇ 0.2°, 22.618° ⁇ 0.2°, 23.802° ⁇ 0.2° and 26.217° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form E of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.001° ⁇ 0.2°, 6.484° ⁇ 0.2°, 8.32° ⁇ 0.2°, 10.676° ⁇ 0.2°, 11.203° ⁇ 0.2°, 12.526° ⁇ 0.2°, 13.09° ⁇ 0.2°, 13.771° ⁇ 0.2°, 14.61° ⁇ 0.2°, 14.982° ⁇ 0.2°, 15.429° ⁇ 0.2°, 16.423° ⁇ 0.2 °, 16.891° ⁇ 0.2°, 18.034° ⁇ 0.2°, 18.757° ⁇ 0.2°, 20.239° ⁇ 0.2°, 20.864° ⁇ 0.2°, 21.179° ⁇ 0.2°, 22.618° ⁇ 0.2°, 23.802° ⁇ 0.2°, 25.594° ⁇ 0.2°, 26.217° ⁇ 0.2°, 27.198° ⁇ 0.2°, 28.009° ⁇ 0.2°, and 30.812° ⁇ 0.2°.
  • the X-ray powder diffraction pattern analysis data of the crystal form E of the compound of formula I are basically as shown in Table 5:
  • the X-ray powder diffraction pattern of Form E of the compound of formula I is substantially as shown in FIG. 17 .
  • thermogravimetric analysis curve (TGA) of the crystalline form E of the compound of formula I shows a weight loss of 1.477% ⁇ 0.5% during heating from 30.78°C ⁇ 3°C to 132.28°C ⁇ 3°C; During the process of heating from 132°C ⁇ 3°C to 232°C ⁇ 3°C, there is a weight loss of 1.849% ⁇ 0.5%.
  • thermogravimetric analysis curve of the crystal form E of the compound of formula I shows that there is a weight loss of 1.477% during heating from 30.78°C to 132.28°C; and 1.849% during heating from 132.28°C to 232.17°C of weightlessness.
  • thermogravimetric analysis curve of Form E of the compound of formula I is substantially as shown in FIG. 18 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form E of the compound of formula I has endothermic peaks with onset temperatures of 190.41°C ⁇ 3°C and 334.9°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form E of the compound of formula I has endothermic peaks with onset temperatures of 190.41°C and 334.9°C, respectively.
  • the differential scanning calorimetry curve of the crystal form E of the compound of formula I has endothermic peaks with peak temperatures of 199.65°C ⁇ 3°C and 336.81°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form E of the compound of formula I has endothermic peaks with peak temperatures of 199.65°C and 336.81°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form E of the compound of formula I has an exothermic peak with a peak temperature of 205.95°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form E of the compound of formula I has an exothermic peak with a peak temperature of 205.95°C.
  • the differential scanning calorimetry curve of Form E of the compound of formula I is substantially as shown in FIG. 19 .
  • the present invention also provides a preparation method of the crystal form E of the compound of formula I, preferably any of the following methods:
  • Method 1 includes the following steps: the crystal form B of the compound of formula I is stirred in methyl tert-butyl ether to precipitate a solid, and the crystal form E of the compound of formula I is obtained after separation and drying; the stirring is carried out at a temperature of 20-30°C Carry out; the stirring time is preferably 1.5 to 2.5 days; the mass volume ratio of the crystal form B of the compound of formula I to the methyl tert-butyl ether is preferably (50 mg to 350 mg): 1 mL;
  • Method 2 includes the following steps: the amorphous compound of formula I is stirred in an organic solvent to precipitate a solid, and the crystal form E of the compound of formula I is obtained after separation and drying; the organic solvent is selected from 2-methyltetrahydrofuran and methyl tertiary One or both of butyl ethers; the stirring is carried out at a temperature of 20-30°C; the stirring time is preferably 1.5-2.5 days; the mass volume of the amorphous compound of the formula I and the solvent The ratio is preferably (250 mg to 350 mg): 1 mL.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the crystal form B of the compound of formula I to the methyl tert-butyl ether is preferably 100 mg: 1 mL or 300 mg: 1 mL.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the amorphous compound of the formula I to the solvent is preferably 300mg: 1mL.
  • the present invention provides a crystal form F of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five or at least six characteristic peaks at the following 2 ⁇ angles: 5.728° ⁇ 0.2°, 9.701° ⁇ 0.2°, 16.658° ⁇ 0.2°, 18.038° ⁇ 0.2°, 19.851° ⁇ 0.2° and 22.382° ⁇ 0.2°;
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern of the crystalline form F of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.728° ⁇ 0.2°, 9.701° ⁇ 0.2° and 18.038° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form F of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.728° ⁇ 0.2°, 9.701° ⁇ 0.2°, 18.038° ⁇ 0.2° and 22.382° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form F of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.728° ⁇ 0.2°, 9.701° ⁇ 0.2°, 18.038° ⁇ 0.2°, 19.851° ⁇ 0.2° and 22.382° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form F of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.728° ⁇ 0.2°, 9.701° ⁇ 0.2°, 16.658° ⁇ 0.2°, 18.038° ⁇ 0.2°, 19.851° ⁇ 0.2°, and 22.382° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form F of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.728° ⁇ 0.2°, 9.701° ⁇ 0.2°, 10.421° ⁇ 0.2°, 11.944° ⁇ 0.2°, 13.616° ⁇ 0.2°, 16.658° ⁇ 0.2°, 17.358° ⁇ 0.2°, 18.038° ⁇ 0.2°, 19.17° ⁇ 0.2°, 19.851° ⁇ 0.2°, 21.116° ⁇ 0.2°, 21.815° ⁇ 0.2 °, 22.382° ⁇ 0.2°, 23.066° ⁇ 0.2°, 23.454° ⁇ 0.2°, 24.334° ⁇ 0.2°, 24.622° ⁇ 0.2°, 25.362° ⁇ 0.2°, 26.376° ⁇ 0.2°, and 27.038° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form F of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.728° ⁇ 0.2°, 8.026° ⁇ 0.2°, 9.701° ⁇ 0.2°, 10.421° ⁇ 0.2°, 10.946° ⁇ 0.2°, 11.333° ⁇ 0.2°, 11.944° ⁇ 0.2°, 12.546° ⁇ 0.2°, 13.616° ⁇ 0.2°, 14.847° ⁇ 0.2°, 15.761° ⁇ 0.2°, 16.658° ⁇ 0.2 °, 17.358° ⁇ 0.2°, 18.038° ⁇ 0.2°, 19.17° ⁇ 0.2°, 19.851° ⁇ 0.2°, 21.116° ⁇ 0.2°, 21.815° ⁇ 0.2°, 22.382° ⁇ 0.2°, 23.066° ⁇ 0.2°, 23.454° ⁇ 0.2°, 24.334° ⁇ 0.2°, 24.622° ⁇ 0.2°, 25.073° ⁇ 0.2°, 25.362° ⁇ 0.2°, 26.376° ⁇ 0.2°, 27.038° ⁇ 0.2°, 27
  • the X-ray powder diffraction pattern analysis data of the crystalline form F of the compound of formula I are basically as shown in Table 6:
  • the X-ray powder diffraction pattern of Form F of the compound of formula I is substantially as shown in FIG. 20 .
  • thermogravimetric analysis curve (TGA) of the crystalline form F of the compound of formula I shows a weight loss of 0.7264% ⁇ 0.2% during heating from 37.55°C ⁇ 3°C to 150.41°C ⁇ 3°C.
  • thermogravimetric analysis curve of the crystal form F of the compound of formula I shows a weight loss of 0.7264% during heating from 37.55°C to 150.41°C.
  • thermogravimetric analysis curve of Form F of the compound of formula I is substantially as shown in FIG. 21 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form F of the compound of formula I has an endothermic peak with an onset temperature of 333.46°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form F of the compound of formula I has an endothermic peak with an onset temperature of 333.46°C.
  • the differential scanning calorimetry curve of the crystalline form F of the compound of formula I has an endothermic peak with a peak temperature of 336.25°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form F of the compound of formula I has an endothermic peak with a peak temperature of 336.25°C.
  • the differential scanning calorimetry curve of the crystalline form F of the compound of formula I has an exothermic peak with a peak temperature of 223.19°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form F of the compound of formula I has an exothermic peak with a peak temperature of 223.19°C.
  • the differential scanning calorimetry curve of Form F of the compound of formula I is substantially as shown in FIG. 22 .
  • the present invention also provides a method for preparing crystal form F of the compound of formula I, preferably comprising the following steps: stirring the crystal form B of the compound of formula I in a mixed solvent with a volume ratio of methanol and water of (0.5-1.5):1
  • the crystal form F of the compound of formula I is obtained by separating and drying the solid; the stirring is carried out at a temperature of 20-30°C; the stirring time is preferably 1.5-2.5 days; the crystal form of the compound of formula I
  • the mass volume ratio of B to the mixed solvent is preferably (50 mg-350 mg): 1 mL.
  • the volume ratio of methanol and water is preferably 1:1.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the crystal form B of the compound of formula I to the methanol is preferably 100 mg: 1 mL or 300 mg: 1 mL.
  • the present invention provides a crystal form G of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five, at least six, at least seven or at least Eight characteristic peaks: 5.279° ⁇ 0.2°, 10.926° ⁇ 0.2°, 11.843° ⁇ 0.2°, 16.187° ⁇ 0.2°, 16.831° ⁇ 0.2°, 20.453° ⁇ 0.2°, 23.55° ⁇ 0.2° and 26.825° ⁇ 0.2°;
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern of the crystalline form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 20.453° ⁇ 0.2° and 23.55° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 11.843° ⁇ 0.2°, 20.453° ⁇ 0.2° and 23.55° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 11.843° ⁇ 0.2°, 16.831° ⁇ 0.2°, 20.453° ⁇ 0.2° and 23.55° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 11.843° ⁇ 0.2°, 16.187° ⁇ 0.2°, 16.831° ⁇ 0.2°, 20.453° ⁇ 0.2°, and 23.55° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 10.926° ⁇ 0.2°, 11.843° ⁇ 0.2°, 16.187° ⁇ 0.2°, 16.831° ⁇ 0.2°, 20.453° ⁇ 0.2°, and 23.55° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 10.926° ⁇ 0.2°, 11.843° ⁇ 0.2°, 16.187° ⁇ 0.2°, 16.831° ⁇ 0.2°, 20.453° ⁇ 0.2°, 23.55° ⁇ 0.2°, and 26.825° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 6.388° ⁇ 0.2°, 9.02° ⁇ 0.2°, 10.926° ⁇ 0.2°, 11.843° ⁇ 0.2°, 12.68° ⁇ 0.2°, 14.96° ⁇ 0.2°, 15.758° ⁇ 0.2°, 16.187° ⁇ 0.2°, 16.831° ⁇ 0.2°, 17.98° ⁇ 0.2°, 18.352° ⁇ 0.2 °, 20.453° ⁇ 0.2°, 20.881° ⁇ 0.2°, 21.194° ⁇ 0.2°, 22.732° ⁇ 0.2°, 23.55° ⁇ 0.2°, 25.208° ⁇ 0.2°, 25.949° ⁇ 0.2°, and 26.825° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 6.388° ⁇ 0.2°, 9.02° ⁇ 0.2°, 10.926 ° ⁇ 0.2°, 11.843° ⁇ 0.2°, 12.68° ⁇ 0.2°, 13.44° ⁇ 0.2°, 14.162° ⁇ 0.2°, 14.96° ⁇ 0.2°, 15.758° ⁇ 0.2°, 16.187° ⁇ 0.2°, 16.831° ⁇ 0.2°, 17.98° ⁇ 0.2°, 18.352° ⁇ 0.2°, 19.423° ⁇ 0.2°, 20.453° ⁇ 0.2°, 20.881° ⁇ 0.2°, 21.194° ⁇ 0.2°, 21.755° ⁇ 0.2°, 22.732° ⁇ 0.2°, 23.55° ⁇ 0.2°, 24.217, 24.772, 25.208° ⁇ 0.2°, 25.949° ⁇ 0.2 °, 26.825° ⁇ 0.2°, 28.694° ⁇ 0.2°, 29.143° ⁇ 0.2°, 30
  • the X-ray powder diffraction pattern of the crystal form G of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.279° ⁇ 0.2°, 6.388° ⁇ 0.2°, 7.147° ⁇ 0.2°, 9.02° ⁇ 0.2°, 10.926° ⁇ 0.2°, 11.843° ⁇ 0.2°, 12.68° ⁇ 0.2°, 13.44° ⁇ 0.2°, 14.162° ⁇ 0.2°, 14.96° ⁇ 0.2°, 15.758° ⁇ 0.2°, 16.187° ⁇ 0.2 °, 16.831° ⁇ 0.2°, 17.98° ⁇ 0.2°, 18.352° ⁇ 0.2°, 19.423° ⁇ 0.2°, 20.453° ⁇ 0.2°, 20.881° ⁇ 0.2°, 21.194° ⁇ 0.2°, 21.755° ⁇ 0.2°, 22.732° ⁇ 0.2°, 23.55° ⁇ 0.2°, 24.217° ⁇ 0.2°, 24.772° ⁇ 0.2°, 25.208° ⁇ 0.2°, 25.949° ⁇ 0.2°, 26.825° ⁇ 0.2°, 27.64°
  • the X-ray powder diffraction pattern analysis data of the crystalline form G of the compound of formula I are basically as shown in Table 7:
  • the X-ray powder diffraction pattern of Form G of the compound of formula I is substantially as shown in FIG. 23 .
  • thermogravimetric analysis curve (TGA) of the crystalline form G of the compound of formula I shows a weight loss of 0.1261% ⁇ 0.2% during heating from 36.93°C ⁇ 3°C to 150.57°C ⁇ 3°C.
  • thermogravimetric analysis curve of the crystalline form G of the compound of formula I shows a weight loss of 0.1261% during heating from 36.93°C to 150.57°C.
  • thermogravimetric analysis curve of Form G of the compound of formula I is substantially as shown in FIG. 24 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form G of the compound of formula I has an endothermic peak with an onset temperature of 334.21°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form G of the compound of formula I has an endothermic peak with an onset temperature of 334.21°C.
  • the differential scanning calorimetry curve of Form G of the compound of formula I is substantially as shown in FIG. 25 .
  • the present invention also provides a preparation method of the crystal form G of the compound of formula I, preferably any of the following methods:
  • Method 1 includes the following steps: the crystal form A of the compound of formula I is stirred in toluene to precipitate a solid, and the crystal form G of the compound of formula I is obtained after separation and drying; the stirring is preferably carried out at a temperature of 20-45°C; the The time of stirring is preferably 1.5 ⁇ 2.5 days;
  • the formula I The mass volume ratio of the crystal form A of the compound to the toluene is preferably (100mg-250mg): 1mL;
  • Method 2 includes the following steps: the crystal form B of the compound of formula I is stirred in methyl tert-butyl ether to precipitate a solid, and the crystal form G of the compound of formula I is obtained after separation and drying; Carry out; the stirring time is preferably 1.5 to 2.5 days; the mass volume ratio of the crystal form B of the compound of formula I to the methyl tert-butyl ether is preferably (250 mg to 350 mg): 1 mL;
  • Method three comprises the following steps: the amorphous compound of formula I is stirred in a solvent to precipitate solids, and the crystal form G of the compound of formula I is obtained after separation and drying; the solvent is the volume of water, heptane, toluene or methanol and water A mixed solvent with a ratio of (0.5-1.5): 1; the stirring is preferably carried out at a temperature of 20-60°C; the stirring time is preferably 1.5-2.5 days; the amorphous form of the compound of formula I and the solvent
  • the mass-to-volume ratio is preferably (250mg-350mg): 1mL; wherein, when the solvent is heptane or a mixed solvent, the stirring is performed at a temperature of 40-60°C.
  • the stirring is preferably performed at a temperature of 25°C or 40°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the crystal form A of the compound of formula I to the toluene is preferably 150 mg: 1 mL or 200 mg: 1 mL.
  • the stirring is preferably performed at a temperature of 50°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the crystal form A of the compound of formula I to the toluene is preferably 300mg: 1mL.
  • the stirring is preferably performed at a temperature of 25°C or 50°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the amorphous compound of the formula I to the solvent is preferably 300mg: 1mL.
  • the volume ratio of methanol to water is preferably 1:1.
  • the stirring is preferably performed at a temperature of 50°C.
  • the present invention provides a crystal form of N-methylpyrrolidone solvate of the compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five or at least six characteristic peaks: 11.493° ⁇ 0.2°, 13.56° ⁇ 0.2°, 16.481° ⁇ 0.2°, 19.713° ⁇ 0.2°, 21.586° ⁇ 0.2° and 24.643° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the crystalline form of the compound N-methylpyrrolidone solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 16.481° ⁇ 0.2°, 19.713° ⁇ 0.2° and 24.643 ° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound N-methylpyrrolidone solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 11.493° ⁇ 0.2°, 16.481° ⁇ 0.2°, 19.713 ° ⁇ 0.2° and 24.643° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form of the compound N-methylpyrrolidone solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 11.493° ⁇ 0.2°, 13.56° ⁇ 0.2°, 16.481 ° ⁇ 0.2°, 19.713° ⁇ 0.2°, and 24.643° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the N-methylpyrrolidone solvate of the compound of formula I is as follows: There are characteristic peaks at the lower 2 ⁇ angles: 11.493° ⁇ 0.2°, 13.56° ⁇ 0.2°, 16.481° ⁇ 0.2°, 19.713° ⁇ 0.2°, 21.586° ⁇ 0.2° and 24.643° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form of the compound N-methylpyrrolidone solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 6.642° ⁇ 0.2°, 11.493° ⁇ 0.2°, 11.783 ° ⁇ 0.2°, 13.56° ⁇ 0.2°, 16.481° ⁇ 0.2°, 17.45° ⁇ 0.2°, 17.807° ⁇ 0.2°, 18.486° ⁇ 0.2°, 18.717° ⁇ 0.2°, 19.013° ⁇ 0.2°, 19.713° ⁇ 0.2°, 20.355° ⁇ 0.2°, 21.233° ⁇ 0.2°, 21.586° ⁇ 0.2°, 22.166° ⁇ 0.2°, 22.752° ⁇ 0.2°, 23.534° ⁇ 0.2°, 24.643° ⁇ 0.2°, 25.014° ⁇ 0.2° , 26.083° ⁇ 0.2°, 26.611° ⁇ 0.2°, 26.976° ⁇ 0.2°, 27.684° ⁇ 0.2°, 28.092° ⁇ 0.2°, 30.179° ⁇ 0.2°, and 32.0
  • the X-ray powder diffraction pattern of the crystal form of the compound N-methylpyrrolidone solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 6.642° ⁇ 0.2°, 8.957° ⁇ 0.2°, 9.545 ° ⁇ 0.2°, 10.679° ⁇ 0.2°, 11.493° ⁇ 0.2°, 11.783° ⁇ 0.2°, 13.56° ⁇ 0.2°, 16.481° ⁇ 0.2°, 17.45° ⁇ 0.2°, 17.807° ⁇ 0.2°, 18.486° ⁇ 0.2°, 18.717° ⁇ 0.2°, 19.013° ⁇ 0.2°, 19.713° ⁇ 0.2°, 20.355° ⁇ 0.2°, 21.233° ⁇ 0.2°, 21.586° ⁇ 0.2°, 22.166° ⁇ 0.2°, 22.752° ⁇ 0.2° , 23.534° ⁇ 0.2°, 24.643° ⁇ 0.2°, 25.014° ⁇ 0.2°, 26.083° ⁇ 0.2°, 26.359° ⁇ 0.2°, 26.611° ⁇ 0.2°, 26.976° ⁇
  • the X-ray powder diffraction pattern analysis data of the crystal form of the N-methylpyrrolidone solvate of the compound of formula I is basically as shown in Table 8:
  • the X-ray powder diffraction pattern of the crystalline form of the N-methylpyrrolidone solvate of the compound of formula I is substantially as shown in FIG. 26 .
  • thermogravimetric analysis curve (TGA) of the crystal form of the N-methylpyrrolidone solvate of the compound of formula I shows that N-methylpyrrolidone is heated from 114.32°C ⁇ 3°C to 209.84°C ⁇ 3°C , there is a weight loss of 15.56% ⁇ 0.5%.
  • thermogravimetric analysis curve of the crystalline form of the N-methylpyrrolidone solvate of the compound of formula I shows that N-methylpyrrolidone has a weight loss of 15.56% during heating from 114.32°C to 209.84°C.
  • thermogravimetric analysis curve of the crystalline form of the N-methylpyrrolidone solvate of the compound of formula I is substantially as shown in FIG. 27 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form of the compound N-methylpyrrolidone solvate of the formula I has an onset temperature of 193.47°C ⁇ 3°C and 335.7°C ⁇ 3°C, respectively. endothermic peak.
  • the differential scanning calorimetry curve of the crystal form of the N-methylpyrrolidone solvate of the compound of formula I has endothermic peaks with onset temperatures of 193.47°C and 335.7°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the N-methylpyrrolidone solvate of the compound of formula I has endothermic peaks with peak temperatures of 198.63°C ⁇ 3°C and 336.81°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystal form of the N-methylpyrrolidone solvate of the compound of formula I has endothermic peaks with peak temperatures of 198.63°C and 336.81°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the N-methylpyrrolidone solvate of the compound of formula I is substantially as shown in FIG. 28 .
  • the hydrogen nuclear magnetic resonance spectrum ( 1 H-NMR) of the crystalline form of the N-methylpyrrolidone solvate of the compound of formula I shows that there is 15.3% ⁇ 0.5% by weight of N-methylpyrrolidone.
  • the proton nuclear magnetic resonance spectrum of the crystalline form of the N-methylpyrrolidone solvate of the compound of formula I shows that there is 15.3% by weight of N-methylpyrrolidone, and its molar ratio to the compound of formula I is 1:0.96.
  • the proton nuclear magnetic resonance spectrum of the crystalline form of the N-methylpyrrolidone solvate of the compound of formula I is shown in FIG. 29 .
  • the present invention also provides a method for preparing the crystal form of the N-methylpyrrolidone solvate of the compound of formula I, preferably comprising the following steps: the amorphous compound of the formula I is stirred in N-methylpyrrolidone to precipitate a solid, and separated After drying, the crystal form of the N-methylpyrrolidone solvate of the compound of formula I is obtained; the stirring is preferably carried out at a temperature of 20-60°C; the stirring time is preferably 1.5-2.5 days; the compound of the formula I
  • the mass-volume ratio of the amorphous form to the N-methylpyrrolidone is preferably (200mg-350mg): 1mL.
  • the stirring is preferably carried out at a temperature of 25°C or 50°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the amorphous compound of the formula I to the N-methylpyrrolidone is preferably 250 mg: 1 mL or 300 mg: 1 mL.
  • the present invention provides a crystal form of a compound DMF solvate of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four or at least five characteristic peaks at the following 2 ⁇ angles: 5.2° ⁇ 0.2 °, 9.503° ⁇ 0.2°, 10.267° ⁇ 0.2°, 17.491° ⁇ 0.2° and 22.283° ⁇ 0.2°;
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern of the crystalline form of the compound DMF solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.2° ⁇ 0.2°, 9.503° ⁇ 0.2° and 10.267° ⁇ 0.2° .
  • the X-ray powder diffraction pattern of the crystalline form of the compound DMF solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.2° ⁇ 0.2°, 9.503° ⁇ 0.2°, 10.267° ⁇ 0.2° and 22.283° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form of the compound DMF solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.2° ⁇ 0.2°, 9.503° ⁇ 0.2°, 10.267° ⁇ 0.2° , 11.008° ⁇ 0.2°, 13.5° ⁇ 0.2°, 13.831° ⁇ 0.2°, 14.32° ⁇ 0.2°, 14.943° ⁇ 0.2°, 15.353° ⁇ 0.2°, 17.491° ⁇ 0.2°, 18.856° ⁇ 0.2°, 19.363 ° ⁇ 0.2°, 20.75° ⁇ 0.2°, 21.018° ⁇ 0.2°, 21.741° ⁇ 0.2°, 22.03° ⁇ 0.2°, 22.283° ⁇ 0.2°, 23.317° ⁇ 0.2°, and 30.874° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form of the compound DMF solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.2° ⁇ 0.2°, 9.503° ⁇ 0.2°, 10.267° ⁇ 0.2° , 11.008° ⁇ 0.2°, 13.5° ⁇ 0.2°, 13.831° ⁇ 0.2°, 14.32° ⁇ 0.2°, 14.943° ⁇ 0.2°, 15.353° ⁇ 0.2°, 16.778° ⁇ 0.2°, 16.986° ⁇ 0.2°, 17.491 ° ⁇ 0.2°, 18.547° ⁇ 0.2°, 18.856° ⁇ 0.2°, 19.363° ⁇ 0.2°, 20.489° ⁇ 0.2°, 20.75° ⁇ 0.2°, 21.018° ⁇ 0.2°, 21.424° ⁇ 0.2°, 21.741° ⁇ 0.2°, 22.03° ⁇ 0.2°, 22.283° ⁇ 0.2°, 22.926° ⁇ 0.2°, 23.317° ⁇ 0.2°, 24.507° ⁇ 0.2°, 24.814° ⁇ 0.2°, 25.068°
  • the X-ray powder diffraction pattern analysis data of the crystal form of the compound DMF solvate of the formula I is basically as shown in Table 9:
  • the X-ray powder diffraction pattern of the crystalline form of the DMF solvate of the compound of formula I is substantially as shown in FIG. 30 .
  • thermogravimetric analysis curve (TGA) of the crystal form of the DMF solvate of the compound of formula I shows that DMF has 3.381% ⁇ 0.5% during heating from 38.31°C ⁇ 3°C to 196.62°C ⁇ 3°C of weightlessness.
  • thermogravimetric analysis curve of the crystalline form of the DMF solvate of the compound of formula I shows that DMF has a weight loss of 3.381% during heating from 38.31°C to 196.62°C.
  • thermogravimetric analysis curve of the DMF benzene solvate of the compound of formula I is substantially as shown in FIG. 31 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form of the compound DMF solvate of the formula I has an onset temperature of 104.94°C ⁇ 3°C, 252.64°C ⁇ 3°C and 338.18°C ⁇ 3°C, respectively. °C endothermic peak.
  • the differential scanning calorimetry curve of the crystalline form of the DMF solvate of the compound of formula I has endothermic peaks with onset temperatures of 104.94°C, 252.64°C, and 338.18°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the compound DMF solvate of the formula I has endotherms with peak temperatures of 114.52°C ⁇ 3°C, 257°C ⁇ 3°C and 338.98°C ⁇ 3°C, respectively peak.
  • the differential scanning calorimetry curve of the crystalline form of the DMF solvate of the compound of formula I has endothermic peaks with peak temperatures of 114.52°C, 257°C and 338.98°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the DMF solvate of the compound of formula I has an exothermic peak with a peak temperature of 260.94°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form of the DMF solvate of the compound of formula I has an exothermic peak with a peak temperature of 260.94°C.
  • the differential scanning calorimetry curve of the crystalline form of the DMF solvate of the compound of formula I is substantially as shown in FIG. 32 .
  • the hydrogen nuclear magnetic resonance spectrum ( 1 H-NMR) of the crystalline form of the DMF solvate of the compound of formula I shows that there is 10.3% ⁇ 0.5% toluene by weight.
  • the proton nuclear magnetic resonance spectrum of the crystalline form of the DMF solvate of the compound of formula I shows that there is 10.3% by weight of DMF, and the molar ratio of it to the compound of formula I is 1:0.83.
  • the proton nuclear magnetic resonance spectrum of the crystalline form of the DMF solvate of the compound of formula I is shown in FIG. 33 .
  • the present invention also provides a preparation method of the crystal form of the DMF solvate of the compound of formula I, which comprises the following steps: the amorphous compound of the formula I is stirred in DMF to precipitate a solid, separated and dried to obtain the compound of the formula I DMF
  • the crystal form of the solvate ; the stirring is preferably carried out at a temperature of 20-60°C; the stirring time is preferably 1.5-2.5 days; the amorphous form of the compound of formula I and the
  • the mass-to-volume ratio of DMF is preferably (200 mg-350 mg): 1 mL.
  • the stirring is preferably performed at a temperature of 25°C or 50°C.
  • the stirring time is preferably 2 days.
  • the mass volume ratio of the amorphous compound of the formula I to the DMF is preferably 250 mg: 1 mL or 300 mg: 1 mL.
  • the present invention provides a crystal form K of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five or at least six characteristic peaks at the following 2 ⁇ angles: 6.233° ⁇ 0.2°, 10.598° ⁇ 0.2°, 12.177° ⁇ 0.2°, 14.844° ⁇ 0.2°, 16.48° ⁇ 0.2° and 20.823° ⁇ 0.2°;
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern of the crystal form K of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 14.844° ⁇ 0.2°, 16.48° ⁇ 0.2° and 20.823° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form K of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.233° ⁇ 0.2°, 14.844° ⁇ 0.2°, 16.48° ⁇ 0.2° and 20.823° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form K of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.233° ⁇ 0.2°, 12.177° ⁇ 0.2°, 14.844° ⁇ 0.2°, 16.48° ⁇ 0.2° and 20.823° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form K of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.233° ⁇ 0.2°, 10.598° ⁇ 0.2°, 12.177° ⁇ 0.2°, 14.844° ⁇ 0.2°, 16.48° ⁇ 0.2°, and 20.823° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form K of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.275° ⁇ 0.2°, 6.233° ⁇ 0.2°, 8.473° ⁇ 0.2°, 9.485° ⁇ 0.2°, 10.305° ⁇ 0.2°, 10.907° ⁇ 0.2°, 11.804° ⁇ 0.2°, 12.117 ⁇ 0.2°, 12.601° ⁇ 0.2°, 13.477° ⁇ 0.2°, 14.844° ⁇ 0.2°, 16.48° ⁇ 0.2° , 16.831° ⁇ 0.2°, 18.038° ⁇ 0.2°, 18.681° ⁇ 0.2°, 20.062° ⁇ 0.2°, 20.083° ⁇ 0.2°, 21.548° ⁇ 0.2°, 22.461° ⁇ 0.2°, 23.298° ⁇ 0.2°, 23.766 ° ⁇ 0.2°, 25.244° ⁇ 0.2°, 25.791° ⁇ 0.2°, 26.886° ⁇ 0.2°, 27.665° ⁇ 0.2°, 28.012° ⁇ 0.2°, 29.513° ⁇ 0.2°, 31.789
  • the X-ray powder diffraction pattern analysis data of the crystal form K of the compound of formula I are basically as shown in Table 10:
  • the X-ray powder diffraction pattern of Form K of the compound of formula I is substantially as shown in FIG. 34 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form K of the compound of formula I has an endothermic peak with an onset temperature of 333.08°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystal form K of the compound of formula I has an endothermic peak with an onset temperature of 333.08°C.
  • the differential scanning calorimetry curve of the crystal form K of the compound of formula I has an endothermic peak with a termination temperature of 339.22°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystal form K of the compound of formula I has an endothermic peak with a termination temperature of 339.22°C.
  • the differential scanning calorimetry curve of the crystal form K of the compound of formula I has an endothermic peak with a peak temperature of 335.88°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystal form K of the compound of formula I has an endothermic peak with a peak temperature of 335.88°C.
  • the differential scanning calorimetry curve of the crystal form K of the compound of formula I has an exothermic peak with a peak temperature of 303.12°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystal form K of the compound of formula I has an exothermic peak with a peak temperature of 303.12°C.
  • the differential scanning calorimetry curve of Form K of the compound of formula I is substantially as shown in FIG. 35 .
  • the present invention also provides a method for preparing crystal form K of the compound of formula I, preferably comprising the following steps: keeping the crystal form B of the compound of formula I at a temperature of 250-300° C. for 1 to 5 minutes to obtain the crystal form of the compound of formula I K.
  • the crystal form B of the compound of formula I is preferably kept at a temperature of 280° C. for 2 minutes.
  • the present invention provides a compound of formula I hydrochloride crystal form A, its X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five, at least six, at least seven at the following 2 ⁇ angles , at least eight characteristic peaks: 5.527° ⁇ 0.2°, 11.026° ⁇ 0.2°, 11.805° ⁇ 0.2°, 16.39° ⁇ 0.2°, 17.572° ⁇ 0.2°, 23.853° ⁇ 0.2°, 24.398° ⁇ 0.2° and 27.683 ° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the hydrochloride salt form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.527° ⁇ 0.2°, 16.39° ⁇ 0.2° and 23.853° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound hydrochloride crystal form A of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.527° ⁇ 0.2°, 16.39° ⁇ 0.2°, 23.853° ⁇ 0.2° and 24.398° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound hydrochloride crystal form A of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.527° ⁇ 0.2°, 16.39° ⁇ 0.2°, 23.853° ⁇ 0.2°, 24.398° ⁇ 0.2° and 27.683° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound hydrochloride crystal form A of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.527° ⁇ 0.2°, 11.805° ⁇ 0.2°, 16.39° ⁇ 0.2°, 23.853° ⁇ 0.2°, 24.398° ⁇ 0.2°, and 27.683° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound hydrochloride crystal form A of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.527° ⁇ 0.2°, 11.026° ⁇ 0.2°, 11.805° ⁇ 0.2°, 16.39° ⁇ 0.2°, 23.853° ⁇ 0.2°, 24.398° ⁇ 0.2°, and 27.683° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound hydrochloride crystal form A of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.527° ⁇ 0.2°, 11.026° ⁇ 0.2°, 11.805° ⁇ 0.2°, 16.39° ⁇ 0.2°, 17.572° ⁇ 0.2°, 23.853° ⁇ 0.2°, 24.398° ⁇ 0.2°, and 27.683° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound hydrochloride crystal form A of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.527° ⁇ 0.2°, 11.026° ⁇ 0.2°, 11.805° ⁇ 0.2°, 12.655° ⁇ 0.2°, 13.027° ⁇ 0.2°, 16.39° ⁇ 0.2°, 17.572° ⁇ 0.2°, 20.57° ⁇ 0.2°, 21.819° ⁇ 0.2°, 22.358° ⁇ 0.2°, 22.685° ⁇ 0.2°, 23.853° ⁇ 0.2°, 24.398° ⁇ 0.2°, 27.037° ⁇ 0.2°, 27.683° ⁇ 0.2°, and 28.304° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the compound hydrochloride crystal form A of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.527° ⁇ 0.2°, 5.911° ⁇ 0.2°, 8.228° ⁇ 0.2°, 11.026° ⁇ 0.2°, 11.805° ⁇ 0.2°, 12.655° ⁇ 0.2°, 13.027° ⁇ 0.2°, 16.39° ⁇ 0.2°, 17.572° ⁇ 0.2°, 18.876° ⁇ 0.2°, 20.57° ⁇ 0.2°, 21.819° ⁇ 0.2°, 22.358° ⁇ 0.2°, 22.685° ⁇ 0.2°, 23.284° ⁇ 0.2°, 23.853° ⁇ 0.2°, 24.398° ⁇ 0.2°, 27.037° ⁇ 0.2°, 27.683° ⁇ 0.2°, 28.304° ⁇ 0.2 °, 29.471° ⁇ 0.2°, 30.051° ⁇ 0.2°, 33.574° ⁇ 0.2°, 36.726° ⁇ 0.2°, and 38.297° ⁇ 0.2°.
  • the X-ray powder diffraction pattern analysis data of the compound hydrochloride crystal form A of the formula I is basically as shown in Table 11:
  • the X-ray powder diffraction pattern of the hydrochloride salt form A of the compound of formula I is substantially as shown in FIG. 36 .
  • thermogravimetric analysis curve (TGA) of the hydrochloride salt form A of the compound of formula I shows a weight loss of 1.033% ⁇ 0.5% during heating from 25.19°C ⁇ 3°C to 108.66°C ⁇ 3°C ; In the process of heating from 108.66°C ⁇ 3°C to 209.57°C ⁇ 3°C, there is a weight loss of 6.683% ⁇ 0.5%.
  • thermogravimetric analysis curve of the compound hydrochloride crystal form A of the formula I shows that there is a weight loss of 1.033% during heating from 25.19°C to 108.66°C; during heating from 108.66°C to 209.57°C, there is 6.683% weight loss.
  • thermogravimetric analysis curve of the hydrochloride salt form A of the compound of formula I is substantially as shown in FIG. 37 .
  • the differential scanning calorimetry curve (DSC) of the hydrochloride salt form A of the compound of formula I has endothermic peaks with onset temperatures of 55.55°C ⁇ 3°C and 190.92°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the hydrochloride salt form A of the compound of formula I has endothermic peaks with onset temperatures of 55.55°C and 190.92°C, respectively.
  • the differential scanning calorimetry curve of the hydrochloride salt form A of the compound of formula I has endothermic peaks with peak temperatures of 97.51°C ⁇ 3°C and 208.18°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the hydrochloride salt form A of the compound of formula I has endothermic peaks with peak temperatures of 97.51°C and 208.18°C, respectively.
  • the differential scanning calorimetry curve of the hydrochloride salt form A of the compound of formula I is substantially as shown in FIG. 38 .
  • the dynamic vapor sorption curve (DVS) of the crystalline form A of the hydrochloride salt of the compound of formula I shows a moisture absorption weight gain of 0.31% ⁇ 0.2% at 25° C. and 80% RH.
  • the dynamic vapor adsorption curve of the compound hydrochloride crystalline form A of the formula I shows adsorption at 25° C. and 80% RH.
  • the wet weight gain was 0.31%.
  • the dynamic vapor adsorption curve of the hydrochloride salt form A of the compound of formula I is shown in FIG. 39 .
  • the present invention also provides a method for preparing the hydrochloride crystal form A of the compound of formula I, preferably comprising the following steps: mixing and stirring the compound of formula I, hydrochloric acid and tetrahydrofuran to precipitate a solid, and obtain the hydrochloride of the compound of formula I after separation and drying Crystal form A; the stirring is carried out at a temperature of 20-45°C; the stirring time is preferably 0.2-0.8 hours; the ratio of the amount of the compound of formula I to the hydrochloric acid is preferably (1-1.5) : 1; the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably (20mg ⁇ 30mg): 1mL.
  • the compound of formula I in the preparation method of the compound of formula I hydrochloride crystal form A, is preferably the compound of formula I in crystal form A.
  • the stirring is preferably performed at a temperature of 25°C or 40°C.
  • the stirring time is preferably 0.5 hour.
  • the ratio of the amount of the compound of formula I to the amount of hydrochloric acid is preferably 1.1:1.
  • the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably 23.85 mg: 1 mL.
  • the present invention provides a crystal form of the compound of formula I hydrochloride ethanol solvate, its X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five or at least six at the following 2 ⁇ angles Characteristic peaks: 6.24° ⁇ 0.2°, 14.43° ⁇ 0.2°, 15.744° ⁇ 0.2°, 18.391° ⁇ 0.2°, 24.01° ⁇ 0.2° and 26.261° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the crystalline form of the compound hydrochloride ethanol solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 6.24° ⁇ 0.2°, 15.744° ⁇ 0.2° and 26.261° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound hydrochloride ethanol solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 6.24° ⁇ 0.2°, 15.744° ⁇ 0.2°, 18.391° ⁇ 0.2° and 26.261° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound hydrochloride ethanol solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 6.24° ⁇ 0.2°, 14.43° ⁇ 0.2°, 15.744° ⁇ 0.2°, 18.391° ⁇ 0.2°, and 26.261° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound hydrochloride ethanol solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 6.24° ⁇ 0.2°, 14.43° ⁇ 0.2°, 15.744° ⁇ 0.2°, 18.391° ⁇ 0.2°, 24.01° ⁇ 0.2°, and 26.261° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form of the compound hydrochloride ethanol solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 6.24° ⁇ 0.2°, 6.673° ⁇ 0.2°, 8.442° ⁇ 0.2°, 13.706° ⁇ 0.2°, 14.43° ⁇ 0.2°, 15.744° ⁇ 0.2°, 15.958° ⁇ 0.2°, 17.924° ⁇ 0.2°, 18.391° ⁇ 0.2°, 18.937° ⁇ 0.2°, 20.84° ⁇ 0.2 °, 21.458° ⁇ 0.2°, 24.01° ⁇ 0.2°, 24.708° ⁇ 0.2°, 25.546° ⁇ 0.2°, and 26.261° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound of formula I hydrochloride ethanol solvate is at the following 2 ⁇ There are characteristic peaks at the angle: 6.24° ⁇ 0.2°, 6.673° ⁇ 0.2°, 7.293° ⁇ 0.2°, 8.442° ⁇ 0.2°, 8.89° ⁇ 0.2°, 10.326° ⁇ 0.2°, 13.706° ⁇ 0.2°, 14.43° ⁇ 0.2°, 15.744° ⁇ 0.2°, 15.958° ⁇ 0.2°, 17.924° ⁇ 0.2°, 18.391° ⁇ 0.2°, 18.937° ⁇ 0.2°, 19.246° ⁇ 0.2°, 20.84° ⁇ 0.2°, 21.458° ⁇ 0.2 °, 22.746° ⁇ 0.2°, 24.01° ⁇ 0.2°, 24.708° ⁇ 0.2°, 25.546° ⁇ 0.2°, 26.261° ⁇ 0.2°, 27.08° ⁇ 0.2°, 31.007° ⁇ 0.2°, 31.298° ⁇ 0.2°, 31.917° ⁇ 0.2° and 33.555° ⁇ 0.2°
  • the X-ray powder diffraction pattern analysis data of the crystal form of the compound hydrochloride ethanol solvate of the formula I is basically as shown in Table 12:
  • the X-ray powder diffraction pattern of the crystalline form of the compound of formula I hydrochloride ethanol solvate is substantially as shown in FIG. 41 .
  • thermogravimetric analysis curve (TGA) of the crystalline form of the compound hydrochloride ethanol solvate of the formula I shows that during heating from 25.07°C ⁇ 3°C to 158.66°C ⁇ 3°C, there is 3.508% ⁇ 0.5% weight loss; in the process of heating from 158.66°C ⁇ 3°C to 214.18°C ⁇ 3°C, there is 5.094% ⁇ 0.5% weight loss.
  • thermogravimetric analysis curve of the crystalline form of the compound hydrochloride ethanol solvate of the formula I shows a weight loss of 3.508% during heating from 25.07°C to 158.66°C; heating from 158.66°C to 214.18°C In the process, there is a weight loss of 5.094%.
  • thermogravimetric analysis curve of the crystalline form of the compound of formula I hydrochloride ethanol solvate is substantially as shown in FIG. 42 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form of the compound hydrochloride ethanol solvate of the formula I has absorptions with onset temperatures of 106°C ⁇ 3°C and 189.22°C ⁇ 3°C, respectively. hot peak.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I hydrochloride ethanol solvate has endothermic peaks with onset temperatures of 106°C and 189.22°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the compound hydrochloride ethanol solvate has endothermic peaks with peak temperatures of 146.54°C ⁇ 3°C and 205.32°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the compound hydrochloride ethanol solvate of the formula I has endothermic peaks with peak temperatures of 146.54°C and 205.32°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I hydrochloride ethanol solvate is substantially as shown in FIG. 43 .
  • the present invention also provides a method for preparing the crystal form of the compound of formula I hydrochloride ethanol solvate, preferably comprising the following steps: stirring the crystal form A of the compound of formula I hydrochloride in ethanol to precipitate a solid, separating and drying Finally, the crystal form of the compound hydrochloride ethanol solvate of the formula I is obtained; the stirring is preferably carried out at a temperature of 25-45°C; the stirring time is preferably 2.5-4.5 days; the compound hydrochloride crystal of the formula I
  • the mass-volume ratio of Form A to the ethanol is selected as (50mg-200mg): 1mL.
  • the stirring is preferably performed at a temperature of 30°C or 40°C.
  • the stirring time is preferably 3 days or 4 days.
  • the mass volume ratio of the hydrochloride salt form A of the compound of formula I to the ethanol is preferably 100mg: 1mL or 150mg: 1mL.
  • the present invention provides a crystal form of the compound of formula I hydrochloride isopropanol solvate, its X-ray powder diffraction pattern (XRPD) has at least three, at least four or at least five characteristic peaks at the following 2 ⁇ angles : 6.301° ⁇ 0.2°, 17.554° ⁇ 0.2°, 19.305° ⁇ 0.2°, 24.378° ⁇ 0.2° and 24.903° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the crystalline form of the compound of formula I hydrochloride isopropanol solvate has characteristic peaks at the following 2 ⁇ angles: 6.301° ⁇ 0.2°, 17.554° ⁇ 0.2° and 24.378° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound of formula I hydrochloride isopropanol solvate has characteristic peaks at the following 2 ⁇ angles: 6.301° ⁇ 0.2°, 17.554° ⁇ 0.2°, 19.305° ⁇ 0.2° and 24.378° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound of formula I hydrochloride isopropanol solvate has characteristic peaks at the following 2 ⁇ angles: 6.301° ⁇ 0.2°, 17.554° ⁇ 0.2°, 19.305° ⁇ 0.2°, 24.378° ⁇ 0.2°, and 24.903° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound of formula I hydrochloride isopropanol solvate has characteristic peaks at the following 2 ⁇ angles: 6.301° ⁇ 0.2°, 8.58° ⁇ 0.2°, 12.172° ⁇ 0.2°, 12.717° ⁇ 0.2°, 13.536° ⁇ 0.2°, 16.098° ⁇ 0.2°, 16.837° ⁇ 0.2°, 17.554° ⁇ 0.2°, 17.964° ⁇ 0.2°, 19.305° ⁇ 0.2°, 20.007° ⁇ 0.2°, 20.355° ⁇ 0.2°, 20.513° ⁇ 0.2°, 22.611° ⁇ 0.2°, 23.606° ⁇ 0.2°, 24.378° ⁇ 0.2°, 24.903° ⁇ 0.2°, 26.57° ⁇ 0.2°, 27.293° ⁇ 0.2 ° and 31.706° ⁇ 0.2°.
  • the X-ray powder diffraction spectrum of the crystal form of the compound of formula I hydrochloride isopropanol solvate has characteristic peaks at the following 2 ⁇ angles: 5.212° ⁇ 0.2°, 6.301° ⁇ 0.2°, 8.58° ⁇ 0.2°, 12.172° ⁇ 0.2°, 12.717° ⁇ 0.2°, 13.536° ⁇ 0.2°, 15.423° ⁇ 0.2°, 16.098° ⁇ 0.2°, 16.837° ⁇ 0.2°, 17.554° ⁇ 0.2°, 17.964° ⁇ 0.2°, 18.737° ⁇ 0.2°, 19.057° ⁇ 0.2°, 19.305° ⁇ 0.2°, 20.007° ⁇ 0.2°, 20.355° ⁇ 0.2°, 20.513° ⁇ 0.2°, 22.437° ⁇ 0.2°, 22.611° ⁇ 0.2 °, 23.191° ⁇ 0.2°, 23.606° ⁇ 0.2°, 24.378° ⁇ 0.2°, 24.903° ⁇ 0.2°, 26.323° ⁇ 0.2°, 26.57° ⁇ 0.2°, 27.293° ⁇ 0.2°, 27.
  • the X-ray powder diffraction pattern analysis data of the crystal form of the compound of formula I hydrochloride isopropanol solvate is basically as shown in Table 13:
  • the X-ray powder diffraction pattern of the crystalline form of the compound of formula I hydrochloride isopropanol solvate is substantially as shown in FIG. 44 .
  • thermogravimetric analysis curve (TGA) of the crystalline form of the compound of formula I hydrochloride isopropanol solvate shows that during heating from 28.2°C ⁇ 3°C to 205.15°C ⁇ 3°C, there is 14.79 % ⁇ 0.5% weight loss.
  • thermogravimetric analysis curve of the crystalline form of the compound of formula I hydrochloride isopropanol solvate shows a weight loss of 14.79% during heating from 28.2°C to 205.15°C.
  • thermogravimetric analysis curve of the crystalline form of the compound of formula I hydrochloride isopropanol solvate is substantially as shown in FIG. 45 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form of the compound of formula I hydrochloride isopropanol solvate has an endothermic peak with an onset temperature of 191.17°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I hydrochloride isopropanol solvate has an endothermic peak with an onset temperature of 191.17°C.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I hydrochloride isopropanol solvate has an endothermic peak with a peak temperature of 200.9°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I hydrochloride isopropanol solvate has an endothermic peak with a peak temperature of 200.9°C.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I hydrochloride isopropanol solvate is substantially as shown in FIG. 46 .
  • the present invention also provides a method for preparing a crystal form of the compound of formula I hydrochloride isopropanol solvate, preferably comprising the following steps: stirring the compound of formula I hydrochloride crystal form A in isopropanol to precipitate a solid, After separation and drying, the crystal form of the compound hydrochloride isopropanol solvate of formula I is obtained; the stirring is preferably carried out at a temperature of 25-45°C; the stirring time is preferably 2.5-4.5 days; the formula The mass volume ratio of compound I hydrochloride crystal form A to the isopropanol is preferably (100 mg-200 mg): 1 mL.
  • the stirring is preferably performed at a temperature of 30°C or 40°C.
  • the stirring time is preferably 3 days or 4 days.
  • the mass volume ratio of the hydrochloride salt form A of the compound of formula I to the ethanol is preferably 133.33 mg: 1 mL or 150 mg: 1 mL.
  • the present invention provides a compound sulfate crystal form A of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three characteristic peaks at the following 2 ⁇ angles: 7.645° ⁇ 0.2°, 15.146° ⁇ 0.2° and 17.17° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the sulfate crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.468° ⁇ 0.2°, 7.645° ⁇ 0.2°, 15.146° ⁇ 0.2°, 17.17° ° ⁇ 0.2°, 19.25° ⁇ 0.2°, 19.813° ⁇ 0.2°, and 24.106° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the sulfate crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.119° ⁇ 0.2°, 5.468° ⁇ 0.2°, 7.645° ⁇ 0.2°, 8.424 ° ⁇ 0.2°, 11.303° ⁇ 0.2°, 15.146° ⁇ 0.2°, 16.289° ⁇ 0.2°, 16.701° ⁇ 0.2°, 17.17° ⁇ 0.2°, 18.176° ⁇ 0.2°, 19.25° ⁇ 0.2°, 19.813° ⁇ 0.2°, 20.826° ⁇ 0.2°, 21.138° ⁇ 0.2°, 21.522° ⁇ 0.2°, 22.476° ⁇ 0.2°, 23.152° ⁇ 0.2°, 24.106° ⁇ 0.2°, 24.456° ⁇ 0.2°, 25.351° ⁇ 0.2° , 26.613° ⁇ 0.2°, 27.41° ⁇ 0.2°, 27.816° ⁇ 0.2°, 28.324° ⁇ 0.2° and 29.084° ⁇ 0.2°.
  • the X-ray powder diffraction pattern analysis data of the sulfate crystal form A of the compound of formula I are basically as shown in Table 14:
  • the X-ray powder diffraction pattern of the sulfate salt form A of the compound of formula I is substantially as shown in FIG. 47 .
  • thermogravimetric analysis curve (TGA) of the sulfate crystal form A of the compound of formula I shows a weight loss of 0.2336% ⁇ 0.2% during heating from 32.19°C ⁇ 3°C to 159.29°C ⁇ 3°C; In the process of heating from 159.29°C ⁇ 3°C to 252.51°C ⁇ 3°C, there is a weight loss of 4.029% ⁇ 0.5%.
  • thermogravimetric analysis curve of the sulfate crystal form A of the compound of formula I shows that there is a weight loss of 0.2336% during heating from 32.19°C to 159.29°C; % weight loss.
  • thermogravimetric analysis curve of the sulfate crystal form A of the compound of formula I is substantially as shown in FIG. 48 .
  • the differential scanning calorimetry curve (DSC) of the sulfate crystal form A of the compound of formula I has an endothermic peak with an onset temperature of 210.46°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the sulfate crystal form A of the compound of formula I has an endothermic peak with an onset temperature of 210.46°C.
  • the differential scanning calorimetry curve of the sulfate crystal form A of the compound of formula I has an endothermic peak with a peak temperature of 224.37°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the sulfate crystal form A of the compound of formula I has an endothermic peak with a peak temperature of 224.37°C.
  • the differential scanning calorimetry curve of the sulfate salt form A of the compound of formula I is substantially as shown in FIG. 49 .
  • the dynamic vapor sorption curve (DVS) of the sulfate crystal form A of the compound of formula I shows that the moisture absorption weight gain is 1.43% ⁇ 0.5% at 25° C. and 80% RH.
  • the dynamic vapor adsorption curve of the sulfate crystal form A of the compound of formula I shows that the moisture absorption weight gain is 1.43% at 25° C. and 80% RH.
  • the dynamic vapor adsorption curve of the sulfate crystal form A of the compound of formula I is shown in FIG. 50 .
  • the present invention also provides a method for preparing the crystal form A of sulfate salt of the compound of formula I, preferably comprising the following steps: mixing and stirring the compound of formula I, sulfuric acid and tetrahydrofuran, adding n-heptane to precipitate a solid, separating and drying to obtain the formula Compound I sulfate crystal form A; the stirring is preferably carried out at a temperature of 20 to 30°C; the stirring time is preferably 0.2 to 0.8 days; the ratio of the amount of the compound of formula I to the sulfuric acid is preferably (1 ⁇ 1.5): 1;
  • the mass volume ratio of described formula I compound and described tetrahydrofuran is preferably (40mg ⁇ 50mg): 1mL;
  • the mass volume ratio of described formula I compound and described n-heptane is (70mg ⁇ 90 mg): 1 mL.
  • the compound of formula I in the preparation method of the sulfate crystal form A of the compound of formula I, is preferably the crystal form A of the compound of formula I.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 0.5 days; the ratio of the amount of the compound of formula I to the sulfuric acid is preferably 1.1:1.
  • the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably 44.71 mg: 1 mL.
  • the mass volume ratio of the compound of formula I to the n-heptane is preferably 82.33 mg: 1 mL.
  • the present invention provides a compound sulfate crystal form B of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three or at least four characteristic peaks at the following 2 ⁇ angles: 5.896° ⁇ 0.2°, 17.498° ⁇ 0.2 °, 20.314° ⁇ 0.2° and 22.806 ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the sulfate crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.896° ⁇ 0.2°, 17.498° ⁇ 0.2° and 20.314° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the sulfate crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.896° ⁇ 0.2°, 17.498° ⁇ 0.2°, 20.314° ⁇ 0.2° and 22.806 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the sulfate crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.896° ⁇ 0.2°, 7.174° ⁇ 0.2°, 16.585° ⁇ 0.2°, 17.498 ° ⁇ 0.2°, 18.294° ⁇ 0.2°, 20.314° ⁇ 0.2°, and 22.806 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the sulfate crystal form B of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.896° ⁇ 0.2°, 7.174° ⁇ 0.2°, 7.589° ⁇ 0.2°, 11.686 ° ⁇ 0.2°, 12.54° ⁇ 0.2°, 13.282° ⁇ 0.2°, 14.199° ⁇ 0.2°, 15.517° ⁇ 0.2°, 15.773° ⁇ 0.2°, 16.205° ⁇ 0.2°, 16.585° ⁇ 0.2°, 17.498° ⁇ 0.2°, 18.294° ⁇ 0.2°, 19.283° ⁇ 0.2°, 19.598° ⁇ 0.2°, 20.314° ⁇ 0.2°, 21.271° ⁇ 0.2°, 21.558° ⁇ 0.2°, 22.105° ⁇ 0.2°, 22.806° ⁇ 0.2° , 23.351° ⁇ 0.2°, 24.05° ⁇ 0.2°, 25.135° ⁇ 0.2°, 25.368° ⁇ 0.2°, 25.892° ⁇ 0.2°, 26.475° ⁇ 0.2°, 26.764° ⁇
  • the X-ray powder diffraction pattern analysis data of the sulfate crystal form B of the compound of formula I are basically as shown in Table 15:
  • the X-ray powder diffraction pattern of the sulfate crystalline form B of the compound of formula I is substantially as shown in FIG. 52 .
  • thermogravimetric analysis curve (TGA) of the sulfate crystal form B of the compound of formula I shows a weight loss of 2.144% ⁇ 0.5% during heating from 33.57°C ⁇ 3°C to 120.18°C ⁇ 3°C; In the process of heating from 120.18°C ⁇ 3°C to 209.36°C ⁇ 3°C, there is a weight loss of 6.564% ⁇ 0.5%.
  • thermogravimetric analysis curve of the sulfate crystal form B of the compound of formula I shows that there is a weight loss of 2.144% during heating from 33.57°C to 120.18°C; % weight loss.
  • thermogravimetric analysis curve of the sulfate crystal form B of the compound of formula I is substantially as shown in FIG. 53 .
  • the differential scanning calorimetry curve (DSC) of the sulfate crystal form B of the compound of formula I has an endothermic peak with an onset temperature of 168.85°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the sulfate crystal form B of the compound of formula I has an endothermic peak with an onset temperature of 168.85°C.
  • the differential scanning calorimetry curve of the sulfate crystal form B of the compound of formula I has an endothermic peak with a peak temperature of 174.37°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the sulfate crystal form B of the compound of formula I has an endothermic peak with a peak temperature of 174.37°C.
  • the differential scanning calorimetry curve of the sulfate crystalline form B of the compound of formula I is substantially as shown in FIG. 54 .
  • the present invention also provides a method for preparing the sulfate crystal form B of the compound of formula I, preferably comprising the following steps: mixing and stirring the compound of formula I, tetrahydrofuran and sulfuric acid to precipitate a solid, and obtaining the sulfate crystal form of the compound of formula I after separation and drying B; the stirring is carried out at a temperature of 20 to 30° C.; the stirring time is preferably 3 to 5 hours; the ratio of the amount of the compound of formula I to the sulfuric acid is (1 to 1.5): 1; The mass volume ratio of the compound of formula I to the tetrahydrofuran is (30 mg-70 mg): 1 mL.
  • the compound of formula I in the preparation method of the sulfate crystal form B of the compound of formula I, is preferably the crystal form A of the compound of formula I.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 4 hours.
  • the compound of formula I and the The ratio of the amount of sulfuric acid to substance is 1.2:1.
  • the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably 43.14 mg: 1 mL.
  • the present invention provides a compound sulfate crystal form C of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three characteristic peaks at the following 2 ⁇ angles: 5.818° ⁇ 0.2°, 6.576° ⁇ 0.2° and 15.904° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the sulfate crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.818° ⁇ 0.2°, 6.576° ⁇ 0.2°, 15.904° ⁇ 0.2°, 16.292° ° ⁇ 0.2° and 22.994° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the sulfate crystal form C of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 5.818° ⁇ 0.2°, 6.576° ⁇ 0.2°, 8.996° ⁇ 0.2°, 9.976° ° ⁇ 0.2°, 10.578° ⁇ 0.2°, 11.55° ⁇ 0.2°, 15.239° ⁇ 0.2°, 15.904° ⁇ 0.2°, 16.292° ⁇ 0.2°, 16.55° ⁇ 0.2°, 17.599° ⁇ 0.2°, 18.818° ⁇ 0.2°, 20.641° ⁇ 0.2°, 21.538° ⁇ 0.2°, 22.14° ⁇ 0.2°, 22.994° ⁇ 0.2°, 23.815° ⁇ 0.2°, 24.237° ⁇ 0.2°, 24.468° ⁇ 0.2°, 26.105° ⁇ 0.2° , 29.566° ⁇ 0.2° and 30.089° ⁇ 0.2°.
  • the X-ray powder diffraction pattern analysis data of the sulfate crystal form C of the compound of formula I are basically as shown in Table 16:
  • the X-ray powder diffraction pattern of the sulfate salt form C of the compound of formula I is substantially as shown in FIG. 55 .
  • the present invention also provides a method for preparing the crystal form C of sulfate salt of the compound of formula I, preferably comprising the following steps: mixing and stirring the compound of formula I, tetrahydrofuran and sulfuric acid, adding n-heptane to precipitate a solid, separating and drying to obtain formula Compound I sulfate crystal form C; the stirring is carried out at a temperature of 20 to 35°C; the stirring time is preferably 3 to 5 hours; the ratio of the amount of the compound of formula I to the sulfuric acid is (1 ⁇ 1.5): 1;
  • the mass volume ratio of described formula I compound and described THF is (40mg ⁇ 50mg): 1mL;
  • the mass volume ratio of described formula I compound and described n-heptane is (15mg ⁇ 35mg): 1mL.
  • the compound of formula I in the preparation method of the sulfate crystal form C of the compound of formula I, is preferably the crystal form A of the compound of formula I.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 4 hours.
  • the ratio of the amount of the compound of formula I to the amount of sulfuric acid is preferably 1.1:1.
  • the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably 45.45 mg: 1 mL.
  • the mass volume ratio of the compound of formula I to the n-heptane is preferably 27.32 mg: 1 mL.
  • the present invention provides a crystal form of the compound sulfate toluene solvate of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three, at least four, at least five, at least six or At least seven characteristic peaks: 5.351° ⁇ 0.2°, 5.819° ⁇ 0.2°, 10.347° ⁇ 0.2°, 19.48° ⁇ 0.2°, 19.792° ⁇ 0.2°, 24.086° ⁇ 0.2° and 24.826° ⁇ 0.2°;
  • XRPD X-ray powder diffraction pattern
  • the X-ray powder diffraction pattern of the crystal form of the compound sulfate toluene solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.351° ⁇ 0.2°, 5.819° ⁇ 0.2° and 24.086° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound sulfate toluene solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.351° ⁇ 0.2°, 5.819° ⁇ 0.2°, 10.347° ⁇ 0.2° and 24.086° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound sulfate toluene solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.351° ⁇ 0.2°, 5.819° ⁇ 0.2°, 10.347° ⁇ 0.2°, 19.48° ⁇ 0.2°, and 24.086° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound sulfate toluene solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.351° ⁇ 0.2°, 5.819° ⁇ 0.2°, 10.347° ⁇ 0.2°, 19.48° ⁇ 0.2°, 19.792° ⁇ 0.2°, and 24.086° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound sulfate toluene solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.351° ⁇ 0.2°, 5.819° ⁇ 0.2°, 10.347° ⁇ 0.2°, 19.48° ⁇ 0.2°, 19.792° ⁇ 0.2°, 24.086° ⁇ 0.2°, and 24.826° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form of the compound sulfate toluene solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.351° ⁇ 0.2°, 5.819° ⁇ 0.2°, 9.765° ⁇ 0.2°, 10.347° ⁇ 0.2°, 11.744° ⁇ 0.2°, 12.154° ⁇ 0.2°, 12.834° ⁇ 0.2°, 13.962° ⁇ 0.2°, 16.933° ⁇ 0.2°, 17.439° ⁇ 0.2°, 18.407° ⁇ 0.2° , 19.48° ⁇ 0.2°, 19.792° ⁇ 0.2°, 20.941° ⁇ 0.2°, 22.066° ⁇ 0.2°, 22.966° ⁇ 0.2°, 23.38° ⁇ 0.2°, 24.086° ⁇ 0.2°, 24.826° ⁇ 0.2°, 25.154 ° ⁇ 0.2°, 26.167° ⁇ 0.2°, and 28.344° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound sulfate toluene solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 5.351° ⁇ 0.2°, 5.819° ⁇ 0.2°, 7.684° ⁇ 0.2°, 8.615° ⁇ 0.2°, 9.765° ⁇ 0.2°, 10.347° ⁇ 0.2°, 11.744° ⁇ 0.2°, 12.154° ⁇ 0.2°, 12.834° ⁇ 0.2°, 13.962° ⁇ 0.2°, 16.414° ⁇ 0.2° , 16.933° ⁇ 0.2°, 17.439° ⁇ 0.2°, 18.407° ⁇ 0.2°, 19.48° ⁇ 0.2°, 19.792° ⁇ 0.2°, 20.941° ⁇ 0.2°, 22.066° ⁇ 0.2°, 22.966° ⁇ 0.2°, 23.38 ° ⁇ 0.2°, 24.086° ⁇ 0.2°, 24.826° ⁇ 0.2°, 25.154° ⁇ 0.2°, 26.167° ⁇ 0.2°, 27.172° ⁇ 0.2°, 28.344
  • the X-ray powder diffraction pattern analysis data of the crystal form of the compound sulfate toluene solvate of the formula I is basically as shown in Table 17:
  • the X-ray powder diffraction pattern of the crystalline form of the compound of formula I sulfate toluene solvate is substantially as shown in FIG. 56 .
  • thermogravimetric analysis curve (TGA) of the crystal form of the sulfate toluene solvate of the compound of formula I shows that during heating from 34.88°C ⁇ 3°C to 109.33°C ⁇ 3°C, there is 0.5679% ⁇ 0.2 % weight loss; during heating from 109.33°C ⁇ 3°C to 192.37°C ⁇ 3°C, there is 3.645% ⁇ 0.5% weight loss; during heating from 192.37°C ⁇ 3°C to 222.48°C ⁇ 3°C, there is 1.535% ⁇ 0.5% % weight loss.
  • thermogravimetric analysis curve of the crystalline form of the sulfate toluene solvate of the compound of formula I shows a weight loss of 0.5679% during heating from 34.88°C to 109.33°C; In the process, there is a weight loss of 3.645%; in the process of heating from 192.37°C to 222.48°C, there is a weight loss of 1.535%.
  • thermogravimetric analysis curve of the crystalline form of the sulfate toluene solvate of the compound of formula I is substantially as shown in FIG. 57 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form of the sulfate toluene solvate of the compound of formula I has an endothermic peak with an onset temperature of 181.87°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form of the sulfate toluene solvate of the compound of formula I has an endothermic peak with an onset temperature of 181.87°C.
  • the differential scanning calorimetry curve of the crystalline form of the sulfate toluene solvate of the compound of formula I has an endothermic peak with a peak temperature of 199.71°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystal form of the sulfate toluene solvate of the compound of formula I has an endothermic peak with a peak temperature of 199.71°C.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I sulfate toluene solvate is substantially as shown in FIG. 58 .
  • the present invention also provides a method for preparing the crystal form of the sulfate toluene solvate of the compound of formula I, preferably comprising the following steps: mixing the crystal form A of the sulfate salt of the compound of formula I with methanol and filtering to obtain a filtrate, adding toluene to precipitate a solid, After separation and drying, the crystal form of the compound sulfate toluene solvate of the formula I is obtained; the mass volume ratio of the compound sulfate crystal form A of the formula I to the methanol is preferably (30mg ⁇ 40mg): 1mL; the formula I The mass volume ratio of compound I sulfate crystal form A to the toluene is preferably (35 mg-45 mg): 1 mL.
  • the filtration is preferably performed with a 0.22 ⁇ m nylon filter membrane.
  • the mass volume ratio of the sulfate crystal form A of the compound of formula I to the methanol is preferably 35.71 mg: 1 mL.
  • the mass volume ratio of the sulfate crystal form A of the compound of formula I to the toluene is preferably 41.67mg: 1mL.
  • the present invention provides a compound p-toluenesulfonate crystal form A of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three characteristic peaks at the following 2 ⁇ angles: 4.788° ⁇ 0.2°, 5.839° ⁇ 0.2° and 17.48° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the p-toluenesulfonate salt crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 4.788° ⁇ 0.2°, 5.839° ⁇ 0.2°, 16.624° ⁇ 0.2 °, 17.48° ⁇ 0.2°, 18.354° ⁇ 0.2°, 20.295° ⁇ 0.2°, and 20.954° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the p-toluenesulfonate salt crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 4.788° ⁇ 0.2°, 5.839° ⁇ 0.2°, 7.235° ⁇ 0.2 °, 9.529° ⁇ 0.2°, 10.656° ⁇ 0.2°, 11.646° ⁇ 0.2°, 12.275° ⁇ 0.2°, 12.931° ⁇ 0.2°, 13.878° ⁇ 0.2°, 14.307° ⁇ 0.2°, 14.598° ⁇ 0.2°, 15.309° ⁇ 0.2°, 15.57° ⁇ 0.2°, 16.136° ⁇ 0.2°, 16.624° ⁇ 0.2°, 17.48° ⁇ 0.2°, 18.354° ⁇ 0.2°, 18.649° ⁇ 0.2°, 19.348° ⁇ 0.2°, 19.655° ⁇ 0.2°, 20.295° ⁇ 0.2°, 20.954° ⁇ 0.2°, 21.385° ⁇ 0.2°, 21.771° ⁇ 0.2°, 21.988° ⁇ 0.2°, 22.397° ⁇ 0.2°
  • the X-ray powder diffraction pattern analysis data of the p-toluenesulfonate salt crystal form A of the compound of formula I is basically as shown in Table 18:
  • the X-ray powder diffraction pattern of the p-toluenesulfonate salt form A of the compound of formula I is substantially as shown in FIG. 59 .
  • thermogravimetric analysis curve (TGA) of the p-toluenesulfonate salt crystal form A of the compound of formula I shows that during heating from 30.7°C ⁇ 3°C to 130°C ⁇ 3°C, there is 0.9963% ⁇ 0.2% of weightlessness.
  • thermogravimetric analysis curve of the p-toluenesulfonate salt form A of the compound of formula I shows that there is a weight loss of 0.9963% during heating from 30.7°C to 130°C.
  • thermogravimetric analysis curve of the tosylate salt Form A of the compound of formula I is substantially as shown in FIG. 60 .
  • the differential scanning calorimetry curve (DSC) of the p-toluenesulfonate salt crystal form A of the compound of formula I has an onset temperature of 85.28°C ⁇ 3°C, 193.65°C ⁇ 3°C and 223.74°C ⁇ 3°C, respectively. Endothermic peak at 3°C.
  • the differential scanning calorimetry curve of the p-toluenesulfonate salt form A of the compound of formula I has endothermic peaks with onset temperatures of 85.28°C, 193.65°C and 223.74°C, respectively.
  • the differential scanning calorimetry curve of the p-toluenesulfonate salt crystal form A of the compound of formula I has absorption peak temperatures of 105.14°C ⁇ 3°C, 204.26°C ⁇ 3°C and 235.34°C ⁇ 3°C, respectively. hot peak.
  • the differential scanning calorimetry curve of the p-toluenesulfonate salt form A of the compound of formula I has endothermic peaks with peak temperatures of 105.14°C, 204.26°C and 235.34°C, respectively.
  • the differential scanning calorimetry curve of the p-toluenesulfonate salt form A of the compound of formula I is substantially as shown in FIG. 61 .
  • the present invention also provides a method for preparing the p-toluenesulfonate crystal form A of the compound of formula I, preferably comprising the following steps: mixing and stirring the compound of formula I, tetrahydrofuran and p-toluenesulfonic acid, adding n-heptane to precipitate a solid, and After separation and drying, the p-toluenesulfonate crystal form A of the compound of formula I is obtained; the stirring is preferably carried out at a temperature of 20-30°C; the stirring time is preferably 0.2-0.8 hours;
  • the ratio of the amount of the compound of the formula I to the p-toluenesulfonic acid is preferably (1-1.5): 1;
  • the mass volume ratio of the compound of the formula I to the tetrahydrofuran is preferably (40mg-60mg): 1mL;
  • the mass volume ratio of the compound of formula I to the n-heptane is preferably (
  • the compound of formula I in the preparation method of the crystal form A of the p-toluenesulfonate salt of the compound of formula I, is preferably the crystal form A of the compound of formula I.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 0.5 hour; the ratio of the compound of formula I to the p-toluenesulfonic acid is preferably 1.1:1.
  • the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably 50.7:1 mL.
  • the mass volume ratio of the compound of formula I to the n-heptane is preferably 84.5 mg: 1 mL.
  • the present invention provides a crystalline form A of besylate salt of a compound of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three or at least four characteristic peaks at the following 2 ⁇ angles: 13.477° ⁇ 0.2°, 15.787° ⁇ 0.2°, 17.362° ⁇ 0.2° and 25.371° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the besylate salt crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 13.477° ⁇ 0.2°, 15.787° ⁇ 0.2° and 17.362° ⁇ 0.2° .
  • the X-ray powder diffraction pattern of the crystalline form A of the besylate salt of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 13.477° ⁇ 0.2°, 15.787° ⁇ 0.2°, 17.362° ⁇ 0.2° and 25.371° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form A of the besylate salt of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.519° ⁇ 0.2°, 8.866° ⁇ 0.2°, 13.477° ⁇ 0.2° , 13.842° ⁇ 0.2°, 15.787° ⁇ 0.2°, 17.362° ⁇ 0.2°, 18.971° ⁇ 0.2°, 20.452° ⁇ 0.2°, 20.802° ⁇ 0.2°, 21.48° ⁇ 0.2°, 21.735° ⁇ 0.2°, 22.067 ° ⁇ 0.2°, 22.668° ⁇ 0.2°, 23.175° ⁇ 0.2°, 25.077° ⁇ 0.2°, 25.371° ⁇ 0.2°, 25.973° ⁇ 0.2°, 26.206° ⁇ 0.2°, and 32.971° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form A of the besylate salt of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 6.519° ⁇ 0.2°, 8.866° ⁇ 0.2°, 10.437° ⁇ 0.2° , 11.044° ⁇ 0.2°, 13.059° ⁇ 0.2°, 13.477° ⁇ 0.2°, 13.842° ⁇ 0.2°, 14.814° ⁇ 0.2°, 15.787° ⁇ 0.2°, 16.036° ⁇ 0.2°, 16.488° ⁇ 0.2°, 17.362 ° ⁇ 0.2°, 18.971° ⁇ 0.2°, 20.452° ⁇ 0.2°, 20.802° ⁇ 0.2°, 21.246° ⁇ 0.2°, 21.48° ⁇ 0.2°, 21.735° ⁇ 0.2°, 22.067° ⁇ 0.2°, 22.668° ⁇ 0.2°, 23.175° ⁇ 0.2°, 23.717° ⁇ 0.2°, 25.077° ⁇ 0.2°, 25.371° ⁇ 0.2°, 25.973° ⁇ 0.2°, 26.206° ⁇
  • the analytical data of the X-ray powder diffraction pattern of the crystalline form A of the besylate salt of the compound of formula I are basically as shown in Table 19:
  • the X-ray powder diffraction pattern of the crystalline form A of the besylate salt of the compound of formula I is substantially as shown in FIG. 62 .
  • thermogravimetric analysis curve (TGA) of the besylate salt crystal form A of the compound of formula I shows that during heating from 30.43°C ⁇ 3°C to 149.29°C ⁇ 3°C, there is 0.02869% ⁇ 0.0005% weightlessness.
  • thermogravimetric analysis curve of the crystalline form A of the besylate salt of the compound of formula I shows that there is a weight loss of 0.02869% during heating from 30.43°C to 149.29°C.
  • thermogravimetric analysis curve of the crystalline form A of the besylate salt of the compound of formula I is substantially as shown in FIG. 63 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form A of the besylate salt of the compound of formula I has an endothermic peak with an onset temperature of 235.01°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form A of the besylate salt of the compound of formula I has an endothermic peak with an onset temperature of 235.01°C.
  • the differential scanning calorimetry curve of the crystalline form A of the besylate salt of the compound of formula I has an endothermic peak with a peak temperature of 245.52°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form A of the besylate salt of the compound of formula I has an endothermic peak with a peak temperature of 245.52°C.
  • the differential scanning calorimetry curve of the crystalline form A of the besylate salt of the compound of formula I is substantially as shown in FIG. 64 .
  • the present invention also provides a preparation method of benzenesulfonate crystal form A of the compound of formula I, preferably comprising the following steps: mixing and stirring the compound of formula I, tetrahydrofuran and benzenesulfonic acid, adding n-heptane to precipitate a solid, separating, After drying, the crystal form A of the benzenesulfonate salt of the compound of formula I is obtained; the stirring is preferably carried out at a temperature of 20 to 30°C; the stirring time is preferably 0.2 to 0.8 hours; the compound of the formula I and the benzenesulfonic acid
  • the ratio of the amount of substance is preferably (1 ⁇ 1.5): 1;
  • the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably (40mg ⁇ 60mg): 1mL; the compound of formula I and the n-heptane
  • the mass-to-volume ratio is preferably (55 mg to 75 mg): 1
  • the compound of the formula I in the preparation method of the crystalline form A of the besylate salt of the compound of the formula I, is preferably the crystalline form A of the compound of the formula I.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 0.5 hour; the ratio of the compound of formula I to the benzenesulfonic acid is preferably 1.1:1.
  • the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably 52.8mg: 1mL.
  • the mass volume ratio of the compound of formula I to the n-heptane is preferably 66mg: 1mL.
  • the present invention provides a compound mesylate crystal form A of formula I, whose X-ray powder diffraction pattern (XRPD) is at the following 2 ⁇ angle Have at least three characteristic peaks: 7.548° ⁇ 0.2°, 15.087° ⁇ 0.2° and 15.554° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the mesylate salt crystal form A of the compound of formula I has characteristic peaks at the following 2 ⁇ angles: 7.548° ⁇ 0.2°, 9.084° ⁇ 0.2°, 10.268° ⁇ 0.2° , 12.268° ⁇ 0.2°, 13.505° ⁇ 0.2°, 15.087° ⁇ 0.2°, 15.554° ⁇ 0.2°, 16.917° ⁇ 0.2°, 18.994° ⁇ 0.2°, 19.853° ⁇ 0.2°, 20.515° ⁇ 0.2°, 22.185 ° ⁇ 0.2°, 22.785° ⁇ 0.2°, 23.075° ⁇ 0.2°, 24.146° ⁇ 0.2°, 25.038° ⁇ 0.2°, 26.533° ⁇ 0.2°, 27.082° ⁇ 0.2°, 28.572° ⁇ 0.2°, 29.68° ⁇ 0.2° and 30.167° ⁇ 0.2°.
  • the X-ray powder diffraction pattern analysis data of the mesylate salt crystal form A of the compound of formula I is basically as shown in Table 20:
  • the X-ray powder diffraction pattern of the crystalline form A of the mesylate salt of the compound of formula I is substantially as shown in FIG. 65 .
  • thermogravimetric analysis curve (TGA) of the mesylate salt crystal form A of the compound of formula I shows that during heating from 30.96°C ⁇ 3°C to 148.39°C ⁇ 3°C, there is 0.03112% ⁇ 0.0005% of weightlessness.
  • thermogravimetric analysis curve of the crystalline form A of the mesylate salt of the compound of formula I shows a weight loss of 0.03112% during heating from 30.96°C to 148.39°C.
  • thermogravimetric analysis curve of the crystalline form A of the mesylate salt of the compound of formula I is substantially as shown in FIG. 66 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form A of the mesylate salt of the compound of formula I has an endothermic peak with an onset temperature of 250.75°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form A of the mesylate salt of the compound of formula I has an endothermic peak with an onset temperature of 250.75°C.
  • the differential scanning calorimetry curve of the crystalline form A of the mesylate salt of the compound of formula I has an endothermic peak with a peak temperature of 262.7°C ⁇ 3°C.
  • the differential scanning calorimetry curve of the crystalline form A of the mesylate salt of the compound of formula I has an endothermic peak with a peak temperature of 262.7°C.
  • the differential scanning calorimetry curve of the crystalline form A of the mesylate salt of the compound of formula I is substantially as shown in FIG. 67 .
  • the dynamic vapor sorption curve (DVS) of the crystalline form A of the mesylate salt of the compound of formula I shows a moisture absorption weight gain of 0.84% ⁇ 0.005% at 25° C. and 80% RH.
  • the dynamic vapor sorption curve of the crystalline form A of the mesylate salt of the compound of formula I shows a moisture absorption weight gain of 0.84% at 25° C. and 80% RH.
  • the dynamic vapor adsorption curve of the crystalline form A of the mesylate salt of the compound of formula I is shown in FIG. 68 .
  • the present invention also provides a method for preparing the mesylate salt crystal form A of the compound of formula I, preferably any of the following methods:
  • Method 1 The compound of formula I, tetrahydrofuran and methanesulfonic acid are mixed and stirred to precipitate solids, and the crystal form A of the mesylate salt of the compound of formula I is obtained after separation and drying; the stirring is carried out at a temperature of 20-30°C; the stirring The time is preferably 0.2 to 0.8 hours; the ratio of the amount of the compound of the formula I to the methanesulfonic acid is preferably (1 to 1.5): 1; the mass volume ratio of the compound of the formula I to the tetrahydrofuran is preferably For (20mg ⁇ 30mg): 1mL;
  • Method 2 The amorphous form of the mesylate salt of the compound of formula I is stirred in an organic solvent to precipitate a solid, and after separation and drying, the crystalline form A of the mesylate salt of the compound of formula I is obtained.
  • the organic solvent is selected from dichloromethane, methane Isobutyl ketone, heptane, acetone, acetonitrile, ethyl acetate, One or more of tetrahydrofuran and toluene; the stirring is preferably carried out at 20-60°C; the stirring time is preferably (4-8) days; the crystal form A of the compound of formula I and the organic solvent
  • the mass volume ratio is preferably (150mg: 1mL ⁇ 250mg): 1mL;
  • the compound of formula I is preferably the crystal form A of the compound of formula I.
  • the stirring is preferably performed at a temperature of 25°C.
  • the stirring time is preferably 0.5 hour; the ratio of the amount of the compound of formula I to the methanesulfonic acid is preferably 1.1:1.
  • the mass volume ratio of the compound of formula I to the tetrahydrofuran is preferably 25.05 mg: 1 mL.
  • the stirring is preferably performed at 25°C or 50°C.
  • the stirring time is preferably 6 days; the mass volume ratio of the crystal form A of the compound of formula I to the organic solvent is preferably 200mg: 1mL.
  • the present invention provides an amorphous mesylate salt of the compound of formula I, whose X-ray powder diffraction pattern is basically shown in Figure 70;
  • thermogravimetric analysis curve (TGA) of the amorphous mesylate of the compound of formula I shows that during heating from 41.74°C ⁇ 3°C to 107.12°C ⁇ 3°C, there is 0.8804% ⁇ 0.005% weightlessness.
  • thermogravimetric analysis curve of the amorphous mesylate salt of the compound of formula I shows a weight loss of 0.8804% during heating from 41.74°C to 107.12°C.
  • thermogravimetric analysis curve of the amorphous form of the mesylate salt of the compound of formula I is substantially as shown in FIG. 71 .
  • the modulated differential scanning calorimetry (mDSC) curve of the amorphous mesylate salt of the compound of formula I shows a glass transition temperature of 139.32°C ⁇ 3°C.
  • the modulated differential scanning calorimetry curve of the amorphous form of the mesylate salt of the compound of formula I shows a glass transition temperature of 139.32°C.
  • the modulated differential scanning calorimetry curve of the amorphous form of the mesylate salt of the compound of formula I is shown in FIG. 72 .
  • the present invention also provides an amorphous preparation method of compound mesylate of formula I, which comprises the following steps: mixing the crystal form A of compound mesylate of formula I with a mixed solvent of dichloromethane and methanol, spray drying and vacuum Dry to obtain the amorphous form of the compound mesylate of formula I; the volume ratio of the dichloromethane to methanol is preferably (1.5-2.5): 1; the spray-drying temperature is preferably 80-100° C.; The temperature of the vacuum drying is preferably 40-60° C.; the mass volume ratio of the mesylate salt crystal form A of the compound of formula I to the mixed solvent is preferably (1.5-2.5):1.
  • the volume ratio of the dichloromethane to methanol is preferably 2:1.
  • the temperature of the spray drying is preferably 90°C; the temperature of the vacuum drying is preferably 50°C.
  • the mass volume ratio of the mesylate salt crystal form A of the compound of formula I to the mixed solvent is preferably 2:1.
  • the invention provides a crystal form of the methanol solvate of the compound mesylate of formula I, whose X-ray powder diffraction pattern (XRPD) has at least three characteristic peaks at the following 2 ⁇ angles: 7.467° ⁇ 0.2°, 21.736° ⁇ 0.2° and 23.056° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the crystalline form of the compound mesylate methanol solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 7.467° ⁇ 0.2°, 8.749° ⁇ 0.2°, 10.402 ° ⁇ 0.2°, 12.311° ⁇ 0.2°, 13.029° ⁇ 0.2°, 14.797° ⁇ 0.2°, 15.301° ⁇ 0.2°, 16.972° ⁇ 0.2°, 17.749° ⁇ 0.2°, 18.506° ⁇ 0.2°, 19.113° ⁇ 0.2°, 19.731° ⁇ 0.2°, 20.376° ⁇ 0.2°, 20.765° ⁇ 0.2°, 21.736° ⁇ 0.2°, 22.341° ⁇ 0.2°, 23.056° ⁇ 0.2°, 24.415° ⁇ 0.2°, 25.173° ⁇ 0.2° , 25.485° ⁇ 0.2°, 25.855° ⁇ 0.2°, 26.711° ⁇ 0.2°, 27.292° ⁇ 0.2°, 28.226° ⁇ 0.2°, 28.516° ⁇ 0.2°, 29.02
  • the X-ray powder diffraction pattern analysis data of the crystalline form of the compound mesylate methanol solvate of the formula I is basically as shown in Table 21:
  • the X-ray powder diffraction pattern of the crystalline form of the mesylate salt methanol solvate of the compound of formula I is substantially as shown in FIG. 73 .
  • thermogravimetric analysis curve (TGA) of the crystalline form of the mesylate methanol solvate of the compound of formula I shows that during heating from 34.15°C ⁇ 3°C to 201.2°C ⁇ 3°C, there is 3.339 % ⁇ 0.5% weight loss.
  • thermogravimetric analysis curve of the crystalline form of the mesylate methanol solvate of the compound of formula I shows a weight loss of 3.339% during heating from 34.15°C to 201.2°C.
  • thermogravimetric analysis curve of the crystalline form of the compound mesylate methanol solvate of the formula I is substantially as shown in FIG. 74 Show.
  • the differential scanning calorimetry curve (DSC) of the crystalline form of the compound mesylate methanol solvate of the formula I has an onset temperature of 162.9°C ⁇ 3°C and 248.02°C ⁇ 3°C, respectively. endothermic peak.
  • the differential scanning calorimetry curve of the crystalline form of the mesylate methanol solvate of the compound of formula I has endothermic peaks with onset temperatures of 162.9°C and 248.02°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the mesylate methanol solvate of the compound of formula I has endothermic peaks with peak temperatures of 176.43°C ⁇ 3°C and 260.81°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the mesylate methanol solvate of the compound of formula I has endothermic peaks with peak temperatures of 176.43°C and 260.81°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I mesylate methanol solvate is substantially as shown in FIG. 75 .
  • the present invention also provides a method for preparing the crystal form of the compound mesylate methanol solvate of formula I, preferably comprising the following steps: the amorphous compound mesylate of formula I is stirred in a solvent to precipitate a solid, separated, After drying, the crystal form of the methanol solvate of the compound mesylate of formula I is obtained; the solvent is methanol or a mixed solvent of methanol and an organic solvent; the organic solvent is selected from one of tetrahydrofuran, ethyl acetate and acetonitrile one or more; the stirring is preferably carried out at 20 to 60°C; the stirring time is preferably 4 to 8 days; the mass volume ratio of the compound mesylate amorphous of the formula I to the solvent is preferably (150mg : 1mL ⁇ 250mg): 1mL; the volume ratio of the methanol to the organic solvent is preferably (0.5 ⁇ 1.5):1.
  • the stirring is preferably performed at 25°C, 40°C or 50°C.
  • the stirring time is preferably 6 days.
  • the mass volume ratio of the amorphous mesylate salt of the compound of formula I to the solvent is preferably 200mg: 1mL.
  • the volume ratio of the methanol to the organic solvent is preferably 1:1.
  • the present invention provides a crystal form of compound mesylate 1,4-dioxane solvate of formula I, whose X-ray powder diffraction pattern (XRPD) has three or at least four characteristic peaks at the following 2 ⁇ angles : 7.1° ⁇ 0.2°, 17.283° ⁇ 0.2°, 20.608° ⁇ 0.2° and 23.6° ⁇ 0.2°;
  • the X-ray powder diffraction pattern of the crystal form of the compound mesylate 1,4-dioxane solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 7.1° ⁇ 0.2°, 20.608 ° ⁇ 0.2° and 23.6° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound mesylate 1,4-dioxane solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 7.1° ⁇ 0.2°, 17.283 ° ⁇ 0.2°, 20.608° ⁇ 0.2°, and 23.6° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal form of the compound mesylate 1,4-dioxane solvate of formula I has characteristic peaks at the following 2 ⁇ angles: 7.1° ⁇ 0.2°, 13.26 ° ⁇ 0.2°, 13.923° ⁇ 0.2°, 17.283° ⁇ 0.2°, 17.596° ⁇ 0.2°, 18.121° ⁇ 0.2°, 18.547° ⁇ 0.2°, 19.424° ⁇ 0.2°, 20.608° ⁇ 0.2°, 22.628° ⁇ 0.2°, 23.116° ⁇ 0.2°, 23.6° ⁇ 0.2°, 23.913° ⁇ 0.2°, and 26.322° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystalline form of the compound mesylate 1,4-dioxane solvate of the formula I has characteristic peaks at the following 2 ⁇ angles: 7.1° ⁇ 0.2°, 11.029 ° ⁇ 0.2°, 12.504° ⁇ 0.2°, 13.26° ⁇ 0.2°, 13.923° ⁇ 0.2°, 14.389° ⁇ 0.2°, 15.55° ⁇ 0.2°, 17.283° ⁇ 0.2°, 17.596° ⁇ 0.2°, 18.121° ⁇ 0.2°, 18.547° ⁇ 0.2°, 19.424° ⁇ 0.2°, 20.608° ⁇ 0.2°, 21.428° ⁇ 0.2°, 21.718° ⁇ 0.2°, 22.628° ⁇ 0.2°, 23.116° ⁇ 0.2°, 23.6° ⁇ 0.2° , 23.913° ⁇ 0.2°, 24.958° ⁇ 0.2°, 25.384° ⁇ 0.2°, 26.322° ⁇ 0.2°, 26.843° ⁇ 0.2°, 27.274° ⁇ 0.2°, 28.05° ⁇ 0.2°, 28.
  • the X-ray powder diffraction pattern analysis data of the crystalline form of the compound mesylate 1,4-dioxane solvate of the formula I is basically as shown in Table 22:
  • the X-ray powder diffraction pattern of the crystalline form of the mesylate salt 1,4-dioxane solvate of the compound of formula I is substantially as shown in FIG. 76 .
  • thermogravimetric analysis curve (TGA) of the crystalline form of the compound mesylate 1,4-dioxane solvate of the formula I shows heating at 33.54°C ⁇ 3°C to 117.32°C ⁇ 3°C In the process of heating, there is a weight loss of 1.573% ⁇ 0.5%; in the process of heating from 117.32°C ⁇ 3°C to 200°C ⁇ 3°C, there is a weight loss of 5.341% ⁇ 0.5%.
  • thermogravimetric analysis curve of the crystalline form of the compound mesylate 1,4-dioxane solvate of the formula I shows a weight loss of 1.573% during heating from 33.54°C to 117.32°C ; In the process of heating from 117.32°C to 200°C, there is a weight loss of 5.341%.
  • thermogravimetric analysis curve of the crystalline form of the mesylate salt 1,4-dioxane solvate of the compound of formula I is substantially as shown in FIG. 77 .
  • the differential scanning calorimetry curve (DSC) of the crystalline form of the compound mesylate 1,4-dioxane solvate of the formula I has an onset temperature of 115.31°C ⁇ 3°C, Endothermic peaks at 156.68°C ⁇ 3°C and 256.2°C ⁇ 3°C.
  • the differential scanning calorimetry curves of the crystalline form of the compound mesylate 1,4-dioxane solvate of the formula I have initial temperatures of 115.31°C, 156.68°C and 256.2°C, respectively. endothermic peak.
  • the differential scanning calorimetry curve of the crystalline form of the compound mesylate 1,4-dioxane solvate of the formula I has There are endothermic peaks with peak temperatures of 120.45°C ⁇ 3°C, 170.41°C ⁇ 3°C and 261.15°C ⁇ 3°C, respectively.
  • the differential scanning calorimetry curve of the crystalline form of the compound mesylate 1,4-dioxane solvate of the formula I has absorption peak temperatures of 120.45°C, 170.41°C and 261.15°C, respectively. hot peak.
  • the differential scanning calorimetry curve of the crystalline form of the compound of formula I mesylate salt 1,4-dioxane solvate is substantially as shown in FIG. 78 .
  • the present invention also provides a method for preparing the crystal form of compound mesylate 1,4 dioxane solvate of formula I, preferably comprising the following steps: the compound mesylate of formula I is amorphous in 1,4 di Stir in oxane to precipitate solids, and obtain the crystal form of the compound mesylate 1,4-dioxane solvate of formula I after separation and drying; the stirring is preferably carried out at 20-60°C; the The stirring time is preferably 4-8 days; the mass volume ratio of the amorphous mesylate salt of the compound of formula I to 1,4-dioxane is preferably (150mg: 1mL-250mg): 1mL.
  • the stirring is preferably performed at 25°C, 40°C or 50°C.
  • the stirring time is preferably 6 days.
  • the mass volume ratio of the amorphous mesylate of the compound of formula I to 1,4-dioxane is preferably 200mg: 1mL.
  • the present invention also provides a pharmaceutical composition, which comprises the macrocyclic compound in the present invention or its salt, solvate in crystal form or amorphous form.
  • the present invention also provides a method of treating or preventing a disease or condition in which inhibition of EED provides benefit, comprising administering to a subject in need thereof a crystalline form or an amorphous form of a macrocyclic compound of the present invention or a salt, solvate thereof form.
  • Said disease or condition in which inhibition of EED provides benefit is preferably cancer or a proliferative disease.
  • the cancer is preferably an EED-mediated cancer.
  • the EED-mediated cancers are cancers known in the art.
  • EED-mediated cancer can be found in WO2021011713A1, which is incorporated herein by reference in its entirety.
  • the crystal form or amorphous form of the macrocyclic compound or its salt, solvate of the present invention includes but not limited to the crystal form A of the compound of formula I, the crystal form B of the compound of formula I, and the crystal form of the compound of formula I C, crystal form of toluene solvate of compound of formula I, crystal form E of compound of formula I, crystal form F of compound of formula I, crystal form G of compound of formula I, crystal of N-methylpyrrolidone solvate of compound of formula I Type, crystal form of DMF solvate of compound of formula I, crystal form K of compound of formula I, crystal form A of compound hydrochloride of formula I, crystal form of ethanol solvate of compound hydrochloride of formula I, hydrochloric acid of compound of formula I Crystal form of salt isopropanol solvate, crystal form A of compound sulfate of formula I, crystal form B of sulfate salt of compound formula I, crystal form C of sulfate salt of compound formula I, crystal form of
  • the X-ray powder diffraction pattern is detected under the condition of Cu-K ⁇ ray source.
  • the differential scanning calorimetry curve is measured under the condition that the heating rate is 10° C./min.
  • thermogravimetric analysis curve (TGA) is measured under the condition that the heating rate is 10° C./min.
  • the modulated differential scanning calorimetry curve (mDSC) is measured at a heating rate of 3° C./min.
  • the hydrogen nuclear magnetic resonance spectrum ( 1 H-NMR) is measured using deuterated DMSO as a solvent.
  • the reagents and raw materials used in the present invention are all commercially available.
  • the positive progress effect of the present invention is that: the crystalline form or amorphous form of macrocyclic compounds or their salts and solvates of the present invention has high crystallinity, good stability, low hygroscopicity, easy formation of solvates and relatively difficult One or more advantages in preparation.
  • Fig. 1 is the amorphous XRPD pattern of compound of formula I;
  • Fig. 2 is the amorphous TGA spectrum of formula I compound
  • Fig. 3 is the amorphous mDSC spectrum of formula I compound
  • Fig. 4 is the XRPD pattern of compound crystal form A of formula I;
  • Fig. 5 is the TGA spectrum of compound crystal form A of formula I;
  • Fig. 6 is the DSC spectrum of Formula I compound crystal form A
  • Fig. 7 is the DVS spectrum of compound crystal form A of formula I;
  • Fig. 8 is the XRPD spectrum of formula I compound crystal form B
  • Figure 9 is a TGA spectrum of the crystal form B of the compound of formula I.
  • Figure 10 is the DSC spectrum of Formula I compound crystal form B
  • Figure 11 is the DVS spectrum of Formula I compound crystal form B
  • Fig. 12 is the XRPD spectrum of formula I compound crystal form C
  • Fig. 13 is the XRPD pattern of formula I compound toluene solvate
  • Fig. 14 is the TGA collection of illustrative plates of formula I compound toluene solvate
  • Fig. 15 is the DSC collection of illustrative plates of formula I compound toluene solvate
  • Figure 16 is the 1 H-NMR spectrum of formula I compound toluene solvate
  • Figure 17 is the XRPD spectrum of Formula I compound crystal form E;
  • Figure 18 is the TGA spectrum of formula I compound crystal form E
  • Figure 19 is the DSC spectrum of Formula I compound crystal form E
  • Figure 20 is the XRPD spectrum of Formula I compound crystal form F
  • Figure 21 is the TGA spectrum of the crystal form F of the compound of formula I;
  • Figure 22 is the DSC spectrum of Formula I compound crystal form F
  • Figure 23 is the XRPD pattern of the crystal form G of the compound of formula I;
  • Figure 24 is the TGA spectrum of the crystal form G of the compound of formula I;
  • Figure 25 is the DSC spectrum of Formula I compound crystal form G
  • Figure 26 is the XRPD spectrum of formula I compound N-methylpyrrolidone solvate
  • Figure 27 is the TGA spectrum of formula I compound N-methylpyrrolidone solvate
  • Figure 28 is the DSC spectrum of formula I compound N-methylpyrrolidone solvate
  • Figure 29 is a 1 H-NMR spectrum of the N-methylpyrrolidone solvate of the compound of formula I;
  • Figure 30 is the XRPD pattern of formula I compound DMF solvate
  • Figure 31 is the TGA spectrum of formula I compound DMF solvate
  • Figure 32 is the DSC spectrum of formula I compound DMF solvate
  • Figure 33 is the 1 H-NMR spectrum of the DMF solvate of the compound of formula I;
  • Figure 34 is the XRPD pattern of the crystal form K of the compound of formula I;
  • Figure 35 is the DSC spectrum of the crystal form K of the compound of formula I;
  • Fig. 36 is the XPRD spectrum of formula I compound hydrochloride crystal form A;
  • Figure 37 is the TGA spectrum of Formula I compound hydrochloride crystal form A
  • Figure 38 is the DSC spectrum of Formula I compound hydrochloride crystal form A
  • Figure 39 is the DVS spectrum of formula I compound hydrochloride crystal form A
  • Figure 40 is the XPRD spectrum of the compound of formula I hydrochloride crystal form A after DVS
  • Figure 41 is the XRPD spectrum of formula I compound hydrochloride ethanol solvate
  • Figure 42 is the TGA spectrum of formula I compound hydrochloride ethanol solvate
  • Figure 43 is the DSC spectrum of formula I compound hydrochloride ethanol solvate
  • Figure 44 is the XRPD pattern of formula I compound hydrochloride isopropanol solvate
  • Figure 45 is the TGA collection of illustrative plates of formula I compound hydrochloride isopropanol solvate
  • Figure 46 is the DSC spectrum of formula I compound hydrochloride isopropanol solvate
  • Figure 47 is the XPRD spectrum of formula I compound sulfate crystal form A
  • Figure 48 is the TGA spectrum of formula I compound sulfate crystal form A
  • Figure 49 is the DSC spectrum of formula I compound sulfate crystal form A
  • Figure 50 is the DVS spectrum of formula I compound sulfate crystal form A
  • Figure 51 is the XPRD spectrum of the compound sulfate crystal form A sample of formula I after DVS;
  • Figure 52 is the XRPD pattern of formula I compound sulfate crystal form B;
  • Figure 53 is the TGA spectrum of formula I compound sulfate crystal form B
  • Figure 54 is the DSC spectrum of formula I compound sulfate crystal form B
  • Figure 55 is the XRPD pattern of formula I compound sulfate crystal form C;
  • Figure 56 is the XRPD pattern of formula I compound sulfate toluene solvate
  • Figure 57 is the TGA spectrum of formula I compound sulfate toluene solvate
  • Figure 58 is the DSC spectrum of formula I compound sulfate toluene solvate
  • Figure 59 is the XRPD pattern of the p-toluenesulfonate salt crystal form A of the compound of formula I;
  • Figure 60 is the TGA spectrum of the p-toluenesulfonate salt crystal form A of the compound of formula I;
  • Figure 61 is the DSC spectrum of the p-toluenesulfonate salt crystal form A of the compound of formula I;
  • Figure 62 is the XRD pattern of formula I compound besylate salt crystal form A
  • Figure 63 is the TGA spectrum of the crystalline form A of the besylate salt of the compound of formula I;
  • Figure 64 is the DSC spectrum of formula I compound besylate salt crystal form A
  • Figure 65 is the XRPD pattern of formula I compound methanesulfonate crystal form A
  • Figure 66 is the TGA spectrum of formula I compound methanesulfonate crystal form A
  • Figure 67 is the DSC spectrum of formula I compound mesylate salt crystal form A
  • Figure 68 is the DVS spectrum of formula I compound methanesulfonate crystal form A
  • Figure 69 is the XRPD pattern of the compound mesylate salt crystal form A of formula I after DVS;
  • Figure 70 is the XRPD spectrum of the amorphous form of mesylate salt of the compound of formula I;
  • Figure 71 is the TGA spectrum of the amorphous form of mesylate of the compound of formula I;
  • Figure 72 is the mDSC spectrum of the amorphous form of the mesylate salt of the compound of formula I;
  • Figure 73 is the XRPD spectrum of formula I compound mesylate methanol solvate
  • Figure 74 is the TGA spectrum of formula I compound mesylate methanol solvate
  • Figure 75 is the DSC spectrum of formula I compound mesylate methanol solvate
  • Figure 76 is the XRPD spectrum of formula I compound methanesulfonate 1,4-dioxane solvate
  • Figure 77 is the TGA spectrum of formula I compound methanesulfonate 1,4 dioxane solvate
  • Fig. 78 is the DSC spectrum of the mesylate salt 1,4-dioxane solvate of the compound of formula I.
  • the 88% acetone is a mixed solvent of acetone and water with a volume ratio of 4:1.
  • each embodiment is operated at room temperature, and the room temperature is generally 20-30°C, preferably 25°C.
  • the time for the overnight stirring is generally 12-16 hours, preferably 14 hours.
  • the parameter setting of DVS test is as follows:
  • TGA and DSC spectra were collected on TA Q5000/5500 thermogravimetric analyzer and TA Q2000/2500 differential scanning calorimeter respectively, and the parameters were set as follows:
  • the parameters of the mDSC test are set as follows: amplitude ⁇ 1°C, modulation period 60s, heating rate 3°C/min, temperature range: 25-350°C.
  • 1 H-NMR is tested by Qone-WNMR-I-AS400, and the parameters are set as: solvent deuterated DMSO, scan times 18, temperature 293.4K, magnetic field strength 400MHz.
  • HPLC high performance liquid chromatography
  • Embodiment 6 is a diagrammatic representation of Embodiment 6
  • Embodiment 7 is a diagrammatic representation of Embodiment 7:
  • Embodiment 8 Preparation of Formula I compound crystal form G:
  • Embodiment 9 is a diagrammatic representation of Embodiment 9:
  • Embodiment 10 the preparation of formula I compound DMF solvate:
  • Embodiment 25-formula I compound crystal form A is the polycrystalline screening test (suspension method) of starting material
  • Embodiment 26-formula I compound crystal form B is the polymorph screening test (suspension method) of starting material
  • Embodiment 27-formula I compound is the polymorph screening test (suspension method) of starting material
  • DCM was used as a good solvent, and MeOH, EtOH, THF, and EA were used as anti-solvents to perform polycrystalline screening of the compound of formula I. It was dissolved in both DCM and MeOH systems, and the suspension samples were stirred for 2 days and then centrifuged quickly. After removal of the supernatant, the resulting pellet was dried under vacuum at 25 °C for 20 h for physical characterization.
  • Example 28 Polymorphic Screening of Formula I Compound Amorphous as Starting Material-(Suspension Method)
  • Table 26 takes the amorphous sample as the polymorph screening result (suspension method) of starting material
  • Example 31 Polymorph screening research on sulfate salt of formula I compound (anti-solvent method)
  • Example 34 Polymorph screening research of compound mesylate of formula I (gas-liquid diffusion method)
  • Example 35 Polymorph screening research of compound mesylate of formula I (slow evaporation method)
  • Example 37 Compound of formula I, hydrochloride, mesylate, sulfate stability study
  • the XRPD results show that: the formula I compound crystal form A, the formula I compound crystal form B, the formula I compound hydrochloride salt crystal form A, the formula I compound mesylate salt crystal form A and the formula I compound sulfate salt crystal form A after 30
  • the crystal form of Tianhou did not change, showing good physical stability.

Abstract

本发明公开了一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式及其制备方法和应用。其中所述的大环类化合物的结构如式I所示。

Description

一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式
本申请要求申请日为2022/1/30的中国专利申请PCT/CN2022/075258的优先权。本申请引用上述中国专利申请的全文。
技术领域
本发明属于药物化学领域，特别涉及一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式及其制备方法和应用。
背景技术
多梳家族(PcG)蛋白是一类许多人类癌症中出现失调的染色质修饰酶。多梳抑制复合物(PRC2，Polycomb Repressive Complex2)包括SUZ12(zeste 12的抑制因子)、EED和催化亚单位EZH2(zeste同源物2的强化子因子)，通过甲基化目标基因启动子区域及其周围的核心组蛋白H3赖氨酸27(H3K27me3)来抑制基因。PRC2是参与基因转录表观遗传调控的细胞机制的重要组成部分，在发育、组织分化和再生中发挥关键作用(Moritz and Trievel，J.Biol.Chem 293(36)：13805-13814(2018)；Fiskus et al.，Mol Cancer Ther 5(12)：3096-3014(2006))。
PRC2的甲基转移酶活性至少需要EED和SUZ12的参与。EED、SUZ12和EZH2在许多癌症中过度表达，包括但不限于乳腺癌、***癌和肝细胞癌。本领域存在对抑制EED活性的小分子用于治疗癌症和其他疾病的需求。
在WO2021011713A1中公开了式I化合物，式I化合物是一种有效的EED抑制剂，可用于治疗或预防EED过度表达介导的一种或多种疾病。
一般来讲，药用活性成分的纯度低、溶解度低和稳定性差，会影响其在体内的吸收，导致生物利用度低，不利于进一步的药物开发。而药用活性成分的盐型、溶剂合物或其结晶形式等结构往往影响 其物理、化学性质。
目前未见式I化合物的盐或其晶型的报道。因此，通过制备盐或其晶型改善式I化合物的各方面性质是很有必要的。
发明内容
本发明要解决的技术问题是为了克服现有的EED抑制剂存在结晶性、溶解度、纯度和/或稳定性差的缺陷，而提供一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式。本发明的大环类化合物或其盐、溶剂合物的结晶形式或无定形形式具有以下一个或多个优点：结晶度高、稳定性好、引湿性低、易形成溶剂合物和较难制备。
本发明是通过下述技术方案来解决上述技术问题。
本发明提供了一种式I化合物的晶型A，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个、至少六个或至少七个特征峰：5.181°±0.2°、6.254°±0.2°、8.708°±0.2°、11.496°±0.2°、11.743°±0.2°、16.538°±0.2°和20.361°±0.2°；
在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、16.538°±0.2°和20.361°±0.2°。
在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、11.743°±0.2°、16.538°±0.2°和20.361°±0.2°。
在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、11.743°±0.2°、16.538°±0.2°和20.361°±0.2°。
在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、11.496°±0.2°、11.743°±0.2°和16.538°±0.2°、20.361°±0.2°。
在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、8.708°±0.2°、11.496°±0.2°、11.743°±0.2°、16.538°±0.2°和20.361°±0.2°。
在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、8.708°±0.2°、10.304°±0.2°、11.496°±0.2°、11.743°±0.2°、16.538°±0.2°、18.275°±0.2°、18.58°±0.2°、20.361°±0.2°、21.113°±0.2°、23.495°±0.2°、24.232°±0.2°、26.337°±0.2°和26.767°±0.2°。
在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、7.052°±0.2°、8.708°±0.2°、10.304°±0.2°、10.633°±0.2°、11.496°±0.2°、11.743°±0.2°、12.466°±0.2°、12.849°±0.2°、13.224°±0.2°、14.047°±0.2°、14.784°±0.2°、15.004°±0.2°、15.917°±0.2°、16.538°±0.2°、17.529°±0.2°、17.726°±0.2°、18.275°±0.2°、18.58°±0.2°、19.083°±0.2°、19.291°±0.2°、19.848°±0.2°、20.361°±0.2°、21.113°±0.2°、22.221°±0.2°、22.458°±0.2°、23.066°±0.2°、23.495°±0.2°、23.743°±0.2°、24.232°±0.2°、25.19°±0.2°、25.885°±0.2°、26.337°±0.2°、26.767°±0.2°、27.119°±0.2°、27.832°±0.2°、28.188°±0.2°、29.263°±0.2°和30.363°±0.2°。
在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱解析数据基本如表1所示：
表1.式I化合物的晶型A的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物的晶型A的X射线粉末衍射图谱基本如图4所示。
在一实施方案中，所述式I化合物的晶型A的热重分析曲线(TGA)显示在29.6℃±3℃加热至150.14℃±3℃过程中，有0.1264％±0.2％的失重。
在一实施方案中，所述式I化合物的晶型A的热重分析曲线显示在29.6℃加热至150.14℃过程中，有0.1264％的失重。
在一实施方案中，所述晶型A的热重分析曲线基本如图5所示。
在一实施方案中，所述式I化合物的晶型A的差示扫描量热曲线(DSC)具有起始温度分别为327.1℃±3℃和334.5℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型A的差示扫描量热曲线具有起始温度分别为327.1℃和334.5℃的吸热峰。
在一实施方案中，所述式I化合物的晶型A的差示扫描量热曲线具有峰值温度分别为330.45℃±3℃和336.58℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型A的差示扫描量热曲线具有峰值温度分别为330.45℃和336.58℃的吸热峰。
在一实施方案中，所述式I化合物的晶型A的差示扫描量热曲线基本如图6所示。
在一实施方案中，所述式I化合物的晶型A的动态蒸汽吸附曲线(DVS)显示在25℃和80％RH 下吸湿增重为0.44％±0.2％。
在一实施方案中，所述式I化合物的晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.44％。
在一实施方案中，所述式I化合物的晶型A的动态蒸汽吸附曲线如图7所示。
本发明还提供了一种式I化合物的晶型A的制备方法，优选下列任一方法：
方法一包括以下步骤：式I化合物的晶型B在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述溶剂为有机溶剂或有机溶剂和水的混合溶剂；所述有机溶剂选自甲醇、乙醇、二氯甲烷和乙腈中的一种或多种；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；在所述式I化合物的晶型B与所述溶剂的质量体积比优选为(250mg～350mg)∶1mL；当所述溶剂为有机溶剂和水的混合溶剂时，所述有机溶剂和水的体积比优选为(0.5～3.5)∶1；其中，当所述有机溶剂为乙醇时，所述搅拌在40～60℃温度下进行；当所述溶剂为甲醇和水体积比为(2.5～3.5)∶1的混合溶剂时，所述搅拌在20～30℃温度下进行；当所述溶剂为甲醇和水的体积比为(0.5～1.5)∶1的混合溶剂时，所述搅拌在40～60℃温度下进行；
方法二包括以下步骤：式I化合物的晶型B在二氯甲烷中搅拌得到混合溶液，加入反溶剂并搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述反溶剂选自乙醇、四氢呋喃和乙酸乙酯中的一种或多种；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型B与所述二氯甲烷的质量体积比优选为(50mg～200mg)∶1mL；所述二氯甲烷与所述反溶剂的体积比优选为(0.5～2.5)∶1；
方法三包括以下步骤：式I化合物的无定形在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述溶剂为有机溶剂或有机溶剂和水的混合溶剂；所述有机溶剂选自甲醇、乙醇、乙腈、异丙醇和二氯甲烷中的一种或多种；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定型与所述溶剂的质量体积比优选为(200mg～350mg)∶1mL；当所述溶剂为有机溶剂和水的混合溶剂时，所述有机溶剂和水的体积比优选为(0.5～3.5)∶1；其中，当所述溶剂为甲醇和水的混合溶剂时，所述甲醇和水的体积比为(2.5～3.5)∶1；当所述溶剂为乙醇或乙醇和水的体积比为1∶1的混合溶剂时，所述搅拌在40～60℃温度下进行；
方法四包括以下步骤：式I化合物盐酸盐晶型A在有机溶剂和水的混合溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述有机溶剂选自甲醇和乙醇中的一种或两种；所述搅拌优选在35～45℃温度下进行；所述搅拌的时间优选为2.5～3.5天；所述式I化合物盐酸盐与所述混合溶剂的质量体积比优选为(100mg～200mg)∶1mL；所述有机溶剂和水的体积比优选为(2.5～3.5)∶1；
方法五包括以下步骤：式I化合物硫酸盐晶型A在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述溶剂为甲醇、有机溶剂和水的混合溶剂或甲醇和二氯甲烷的混合溶剂；所述有机溶剂选自甲醇、乙醇和乙腈中的一种或多种；所述搅拌优选在35～45℃温度下进行；所述搅拌的时间优选为2.5～3.5天；所述式I化合物硫酸盐晶型A与所述溶剂的质量体积比优选为(100mg～200mg)∶1mL；所述有机溶剂和水的体积比优选为(0.5～3.5)∶1；
方法六包括以下步骤：式I化合物硫酸盐晶型A和甲醇混合，加入庚烷至析出固体并搅拌，经分离、干燥后得到式I化合物的晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.5～1.5天；所述式I化合物硫酸盐晶型A与所述甲醇的质量体积比优选为(30mg～40mg)∶1mL；
方法七包括以下步骤：式I化合物甲磺酸盐晶型A在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述溶剂为水或有机溶剂和水的混合溶剂；所述有机溶剂选自甲醇和乙腈中的一种或两种；所述搅拌优选在35～45℃温度下进行；所述搅拌的时间优选为2.5～3.5天；所述式I化合物甲磺酸盐晶型A与所述溶剂的质量体积比优选为(100mg～200mg)∶1mL；
方法八包括以下步骤：式I化合物甲磺酸盐晶型A和DMF混合，加入乙腈至析出固体并搅拌，经分离、干燥后得到式I化合物的晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为12～16小时；所述式I化合物甲磺酸盐与所述DMF的质量体积比优选为(30mg～70mg)∶1mL；
方法九包括以下步骤：式I化合物甲磺酸盐晶型A在溶剂中搅拌至澄清，经挥发、干燥后得到式I化合物的晶型A；所述溶剂为甲醇，或乙醇和乙酸甲酯的混合溶剂；所述有机溶剂选自甲醇和乙腈中的一种或两种；所述挥发、干燥优选在20～30℃温度下进行；所述乙醇和乙酸甲酯的体积比优选为(1.5～2.5)∶1。
在一实施方案中，所述方法一中，所述搅拌优选在25℃或50℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的晶型B与所述溶剂的质量体积比优选为300mg∶1mL。当所述溶剂为有机溶剂和水的混合溶剂时，所述有机溶剂和水的体积比优选为1∶1或3∶1。其中，当所述有机溶剂为乙醇时，所述搅拌优选在50℃温度下进行。当所述溶剂为甲醇和水体积比为3∶1的混合溶剂时，所述搅拌优选在25℃温度下进行。当所述溶剂为甲醇和水的体积比为1∶1的混合溶剂时，所述搅拌优选在50℃温度下进行。
在一实施方案中，所述方法二中，所述搅拌优选在25℃或50℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的晶型B与所述二氯甲烷的质量体积比优选为100mg∶1mL或180mg∶1mL。所述二氯甲烷与所述反溶剂的体积比优选为1∶1或2∶1。
在一实施方案中，所述方法三中，所述搅拌优选在25℃或50℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的无定型与所述溶剂的质量体积比优选为250mg∶1mL或300mg∶1mL。当所述溶剂为有机溶剂和水的混合溶剂时，所述有机溶剂和水的体积比优选为1∶1或3∶1。其中，当所述溶剂为甲醇和水的混合溶剂时，所述甲醇和水的体积比优选为3∶1。当所述溶剂为乙醇或乙醇和水的体积比为1∶1的混合溶剂时，所述搅拌优选在50℃温度下进行。
在一实施方案中，所述方法四中，所述搅拌优选在40℃温度下进行。所述搅拌的时间优选为3天。所述式I化合物盐酸盐与所述混合溶剂的质量体积比优选为150mg∶1mL。所述有机溶剂和水的体积比优选为3∶1。
在一实施方案中，所述方法五中，所述搅拌优选在40℃温度下进行。所述搅拌的时间优选为3天。所述式I化合物硫酸盐与所述溶剂的质量体积比优选为150mg∶1mL。所述有机溶剂和水的体积比 优选为1∶1或3∶1。
在一实施方案中，所述方法六中，所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为1天。所述式I化合物硫酸盐与所述甲醇的质量体积比优选为35.71mg∶1mL。
在一实施方案中，所述方法七中，所述搅拌优选在40℃温度下进行。所述搅拌的时间优选为3天。所述式I化合物甲磺酸盐与所述溶剂的质量体积比优选为150mg∶1mL。
在一实施方案中，所述方法八中，所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为14小时。所述式I化合物甲磺酸盐与所述DMF的质量体积比优选为50mg∶1mL。
在一实施方案中，所述方法九中，所述挥发、干燥优选在25℃温度下进行。所述乙醇和乙酸甲酯的体积比优选为2∶1。
本发明提供了一种式I化合物的晶型B，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个、至少六个或至少七个特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°、18.116°±0.2°、19.987°±0.2°、22.225°±0.2°和26.884°±0.2°；
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°和16.575°±0.2°。
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°和18.116°±0.2°。
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°、18.116°±0.2°和26.884°±0.2°。
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°、18.116°±0.2°、19.987°±0.2°和26.884°±0.2°。
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°、18.116°±0.2°、19.987°±0.2°、22.225°±0.2°和26.884°±0.2°。
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、13.263°±0.2°、14.747°±0.2°、16.575°±0.2°、17.259°±0.2°、18.116°±0.2°、19.558°±0.2°、19.987°±0.2°、21.566°±0.2°、22.225°±0.2°、23.456°±0.2°、23.999°±0.2°和26.884°±0.2°。
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰： 5.884°±0.2°、13.263°±0.2°、13.868°±0.2°、14.299°±0.2°、14.747°±0.2°、15.622°±0.2°、16.575°±0.2°、17.259°±0.2°、18.116°±0.2°、19.558°±0.2°、19.987°±0.2°、21.566°±0.2°、22.225°±0.2°、23.258°±0.2°、23.456°±0.2°、23.999°±0.2°、24.894°±0.2°、26.884°±0.2°、29.551°±0.2°、31.442°±0.2°和31.695°±0.2°。
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、10.54°±0.2°、11.629°±0.2°、12.427°±0.2°、13.263°±0.2°、13.868°±0.2°、14.299°±0.2°、14.747°±0.2°、15.622°±0.2°、16.575°±0.2°、17.259°±0.2°、18.116°±0.2°、19.558°±0.2°、19.987°±0.2°、21.566°±0.2°、22.225°±0.2°、23.258°±0.2°、23.456°±0.2°、23.999°±0.2°、24.894°±0.2°、25.501°±0.2°、26.884°±0.2°、27.328°±0.2°、27.7°±0.2°、28.048°±0.2°、28.557°±0.2°、29.551°±0.2°、30.497°±0.2°、30.859°±0.2°、31.442°±0.2°、31.695°±0.2°、32.436°±0.2°、33.328°±0.2°、34.071°±0.2°、34.715°±0.2°、35.553°±0.2°、35.842°±0.2°和36.347°±0.2°。
在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱解析数据基本如表2所示：
表2.式I化合物的晶型B的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物的晶型B的X射线粉末衍射图谱基本如图8所示。
在一实施方案中，所述式I化合物的晶型B的热重分析曲线(TGA)显示在28.73℃±3℃加热至149.63℃±3℃过程中，有0.1817％±0.2％的失重。
在一实施方案中，所述式I化合物的晶型B的热重分析曲线显示在28.73℃加热至149.63℃过程中，有0.1817％的失重。
在一实施方案中，所述式I化合物的晶型B的热重分析曲线基本如图9所示。
在一实施方案中，所述式I化合物的晶型B的差示扫描量热曲线(DSC)具有起始温度分别为249.1℃±3℃和336.8℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型B的差示扫描量热曲线具有起始温度分别为249.1℃和336.8℃的吸热峰。
在一实施方案中，所述式I化合物的晶型B的差示扫描量热曲线具有峰值温度分别为252.54℃±3℃和337.59℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型B的差示扫描量热曲线具有峰值温度分别为252.54℃和337.59℃的吸热峰。
在一实施方案中，所述式I化合物的晶型B的差示扫描量热曲线具有峰值温度为255.28℃±3℃的 放热峰。
在一实施方案中，所述式I化合物的晶型B的差示扫描量热曲线具有峰值温度为255.28℃的放热峰。
在一实施方案中，所述式I化合物的晶型B的差示扫描量热曲线基本如图10所示。
在一实施方案中，所述式I化合物的晶型B的动态蒸汽吸附曲线(DVS)显示在25℃和80％RH下吸湿增重为0.84％±0.2％。
在一实施方案中，所述式I化合物的晶型B的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.84％。
在一实施方案中，所述式I化合物的晶型B的动态蒸汽吸附曲线如图11所示。
本发明还提供了一种式I化合物的晶型B的制备方法，优选下列任一方法：
方法一包括以下步骤：式I化合物的晶型A在有机溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物晶型B，所述有机溶剂选自乙酸乙酯、丙酮、88％丙酮和四氢呋喃中的一种或多种；所述搅拌优选在20～60℃下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型A与有机溶剂的质量体积比优选为(80mg∶1mL～250mg)∶1mL；其中，当所述有机溶剂为四氢呋喃时，所述搅拌在35～45℃温度下进行；
方法二包括以下步骤：式I化合物的无定形在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型B；所述溶剂为有机溶剂或丙酮和水的体积比为(0.25～0.75)∶1的混合溶剂；所述有机溶剂选自乙醇、乙酸乙酯、丙酮、甲基异丁基酮和甲基叔丁基醚中的一种或多种；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定型与所述溶剂的质量体积比优选为(250mg～350mg)∶1mL；其中，当所述有机溶剂为乙酸乙酯或甲基叔丁基醚时，所述搅拌在40～60℃温度下进行；当所述有机溶剂为乙醇或甲基异丁基酮时，所述搅拌在20～30℃温度下进行；
方法三包括以下步骤：式I化合物盐酸盐晶型A或式I化合物硫酸盐晶型A在88％丙酮中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型B；所述搅拌优选在35～45℃温度下进行；所述搅拌的时间优选为2.5～3.5天；所述式I化合物盐酸盐晶型A或式I化合物硫酸盐晶型A与所述88％丙酮的质量体积比优选为(100mg～200mg)∶1mL；
方法四包括以下步骤：式I化合物硫酸盐晶型A和甲醇混合，加入丙酮至析出固体并搅拌，经分离、干燥后得到式I化合物的晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.5～1.5天；所述式I化合物硫酸盐晶型A与所述甲醇的质量体积比优选为(30mg～40mg)∶1mL；
方法五包括以下步骤：式I化合物甲磺酸盐晶型A在溶剂中搅拌至澄清，经挥发、干燥后得到式I化合物的晶型A；所述溶剂为乙醇，或甲醇和有机溶剂的混合溶剂；所述有机溶剂选自乙酸甲酯和二氯甲烷中的一种或两种；所述挥发、干燥优选在20～30℃温度下进行；所述乙醇和乙酸甲酯的体积比优选为(1.5～2.5)∶1。
在一实施方案中，所述方法一中，所述搅拌优选在25℃、40℃或50℃温度下进行。所述搅拌的 时间优选为2天。所述式I化合物的晶型A与有机溶剂的质量体积比优选为100mg∶1mL、150mg∶1mL或200mg∶1mL。其中，当所述有机溶剂为四氢呋喃时，所述搅拌优选在40℃温度下进行。
在一实施方案中，所述方法二中，所述丙酮和水的体积比优选为1∶2。所述搅拌优选在25℃或50℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的无定型与所述溶剂的质量体积比优选为300mg∶1mL。其中，当所述有机溶剂为乙酸乙酯或甲基叔丁基醚时，所述搅拌优选在50℃温度下进行。当所述有机溶剂为乙醇或甲基异丁基酮时，所述搅拌优选在25℃温度下进行。
在一实施方案中，所述方法三中，所述搅拌优选在40℃温度下进行。所述搅拌的时间优选为3天。所述式I化合物盐酸盐晶型A或式I化合物硫酸盐晶型A与所述88％丙酮的质量体积比优选为150mg∶1mL。
在一实施方案中，所述方法四中，所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为1天。所述式I化合物硫酸盐晶型A与所述甲醇的质量体积比优选为35.71mg∶1mL。
在一实施方案中，所述方法五中，所述挥发、干燥优选在25℃温度下进行。所述甲醇和有机溶剂的体积比优选为2∶1。
本发明提供了一种式I化合物的晶型C，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个、至少六个、至少七个或至少八个特征峰：5.085°±0.2°、9.623°±0.2°、10.012°±0.2°、10.95°±0.2°、15.058°±0.2°、18.077°±0.2°、19.423°±0.2°和22.479°±0.2°；
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.085°±0.2°、9.623°±0.2°和22.479°±0.2°。
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.085°±0.2°、9.623°±0.2°、18.077°±0.2°和22.479°±0.2°。
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.085°±0.2°、9.623°±0.2°、15.058°±0.2°、18.077°±0.2°和22.479°±0.2°。
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.085°±0.2°、9.623°±0.2°、10.95°±0.2°、15.058°±0.2°和18.077°±0.2°、22.479°±0.2°。
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.085°±0.2°、9.623°±0.2°、10.012°±0.2°、10.95°±0.2°、15.058°±0.2°、18.077°±0.2°和22.479°±0.2°。
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.085°±0.2°、9.623°±0.2°、10.012°±0.2°、10.95°±0.2°、15.058°±0.2°、18.077°±0.2°、19.423°±0.2°和22.479°±0.2°。
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.085°±0.2°、9.623°±0.2°、10.012°±0.2°、10.637°±0.2°、10.95°±0.2°、13.558°±0.2°、14.065°±0.2°、15.058°±0.2°、17.435°±0.2°、18.077°±0.2°、19.129°±0.2°、19.423°±0.2°、19.947°±0.2°、20.709°±0.2°、22.147°±0.2°、22.479°±0.2°、23.435°±0.2°、24.781°±0.2°、26.883°±0.2°、29.492°±0.2°和31.713°±0.2°。
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.085°±0.2°、9.623°±0.2°、10.012°±0.2°、10.637°±0.2°、10.95°±0.2°、11.707°±0.2°、13.558°±0.2°、14.065°±0.2°、15.058°±0.2°、17.435°±0.2°、18.077°±0.2°、19.129°±0.2°、19.423°±0.2°、19.947°±0.2°、20.709°±0.2°、22.147°±0.2°、22.479°±0.2°、23.435°±0.2°、24.781°±0.2°、25.439°±0.2°、26.548°±0.2°、26.883°±0.2°、28.552°±0.2°、28.853°±0.2°、29.492°±0.2°、31.713°±0.2°、32.514°±0.2°和33.392°±0.2°。
在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱解析数据基本如表3所示：
表3.式1化合物晶型C的XRPD衍射数据

在一实施方案中，所述式I化合物的晶型C的X射线粉末衍射图谱基本如图12所示。
本发明还提供了一种式I化合物的晶型C的制备方法，优选包括以下步骤：式I化合物的晶型A在四氢呋喃中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型C；所述搅拌在20～30℃温度下进行；所述搅拌的时间优选为0.5～1.5天；所述式I化合物的晶型A与所述四氢呋喃的质量体积比优选为20mg∶1mL～50mg∶1mL。
在一实施方案中，所述式I化合物的晶型C的制备方法中，所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为1天。所述式I化合物的晶型A与所述四氢呋喃的质量体积比优选为33.33mg∶1mL。
本发明提供了一种式I化合物甲苯溶剂合物的晶型，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个或至少五个特征峰：5.298°±0.2°、14.611°±0.2°、18.098°±0.2°、20.024°±0.2°和20.9°±0.2°；
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.298°±0.2°、14.611°±0.2°和20.9°±0.2°。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具 有特征峰：5.298°±0.2°、14.611°±0.2°、18.098°±0.2°和20.9°±0.2°。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.298°±0.2°、14.611°±0.2°、18.098°±0.2°、20.024°±0.2°和20.9°±0.2°。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.298°±0.2°、10.439°±0.2°、11.496°±0.2°、13.324°±0.2°、14.611°±0.2°、18.098°±0.2°、20.024°±0.2°、20.9°±0.2°、21.837°±0.2°、22.303°±0.2°、23.122°±0.2°、24.506°±0.2°、25.886°±0.2°和27.506°±0.2°。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的X射线粉末衍射图谱解析数据基本如表4所示：5.298°±0.2°、5.745°±0.2°、9.662°±0.2°、10.439°±0.2°、11.496°±0.2°、13.324°±0.2°、14.101°±0.2°、14.611°±0.2°、14.98°±0.2°、15.64°±0.2°、16.769°±0.2°、17.628°±0.2°、18.098°±0.2°、19.258°±0.2°、20.024°±0.2°、20.9°±0.2°、21.232°±0.2°、21.837°±0.2°、22.303°±0.2°、22.698°±0.2°、23.122°±0.2°、24.506°±0.2°、25.128°±0.2°、25.886°±0.2°、26.977°±0.2°、27.506°±0.2°、28.28°±0.2°、29.357°±0.2°、30.232°±0.2°、31.28°±0.2°、31.492°±0.2°、33.412°±0.2°、33.764°±0.2°、35.277°±0.2°和35.683°±0.2°。
表4.式I化合物甲苯溶剂合物的晶型的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的X射线粉末衍射图谱基本如图13所示。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的热重分析曲线(TGA)显示在34.82℃±3℃加热至147.13℃±3℃过程中，有5.19％±0.5％的失重。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的热重分析曲线显示在34.82℃加热至147.13℃过程中，有5.19％的失重。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的热重分析曲线基本如图14所示。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的差示扫描量热曲线(DSC)具有起始温度分别为120.68℃±3℃和334.15℃±3℃的吸热峰。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的差示扫描量热曲线具有起始温度分别为120.68℃和334.15℃的吸热峰。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为151.28℃±3℃和336.25℃±3℃的吸热峰。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为151.28℃和336.25℃的吸热峰。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的差示扫描量热曲线具有峰值温度为238.88℃±3℃的放热峰。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的差示扫描量热曲线具有峰值温度为 238.88℃的放热峰。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的差示扫描量热曲线基本如图15所示。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的核磁共振氢谱(1H-NMR)显示有重量百分比为3.27％±0.5％的甲苯。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的核磁共振氢谱显示有重量百分比为3.27％的甲苯。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的核磁共振氢谱基本如图16所示。
本发明还提供了一种式I化合物甲苯溶剂合物的晶型的制备方法，优选包括以下步骤：式I化合物的晶型B在甲苯中搅拌以析出固体，经分离、干燥后得到式I化合物甲苯溶剂合物的晶型；所述搅拌在20～30℃的温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型B与所述甲苯的质量体积比优选为(250mg～350mg)∶1mL。
在一实施方案中，所述式I化合物甲苯溶剂合物的晶型的制备方法中，所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的晶型B与所述甲苯的质量体积比优选为300mg∶1mL。
本发明提供了一种式I化合物的晶型E，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个、至少六个或至少七个特征峰：6.001°±0.2°、10.676°±0.2°、11.203°±0.2°、12.526°±0.2°、13.09°±0.2°、16.891°±0.2°和21.179°±0.2°；
在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.001°±0.2°、10.676°±0.2°和11.203°±0.2°。
在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.001°±0.2°、10.676°±0.2°、11.203°±0.2°和12.526°±0.2°。
在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.001°±0.2°、10.676°±0.2°、11.203°±0.2°、12.526°±0.2°和16.891°±0.2°。
在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.001°±0.2°、10.676°±0.2°、11.203°±0.2°、12.526°±0.2°、16.891°±0.2°和21.179°±0.2°。
在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱在如下2θ角处具有特征峰： 6.001°±0.2°、10.676°±0.2°、11.203°±0.2°、12.526°±0.2°、13.09°±0.2°、16.891°±0.2°和21.179°±0.2°。
在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.001°±0.2°、6.484°±0.2°、8.32°±0.2°、10.676°±0.2°、11.203°±0.2°、12.526°±0.2°、13.09°±0.2°、13.771°±0.2°、14.61°±0.2°、14.982°±0.2°、15.429°±0.2°、16.423°±0.2°、16.891°±0.2°、18.034°±0.2°、18.757°±0.2°、20.239°±0.2°、20.864°±0.2°、21.179°±0.2°、22.618°±0.2°、23.802°±0.2°和26.217°±0.2°。
在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.001°±0.2°、6.484°±0.2°、8.32°±0.2°、10.676°±0.2°、11.203°±0.2°、12.526°±0.2°、13.09°±0.2°、13.771°±0.2°、14.61°±0.2°、14.982°±0.2°、15.429°±0.2°、16.423°±0.2°、16.891°±0.2°、18.034°±0.2°、18.757°±0.2°、20.239°±0.2°、20.864°±0.2°、21.179°±0.2°、22.618°±0.2°、23.802°±0.2°、25.594°±0.2°、26.217°±0.2°、27.198°±0.2°、28.009°±0.2°和30.812°±0.2°。
在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱解析数据基本如表5所示：
表5.式I化合物的晶型E的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物的晶型E的X射线粉末衍射图谱基本如图17所示。
在一实施方案中，所述式I化合物的晶型E的热重分析曲线(TGA)显示在30.78℃±3℃加热至132.28℃±3℃过程中，有1.477％±0.5％的失重；在132℃±3℃加热至232℃±3℃过程中，有1.849％±0.5％的失重。
在一实施方案中，所述式I化合物的晶型E的热重分析曲线显示在30.78℃加热至132.28℃过程中，有1.477％的失重；在132.28℃加热至232.17℃过程中，有1.849％的失重。
在一实施方案中，所述式I化合物的晶型E的热重分析曲线基本如图18所示。
在一实施方案中，所述式I化合物的晶型E的差示扫描量热曲线(DSC)具有起始温度分别为190.41℃±3℃和334.9℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型E的差示扫描量热曲线具有起始温度分别为190.41℃和334.9℃的吸热峰。
在一实施方案中，所述式I化合物的晶型E的差示扫描量热曲线具有峰值温度分别为199.65℃±3℃和336.81℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型E的差示扫描量热曲线具有峰值温度分别为199.65℃和336.81℃的吸热峰。
在一实施方案中，所述式I化合物的晶型E的差示扫描量热曲线具有峰值温度为205.95℃±3℃的放热峰。
在一实施方案中，所述式I化合物的晶型E的差示扫描量热曲线具有峰值温度为205.95℃的放热峰。
在一实施方案中，所述式I化合物的晶型E的差示扫描量热曲线基本如图19所示。
本发明还提供了一种式I化合物的晶型E的制备方法，优选下列任一方法：
方法一包括以下步骤：式I化合物的晶型B在甲基叔丁基醚中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型E；所述搅拌在20～30℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型B与所述甲基叔丁基醚的质量体积比优选为(50mg～350mg)∶1mL；
方法二包括以下步骤：式I化合物的无定型在有机溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型E；所述有机溶剂选自2-甲基四氢呋喃和甲基叔丁基醚中的一种或两种；所述搅拌在20～30℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定型与所述溶剂的质量体积比优选为(250mg～350mg)∶1mL。
在一实施方案中，所述方法一中，所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的晶型B与所述甲基叔丁基醚的质量体积比优选为100mg∶1mL或300mg∶1mL。
在一实施方案中，所述方法二中，所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的无定型与所述溶剂的质量体积比优选为300mg∶1mL。
本发明提供了一种式I化合物的晶型F，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个或至少六个特征峰：5.728°±0.2°、9.701°±0.2°、16.658°±0.2°、18.038°±0.2°、19.851°±0.2°和22.382°±0.2°；
在一实施方案中，所述式I化合物的晶型F的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.728°±0.2°、9.701°±0.2°和18.038°±0.2°。
在一实施方案中，所述式I化合物的晶型F的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.728°±0.2°、9.701°±0.2°、18.038°±0.2°和22.382°±0.2°。
在一实施方案中，所述式I化合物的晶型F的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.728°±0.2°、9.701°±0.2°、18.038°±0.2°、19.851°±0.2°和22.382°±0.2°。
在一实施方案中，所述式I化合物的晶型F的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.728°±0.2°、9.701°±0.2°、16.658°±0.2°、18.038°±0.2°、19.851°±0.2°和22.382°±0.2°。
在一实施方案中，所述式I化合物的晶型F的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.728°±0.2°、9.701°±0.2°、10.421°±0.2°、11.944°±0.2°、13.616°±0.2°、16.658°±0.2°、17.358°±0.2°、18.038°±0.2°、19.17°±0.2°、19.851°±0.2°、21.116°±0.2°、21.815°±0.2°、22.382°±0.2°、23.066°±0.2°、23.454°±0.2°、24.334°±0.2°、24.622°±0.2°、25.362°±0.2°、26.376°±0.2°和27.038°±0.2°。
在一实施方案中，所述式I化合物的晶型F的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.728°±0.2°、8.026°±0.2°、9.701°±0.2°、10.421°±0.2°、10.946°±0.2°、11.333°±0.2°、11.944°±0.2°、12.546°±0.2°、13.616°±0.2°、14.847°±0.2°、15.761°±0.2°、16.658°±0.2°、17.358°±0.2°、18.038°±0.2°、19.17°±0.2°、19.851°±0.2°、21.116°±0.2°、21.815°±0.2°、22.382°±0.2°、23.066°±0.2°、23.454°±0.2°、24.334°±0.2°、24.622°±0.2°、25.073°±0.2°、25.362°±0.2°、26.376°±0.2°、27.038°±0.2°、27.683°±0.2°、28.279°±0.2°、29.787°±0.2°、30.379°±0.2°、31.242°±0.2°、31.967°±0.2°、32.593°±0.2°、32.844°±0.2°、33.425°±0.2°、35.629°±0.2°、35.996°±0.2°、37.988°±0.2°和38.737°±0.2°。
在一实施方案中，所述式I化合物的晶型F的X射线粉末衍射图谱解析数据基本如表6所示：
表6.式I化合物的晶型F的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物的晶型F的X射线粉末衍射图谱基本如图20所示。
在一实施方案中，所述式I化合物的晶型F的热重分析曲线(TGA)显示在37.55℃±3℃加热至150.41℃±3℃过程中，有0.7264％±0.2％的失重。
在一实施方案中，所述式I化合物的晶型F的热重分析曲线显示在37.55℃加热至150.41℃过程中，有0.7264％的失重。
在一实施方案中，所述式I化合物的晶型F的热重分析曲线基本如图21所示。
在一实施方案中，所述式I化合物的晶型F的差示扫描量热曲线(DSC)具有起始温度为333.46℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型F的差示扫描量热曲线具有起始温度为333.46℃的吸热峰。
在一实施方案中，所述式I化合物的晶型F的差示扫描量热曲线具有峰值温度为336.25℃±3℃吸热峰。
在一实施方案中，所述式I化合物的晶型F的差示扫描量热曲线具有峰值温度为336.25℃的吸热峰。
在一实施方案中，所述式I化合物的晶型F的差示扫描量热曲线具有峰值温度为223.19℃±3℃的放热峰。
在一实施方案中，所述式I化合物的晶型F的差示扫描量热曲线具有峰值温度为223.19℃的放热峰。
在一实施方案中，所述式I化合物的晶型F的差示扫描量热曲线基本如图22所示。
本发明还提供了一种式I化合物的晶型F的制备方法，优选包括以下步骤：式I化合物的晶型B在甲醇和水的体积比为(0.5～1.5)∶1的混合溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型F；所述搅拌在20～30℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型B与所述混合溶剂的质量体积比优选为(50mg～350mg)∶1mL。
在一实施方案中，所述式I化合物的晶型F的制备方法中，所述甲醇和水的体积比优选为1∶1。所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的晶型B与所述甲醇的质量体积比优选为100mg∶1mL或300mg∶1mL。
本发明提供了一种式I化合物的晶型G，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个、至少六个、至少七个或至少八个特征峰：5.279°±0.2°、10.926°±0.2°、11.843°±0.2°、16.187°±0.2°、16.831°±0.2°、20.453°±0.2°、23.55°±0.2°和26.825°±0.2°；
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、20.453°±0.2°和23.55°±0.2°。
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、11.843°±0.2°、20.453°±0.2°和23.55°±0.2°。
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、11.843°±0.2°、16.831°±0.2°、20.453°±0.2°和23.55°±0.2°。
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、11.843°±0.2°、16.187°±0.2°、16.831°±0.2°、20.453°±0.2°和23.55°±0.2°。
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、10.926°±0.2°、11.843°±0.2°、16.187°±0.2°、16.831°±0.2°、20.453°±0.2°和23.55°±0.2°。
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、10.926°±0.2°、11.843°±0.2°、16.187°±0.2°、16.831°±0.2°、20.453°±0.2°、23.55°±0.2°和26.825°±0.2°。
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、6.388°±0.2°、9.02°±0.2°、10.926°±0.2°、11.843°±0.2°、12.68°±0.2°、14.96°±0.2°、15.758°±0.2°、16.187°±0.2°、16.831°±0.2°、17.98°±0.2°、18.352°±0.2°、20.453°±0.2°、20.881°±0.2°、21.194°±0.2°、22.732°±0.2°、23.55°±0.2°、25.208°±0.2°、25.949°±0.2°和26.825°±0.2°。
在一实施方案中，所述-式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、6.388°±0.2°、9.02°±0.2°、10.926°±0.2°、11.843°±0.2°、12.68°±0.2°、13.44°±0.2°、14.162°±0.2°、14.96°±0.2°、15.758°±0.2°、16.187°±0.2°、16.831°±0.2°、17.98°±0.2°、18.352°±0.2°、19.423°±0.2°、 20.453°±0.2°、20.881°±0.2°、21.194°±0.2°、21.755°±0.2°、22.732°±0.2°、23.55°±0.2°、24.217、24.772、25.208°±0.2°、25.949°±0.2°、26.825°±0.2°、28.694°±0.2°、29.143°±0.2°、30.154°±0.2°、30.774°±0.2°、31.537°±0.2°、32.318°±0.2°和33.834°±0.2°。
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、6.388°±0.2°、7.147°±0.2°、9.02°±0.2°、10.926°±0.2°、11.843°±0.2°、12.68°±0.2°、13.44°±0.2°、14.162°±0.2°、14.96°±0.2°、15.758°±0.2°、16.187°±0.2°、16.831°±0.2°、17.98°±0.2°、18.352°±0.2°、19.423°±0.2°、20.453°±0.2°、20.881°±0.2°、21.194°±0.2°、21.755°±0.2°、22.732°±0.2°、23.55°±0.2°、24.217°±0.2°、24.772°±0.2°、25.208°±0.2°、25.949°±0.2°、26.825°±0.2°、27.64°±0.2°、28.694°±0.2°、29.143°±0.2°、30.154°±0.2°、30.774°±0.2°、31.537°±0.2°、32.318°±0.2°、33.834°±0.2°、35.49°±0.2°、36.347°±0.2°、37.793°±0.2°和38.493°±0.2°。
在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱解析数据基本如表7所示：
表7.式I化合物的晶型G的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物的晶型G的X射线粉末衍射图谱基本如图23所示。
在一实施方案中，所述式I化合物的晶型G的热重分析曲线(TGA)显示在36.93℃±3℃加热至150.57℃±3℃过程中，有0.1261％±0.2％的失重。
在一实施方案中，所述式I化合物的晶型G的热重分析曲线显示在36.93℃加热至150.57℃过程中，有0.1261％的失重。
在一实施方案中，所述式I化合物的晶型G的热重分析曲线基本如图24所示。
在一实施方案中，所述式I化合物的晶型G的差示扫描量热曲线(DSC)具有起始温度为334.21℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型G的差示扫描量热曲线具有起始温度为334.21℃的吸热峰。
在一实施方案中，所述式I化合物的晶型G的差示扫描量热曲线基本如图25所示。
本发明还提供了一种式I化合物的晶型G的制备方法，优选下列任一方法：
方法一包括以下步骤：式I化合物的晶型A在甲苯中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型G；所述搅拌优选在20～45℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I 化合物的晶型A与所述甲苯的质量体积比优选为(100mg～250mg)∶1mL；
方法二包括以下步骤：式I化合物的晶型B在甲基叔丁基醚中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型G；所述搅拌在40～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型B与所述甲基叔丁基醚的质量体积比优选为(250mg～350mg)∶1mL；
方法三包括以下步骤：式I化合物的无定型在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型G；所述溶剂为水、庚烷、甲苯或甲醇与水的体积比为(0.5～1.5)∶1的混合溶剂；所述搅拌在优选20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定型与所述溶剂的质量体积比优选为(250mg～350mg)∶1mL；其中，当所述溶剂为庚烷或混合溶剂时，所述搅拌在40～60℃温度下进行。
在一实施方案中，所述方法一中，所述搅拌优选在25℃或40℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的晶型A与所述甲苯的质量体积比优选为150mg∶1mL或200mg∶1mL。
在一实施方案中，所述方法二中，所述搅拌优选在50℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的晶型A与所述甲苯的质量体积比优选为300mg∶1mL。
在一实施方案中，所述方法三中，所述搅拌优选在25℃或50℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的无定型与所述溶剂的质量体积比优选为300mg∶1mL。所述甲醇与水的体积比优选为1∶1。其中，当所述溶剂为庚烷或混合溶剂时，所述搅拌优选在50℃温度下进行。
本发明提供了一种式I化合物N-甲基吡咯烷酮溶剂合物的晶型，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个或至少六个特征峰：11.493°±0.2°、13.56°±0.2°、16.481°±0.2°、19.713°±0.2°、21.586°±0.2°和24.643°±0.2°；
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：16.481°±0.2°、19.713°±0.2°和24.643°±0.2°。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：11.493°±0.2°、16.481°±0.2°、19.713°±0.2°和24.643°±0.2°。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：11.493°±0.2°、13.56°±0.2°、16.481°±0.2°、19.713°±0.2°和24.643°±0.2°。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱在如 下2θ角处具有特征峰：11.493°±0.2°、13.56°±0.2°、16.481°±0.2°、19.713°±0.2°、21.586°±0.2°和24.643°±0.2°。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.642°±0.2°、11.493°±0.2°、11.783°±0.2°、13.56°±0.2°、16.481°±0.2°、17.45°±0.2°、17.807°±0.2°、18.486°±0.2°、18.717°±0.2°、19.013°±0.2°、19.713°±0.2°、20.355°±0.2°、21.233°±0.2°、21.586°±0.2°、22.166°±0.2°、22.752°±0.2°、23.534°±0.2°、24.643°±0.2°、25.014°±0.2°、26.083°±0.2°、26.611°±0.2°、26.976°±0.2°、27.684°±0.2°、28.092°±0.2°、30.179°±0.2°和32.024°±0.2°。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.642°±0.2°、8.957°±0.2°、9.545°±0.2°、10.679°±0.2°、11.493°±0.2°、11.783°±0.2°、13.56°±0.2°、16.481°±0.2°、17.45°±0.2°、17.807°±0.2°、18.486°±0.2°、18.717°±0.2°、19.013°±0.2°、19.713°±0.2°、20.355°±0.2°、21.233°±0.2°、21.586°±0.2°、22.166°±0.2°、22.752°±0.2°、23.534°±0.2°、24.643°±0.2°、25.014°±0.2°、26.083°±0.2°、26.359°±0.2°、26.611°±0.2°、26.976°±0.2°、27.684°±0.2°、28.092°±0.2°、28.482°±0.2°、29.955°±0.2°、30.179°±0.2°、30.702°±0.2°、31.062°±0.2°、31.749°±0.2°、32.024°±0.2°、32.71°±0.2°、33.62°±0.2°、33.877°±0.2°、34.174°±0.2°、35.648°±0.2°、36.8°±0.2°、37.301°±0.2°、38.369°±0.2°和39.036°±0.2°。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱解析数据基本如表8所示：
表8.式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的X射线粉末衍射图谱基本如图26所示。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的热重分析曲线(TGA)显示N-甲基吡咯烷酮在114.32℃±3℃加热至209.84℃±3℃过程中，有15.56％±0.5％的失重。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的热重分析曲线显示N-甲基吡咯烷酮在114.32℃加热至209.84℃过程中，有15.56％的失重。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的热重分析曲线基本如图27所示。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的差示扫描量热曲线(DSC)具有起始温度分别为193.47℃±3℃和335.7℃±3℃的吸热峰。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的差示扫描量热曲线具有起始温度分别为193.47℃和335.7℃的吸热峰。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为198.63℃±3℃和336.81℃±3℃的吸热峰。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为198.63℃和336.81℃的吸热峰。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的差示扫描量热曲线基本如图28所示。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的核磁共振氢谱(1H-NMR)显示有重量百分比为15.3％±0.5％的N-甲基吡咯烷酮。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的核磁共振氢谱显示有重量百分比为15.3％的N-甲基吡咯烷酮，其与式I化合物的摩尔比为1∶0.96。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的核磁共振氢谱如图29所示。
本发明还提供了一种式I化合物N-甲基吡咯烷酮溶剂合物的晶型的制备方法，优选包括以下步骤：式I化合物的无定形在N-甲基吡咯烷酮中搅拌以析出固体，经分离、干燥后得到式I化合物N-甲基吡咯烷酮溶剂合物的晶型；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定形与所述N-甲基吡咯烷酮的质量体积比优选为(200mg～350mg)∶1mL。
在一实施方案中，所述式I化合物N-甲基吡咯烷酮溶剂合物的晶型的制备方法，所述搅拌优选在25℃或50℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的无定形与所述N-甲基吡咯烷酮的质量体积比优选为250mg∶1mL或300mg∶1mL。
本发明提供了一种式I化合物DMF溶剂合物的晶型，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个或至少五个特征峰：5.2°±0.2°、9.503°±0.2°、10.267°±0.2°、17.491°±0.2°和22.283°±0.2°；
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.2°±0.2°、9.503°±0.2°和10.267°±0.2°。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.2°±0.2°、9.503°±0.2°、10.267°±0.2°和22.283°±0.2°。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.2°±0.2°、9.503°±0.2°、10.267°±0.2°、11.008°±0.2°、13.5°±0.2°、13.831°±0.2°、14.32°±0.2°、14.943°±0.2°、15.353°±0.2°、17.491°±0.2°、18.856°±0.2°、19.363°±0.2°、20.75°±0.2°、21.018°±0.2°、21.741°±0.2°、22.03°±0.2°、22.283°±0.2°、23.317°±0.2°和30.874°±0.2°。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.2°±0.2°、9.503°±0.2°、10.267°±0.2°、11.008°±0.2°、13.5°±0.2°、13.831°±0.2°、14.32°±0.2°、14.943°±0.2°、15.353°±0.2°、16.778°±0.2°、16.986°±0.2°、17.491°±0.2°、18.547°±0.2°、18.856°±0.2°、19.363°±0.2°、20.489°±0.2°、20.75°±0.2°、21.018°±0.2°、21.424°±0.2°、21.741°±0.2°、22.03°±0.2°、22.283°±0.2°、22.926°±0.2°、23.317°±0.2°、24.507°±0.2°、24.814°±0.2°、25.068°±0.2°、25.771°±0.2°、26.1°±0.2°、26.33°±0.2°、27.544°±0.2°、27.835°±0.2°、28.532°±0.2°、28.784°±0.2°、29.572°±0.2°、30.194°±0.2°、30.874°±0.2°、31.738°±0.2°、32.49°±0.2°、34.71°±0.2°、34.933°±0.2°、35.709°±0.2°和36.156°±0.2°。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的X射线粉末衍射图谱解析数据基本如表9所示：
表9.式I化合物DMF溶剂合物的晶型的X射线粉末衍射图谱解析数据


在一实施方案中，所述式I化合物DMF溶剂合物的晶型的X射线粉末衍射图谱基本如图30所示。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的热重分析曲线(TGA)显示DMF在38.31℃±3℃加热至196.62℃±3℃过程中，有3.381％±0.5％的失重。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的热重分析曲线显示DMF在38.31℃加热至196.62℃过程中，有3.381％的失重。
在一实施方案中，所述式I化合物DMF苯溶剂合物的热重分析曲线基本如图31所示。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的差示扫描量热曲线(DSC)具有起始温度分别为104.94℃±3℃、252.64℃±3℃和338.18℃±3℃的吸热峰。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的差示扫描量热曲线具有起始温度分别为104.94℃、252.64℃、338.18℃的吸热峰。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为114.52℃±3℃、257℃±3℃和338.98℃±3℃的吸热峰。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为114.52℃、257℃和338.98℃的吸热峰。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的差示扫描量热曲线具有峰值温度为260.94℃±3℃的放热峰。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的差示扫描量热曲线具有峰值温度为260.94℃的放热峰。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的差示扫描量热曲线基本如图32所示。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的核磁共振氢谱(1H-NMR)显示有重量百分比为10.3％±0.5％的甲苯。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的核磁共振氢谱显示有重量百分比为10.3％的DMF，其与式I化合物的摩尔比为1∶0.83。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的核磁共振氢谱如图33所示。
本发明还提供了一种式I化合物DMF溶剂合物的晶型的制备方法，其包括以下步骤：式I化合物的无定形在DMF中搅拌以析出固体，经分离、干燥后得到式I化合物DMF溶剂合物的晶型；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定形与所述 DMF的质量体积比优选为(200mg～350mg)∶1mL。
在一实施方案中，所述式I化合物DMF溶剂合物的晶型的制备方法中，所述搅拌优选在25℃或50℃温度下进行。所述搅拌的时间优选为2天。所述式I化合物的无定形与所述DMF的质量体积比优选为250mg∶1mL或300mg∶1mL。
本发明提供了一种式I化合物的晶型K，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个或至少六个特征峰：6.233°±0.2°、10.598°±0.2°、12.177°±0.2°、14.844°±0.2°、16.48°±0.2°和20.823°±0.2°；
在一实施方案中，所述式I化合物的晶型K的X射线粉末衍射图谱在如下2θ角处具有特征峰：14.844°±0.2°、16.48°±0.2°和20.823°±0.2°。
在一实施方案中，所述式I化合物的晶型K的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.233°±0.2°、14.844°±0.2°、16.48°±0.2°和20.823°±0.2°。
在一实施方案中，所述式I化合物的晶型K的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.233°±0.2°、12.177°±0.2°、14.844°±0.2°、16.48°±0.2°和20.823°±0.2°。
在一实施方案中，所述式I化合物的晶型K的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.233°±0.2°、10.598°±0.2°、12.177°±0.2°、14.844°±0.2°、16.48°±0.2°和20.823°±0.2°。
在一实施方案中，所述式I化合物的晶型K的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.275°±0.2°、6.233°±0.2°、8.473°±0.2°、9.485°±0.2°、10.305°±0.2°、10.907°±0.2°、11.804°±0.2°、12.117±0.2°、12.601°±0.2°、13.477°±0.2°、14.844°±0.2°、16.48°±0.2°、16.831°±0.2°、18.038°±0.2°、18.681°±0.2°、20.062°±0.2°、20.083°±0.2°、21.548°±0.2°、22.461°±0.2°、23.298°±0.2°、23.766°±0.2°、25.244°±0.2°、25.791°±0.2°、26.886°±0.2°、27.665°±0.2°、28.012°±0.2°、29.513°±0.2°、31.789°±0.2°、33.973°±0.2°和35.645°±0.2°。
在一实施方案中，所述式I化合物的晶型K的X射线粉末衍射图谱解析数据基本如表10所示：
表10.式I化合物的晶型K的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物的晶型K的X射线粉末衍射图谱基本如图34所示。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线(DSC)具有起始温度为333.08℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线具有起始温度为333.08℃的吸热峰。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线具有终止温度为339.22℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线具有终止温度为339.22℃的吸热峰。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线具有峰值温度为335.88℃±3℃的吸热峰。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线具有峰值温度为335.88℃的吸热峰。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线具有峰值温度为303.12℃±3℃的放热峰。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线具有峰值温度为303.12℃的放热峰。
在一实施方案中，所述式I化合物的晶型K的差示扫描量热曲线基本如图35所示。
本发明还提供了一种式I化合物的晶型K的制备方法，优选包括以下步骤：式I化合物的晶型B在250-300℃温度下保持1～5min，即得式I化合物的晶型K。
在一实施方案中，所述式I化合物的晶型K的制备方法中，所述式I化合物的晶型B优选在280℃温度下保持2min。
本发明提供了一种式I化合物盐酸盐晶型A，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个、至少六个、至少七个、至少八个特征峰：5.527°±0.2°、11.026°±0.2°、11.805°±0.2°、16.39°±0.2°、17.572°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°；
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、16.39°±0.2°和23.853°±0.2°。
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、16.39°±0.2°、23.853°±0.2°和24.398°±0.2°。
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、16.39°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°。
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、11.805°±0.2°、16.39°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°。
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、11.026°±0.2°、11.805°±0.2°、16.39°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°。
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、11.026°±0.2°、11.805°±0.2°、16.39°±0.2°、17.572°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°。
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、11.026°±0.2°、11.805°±0.2°、12.655°±0.2°、13.027°±0.2°、16.39°±0.2°、17.572°±0.2°、20.57°±0.2°、21.819°±0.2°、22.358°±0.2°、22.685°±0.2°、23.853°±0.2°、24.398°±0.2°、27.037°±0.2°、27.683°±0.2°和28.304°±0.2°。
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、5.911°±0.2°、8.228°±0.2°、11.026°±0.2°、11.805°±0.2°、12.655°±0.2°、13.027°±0.2°、16.39°±0.2°、17.572°±0.2°、18.876°±0.2°、20.57°±0.2°、21.819°±0.2°、22.358°±0.2°、22.685°±0.2°、23.284°±0.2°、23.853°±0.2°、24.398°±0.2°、27.037°±0.2°、27.683°±0.2°、28.304°±0.2°、29.471°±0.2°、30.051°±0.2°、33.574°±0.2°、36.726°±0.2°和38.297°±0.2°。
在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱解析数据基本如表11所示：
表11.式I化合物盐酸盐晶型A的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱基本如图36所示。
在一实施方案中，所述式I化合物盐酸盐晶型A的热重分析曲线(TGA)显示在25.19℃±3℃加热至108.66℃±3℃过程中，有1.033％±0.5％的失重；在108.66℃±3℃加热至209.57℃±3℃过程中，有6.683％±0.5％的失重。
在一实施方案中，所述式I化合物盐酸盐晶型A的热重分析曲线显示在25.19℃加热至108.66℃过程中，有1.033％的失重；在108.66℃加热至209.57℃过程中，有6.683％的失重。
在一实施方案中，所述式I化合物盐酸盐晶型A的热重分析曲线基本如图37所示。
在一实施方案中，所述式I化合物盐酸盐晶型A的差示扫描量热曲线(DSC)具有起始温度分别为55.55℃±3℃和190.92℃±3℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐晶型A的差示扫描量热曲线具有起始温度分别为55.55℃和190.92℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐晶型A的差示扫描量热曲线具有峰值温度分别为97.51℃±3℃和208.18℃±3℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐晶型A的差示扫描量热曲线具有峰值温度分别为97.51℃和208.18℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐晶型A的差示扫描量热曲线基本如图38所示。
在一实施方案中，所述式I化合物盐酸盐晶型A的动态蒸汽吸附曲线(DVS)显示在25℃和80％RH下吸湿增重为0.31％±0.2％。
在一实施方案中，所述式I化合物盐酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸 湿增重为0.31％。
在一实施方案中，所述式I化合物盐酸盐晶型A的动态蒸汽吸附曲线如图39所示。
本发明还提供了一种式I化合物盐酸盐晶型A的制备方法，优选包括以下步骤：式I化合物、盐酸和四氢呋喃混合搅拌以析出固体，经分离、干燥后得到式I化合物盐酸盐晶型A；所述搅拌在20～45℃温度下进行；所述搅拌的时间优选为0.2～0.8小时；所述式I化合物与所述盐酸的物质的量之比优选为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比优选为(20mg～30mg)∶1mL。
在一实施方案中，所述式I化合物盐酸盐晶型A的制备方法中，所述式I化合物优选为式I化合物晶型A。所述搅拌优选在25℃或40℃温度下进行。所述搅拌的时间优选为0.5小时。所述式I化合物与所述盐酸的物质的量之比优选为1.1∶1。所述式I化合物与所述四氢呋喃的质量体积比优选为23.85mg∶1mL。
本发明提供了一种式I化合物盐酸盐乙醇溶剂合物的晶型，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个或至少六个特征峰：6.24°±0.2°、14.43°±0.2°、15.744°±0.2°、18.391°±0.2°、24.01°±0.2°和26.261°±0.2°；
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.24°±0.2°、15.744°±0.2°和26.261°±0.2°。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.24°±0.2°、15.744°±0.2°、18.391°±0.2°和26.261°±0.2°。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.24°±0.2°、14.43°±0.2°、15.744°±0.2°、18.391°±0.2°和26.261°±0.2°。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.24°±0.2°、14.43°±0.2°、15.744°±0.2°、18.391°±0.2°、24.01°±0.2°和26.261°±0.2°。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.24°±0.2°、6.673°±0.2°、8.442°±0.2°、13.706°±0.2°、14.43°±0.2°、15.744°±0.2°、15.958°±0.2°、17.924°±0.2°、18.391°±0.2°、18.937°±0.2°、20.84°±0.2°、21.458°±0.2°、24.01°±0.2°、24.708°±0.2°、25.546°±0.2°和26.261°±0.2°。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ 角处具有特征峰：6.24°±0.2°、6.673°±0.2°、7.293°±0.2°、8.442°±0.2°、8.89°±0.2°、10.326°±0.2°、13.706°±0.2°、14.43°±0.2°、15.744°±0.2°、15.958°±0.2°、17.924°±0.2°、18.391°±0.2°、18.937°±0.2°、19.246°±0.2°、20.84°±0.2°、21.458°±0.2°、22.746°±0.2°、24.01°±0.2°、24.708°±0.2°、25.546°±0.2°、26.261°±0.2°、27.08°±0.2°、31.007°±0.2°、31.298°±0.2°、31.917°±0.2°和33.555°±0.2°。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱解析数据基本如表12所示：
表12.式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的X射线粉末衍射图谱基本如图41所示。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的热重分析曲线(TGA)显示在25.07℃±3℃加热至158.66℃±3℃过程中，有3.508％±0.5％的失重；在158.66℃±3℃加热至214.18℃±3℃过程中，有5.094％±0.5％的失重。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的热重分析曲线显示在25.07℃加热至158.66℃过程中，有3.508％的失重；在158.66℃加热至214.18℃过程中，有5.094％的失重。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的热重分析曲线基本如图42所示。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的差示扫描量热曲线(DSC)具有起始温度分别为106℃±3℃和189.22℃±3℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的差示扫描量热曲线具有起始温度分别为106℃和189.22℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为146.54℃±3℃和205.32℃±3℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为146.54℃和205.32℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐乙醇溶剂合物的晶型的差示扫描量热曲线基本如图43所示。
本发明还提供了一种式I化合物盐酸盐乙醇溶剂合物的晶型的制备方法，优选包括以下步骤：式I化合物盐酸盐晶型A在乙醇中搅拌以析出固体，经分离、干燥后得到式I化合物盐酸盐乙醇溶剂合物的晶型；所述搅拌优选在25～45℃温度下进行；所述搅拌的时间优选为2.5～4.5天；所述式I化合物盐酸盐晶型A与所述乙醇的质量体积比哟选为(50mg～200mg)∶1mL。
在一实施方案中，式I化合物盐酸盐乙醇溶剂合物的晶型的制备方法中，所述搅拌优选在30℃或40℃温度下进行。所述搅拌的时间优选为3天或4天。所述式I化合物盐酸盐晶型A与所述乙醇的质量体积比优选为100mg∶1mL或150mg∶1mL。
本发明提供了一种式I化合物盐酸盐异丙醇溶剂合物的晶型，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个或至少五个特征峰：6.301°±0.2°、17.554°±0.2°、19.305°±0.2°、24.378°±0.2°和24.903°±0.2°；
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.301°±0.2°、17.554°±0.2°和24.378°±0.2°。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.301°±0.2°、17.554°±0.2°、19.305°±0.2°和24.378°±0.2°。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.301°±0.2°、17.554°±0.2°、19.305°±0.2°、24.378°±0.2°和24.903°±0.2°。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.301°±0.2°、8.58°±0.2°、12.172°±0.2°、12.717°±0.2°、13.536°±0.2°、16.098°±0.2°、16.837°±0.2°、17.554°±0.2°、17.964°±0.2°、19.305°±0.2°、20.007°±0.2°、20.355°±0.2°、20.513°±0.2°、22.611°±0.2°、23.606°±0.2°、24.378°±0.2°、24.903°±0.2°、26.57°±0.2°、27.293°±0.2°和31.706°±0.2°。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.212°±0.2°、6.301°±0.2°、8.58°±0.2°、12.172°±0.2°、12.717°±0.2°、13.536°±0.2°、15.423°±0.2°、16.098°±0.2°、16.837°±0.2°、17.554°±0.2°、17.964°±0.2°、18.737°±0.2°、19.057°±0.2°、19.305°±0.2°、20.007°±0.2°、20.355°±0.2°、20.513°±0.2°、22.437°±0.2°、22.611°±0.2°、23.191°±0.2°、23.606°±0.2°、24.378°±0.2°、24.903°±0.2°、26.323°±0.2°、26.57°±0.2°、27.293°±0.2°、27.665°±0.2°、28.499°±0.2°、29.16°±0.2°、29.739°±0.2°、30.889°±0.2°、31.706°±0.2°、32.957°±0.2°、33.603°±0.2°、34.927°±0.2°、37.052°±0.2°、37.901°±0.2°和38.625°±0.2°。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的X射线粉末衍射图谱解析数据基本如表13所示：
表13.式I化合物盐酸盐异丙醇溶剂合物的晶型的X射线粉末衍射图谱解析数据


在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的X射线粉末衍射图谱基本如图44所示。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的热重分析曲线(TGA)显示在28.2℃±3℃加热至205.15℃±3℃过程中，有14.79％±0.5％的失重。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的热重分析曲线显示在28.2℃加热至205.15℃过程中，有14.79％的失重。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的热重分析曲线基本如图45所示。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的差示扫描量热曲线(DSC)具有起始温度为191.17℃±3℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的差示扫描量热曲线具有起始温度为191.17℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的差示扫描量热曲线具有峰值温度为200.9℃±3℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的差示扫描量热曲线具有峰值温度为200.9℃的吸热峰。
在一实施方案中，所述式I化合物盐酸盐异丙醇溶剂合物的晶型的差示扫描量热曲线基本如图46所示。
本发明还提供了一种式I化合物盐酸盐异丙醇溶剂合物的晶型的制备方法，优选包括以下步骤：式I化合物盐酸盐晶型A在异丙醇中搅拌以析出固体，经分离、干燥后得到式I化合物盐酸盐异丙醇溶剂合物的晶型；所述搅拌优选在25～45℃温度下进行；所述搅拌的时间优选为2.5～4.5天；所述式I化合物盐酸盐晶型A与所述异丙醇的质量体积比优选为(100mg～200mg)∶1mL。
在一实施方案中，式I化合物盐酸盐异丙醇溶剂合物的晶型的制备方法中，所述搅拌优选在30℃或40℃温度下进行。所述搅拌的时间优选为3天或4天。所述式I化合物盐酸盐晶型A与所述乙醇的质量体积比优选为133.33mg∶1mL或150mg∶1mL。
本发明提供了一种式I化合物硫酸盐晶型A，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个特征峰：7.645°±0.2°、15.146°±0.2°和17.17°±0.2°；
在一实施方案中，所述式I化合物硫酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.468°±0.2°、7.645°±0.2°、15.146°±0.2°、17.17°±0.2°、19.25°±0.2°、19.813°±0.2°和24.106°±0.2°。
在一实施方案中，所述式I化合物硫酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.119°±0.2°、5.468°±0.2°、7.645°±0.2°、8.424°±0.2°、11.303°±0.2°、15.146°±0.2°、16.289°±0.2°、16.701°±0.2°、17.17°±0.2°、18.176°±0.2°、19.25°±0.2°、19.813°±0.2°、20.826°±0.2°、21.138°±0.2°、21.522°±0.2°、22.476°±0.2°、23.152°±0.2°、24.106°±0.2°、24.456°±0.2°、25.351°±0.2°、26.613°±0.2°、27.41°±0.2°、27.816°±0.2°、28.324°±0.2°和29.084°±0.2°。
在一实施方案中，所述式I化合物硫酸盐晶型A的X射线粉末衍射图谱解析数据基本如表14所示：
表14.式I化合物硫酸盐晶型A的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物硫酸盐晶型A的X射线粉末衍射图谱基本如图47所示。
在一实施方案中，所述式I化合物硫酸盐晶型A的热重分析曲线(TGA)显示在32.19℃±3℃加热至159.29℃±3℃过程中，有0.2336％±0.2％的失重；在159.29℃±3℃加热至252.51℃±3℃过程中，有4.029％±0.5％的失重。
在一实施方案中，所述式I化合物硫酸盐晶型A的热重分析曲线显示在32.19℃加热至159.29℃过程中，有0.2336％的失重；在159.29℃加热至252.51℃过程中，有4.029％的失重。
在一实施方案中，所述式I化合物硫酸盐晶型A的热重分析曲线基本如图48所示。
在一实施方案中，所述式I化合物硫酸盐晶型A的差示扫描量热曲线(DSC)具有起始温度为210.46℃±3℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐晶型A的差示扫描量热曲线具有起始温度为210.46℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐晶型A的差示扫描量热曲线具有峰值温度为224.37℃±3℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐晶型A的差示扫描量热曲线具有峰值温度为224.37℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐晶型A的差示扫描量热曲线基本如图49所示。
在一实施方案中，所述式I化合物硫酸盐晶型A的动态蒸汽吸附曲线(DVS)显示在25℃和80％RH下吸湿增重为1.43％±0.5％。
在一实施方案中，所述式I化合物硫酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为1.43％。
在一实施方案中，所述式I化合物硫酸盐晶型A的动态蒸汽吸附曲线如图50所示。
本发明还提供了一种式I化合物硫酸盐晶型A的制备方法，优选包括以下步骤：式I化合物、硫酸和四氢呋喃混合并搅拌，加入正庚烷以析出固体，经分离、干燥后得到式I化合物硫酸盐晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.2～0.8天；所述式I化合物与所述硫酸的物质的量之比优选为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比优选为(40mg～50mg)∶1mL；所述式I化合物与所述正庚烷的质量体积比为(70mg～90mg)∶1mL。
在一实施方案中，所述式I化合物硫酸盐晶型A的制备方法中，所述式I化合物优选为式I化合物晶型A。所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为0.5天；所述式I化合物与所述硫酸的物质的量之比优选为1.1∶1。所述式I化合物与所述四氢呋喃的质量体积比优选为44.71mg∶1mL。所述式I化合物与所述正庚烷的质量体积比优选为82.33mg∶1mL。
本发明提供了一种式I化合物硫酸盐晶型B，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个或至少四个特征峰：5.896°±0.2°、17.498°±0.2°、20.314°±0.2°和22.806±0.2°；
在一实施方案中，所述式I化合物硫酸盐晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.896°±0.2°、17.498°±0.2°和20.314°±0.2°。
在一实施方案中，所述式I化合物硫酸盐晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.896°±0.2°、17.498°±0.2°、20.314°±0.2°和22.806±0.2°。
在一实施方案中，所述式I化合物硫酸盐晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.896°±0.2°、7.174°±0.2°、16.585°±0.2°、17.498°±0.2°、18.294°±0.2°、20.314°±0.2°和22.806±0.2°。
在一实施方案中，所述式I化合物硫酸盐晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.896°±0.2°、7.174°±0.2°、7.589°±0.2°、11.686°±0.2°、12.54°±0.2°、13.282°±0.2°、14.199°±0.2°、15.517°±0.2°、15.773°±0.2°、16.205°±0.2°、16.585°±0.2°、17.498°±0.2°、18.294°±0.2°、19.283°±0.2°、19.598°±0.2°、20.314°±0.2°、21.271°±0.2°、21.558°±0.2°、22.105°±0.2°、22.806°±0.2°、23.351°±0.2°、24.05°±0.2°、25.135°±0.2°、25.368°±0.2°、25.892°±0.2°、26.475°±0.2°、26.764°±0.2°、27.837°±0.2°、28.069°±0.2°、29.259°±0.2°、29.956°±0.2°、30.399°±0.2°、30.807°±0.2°、31.687°±0.2°、31.874°±0.2°、32.464°±0.2°、33.591°±0.2°、35.259°±0.2°、36.912°±0.2°、37.375°±0.2°和38.703°±0.2°。
在一实施方案中，所述式I化合物硫酸盐晶型B的X射线粉末衍射图谱解析数据基本如表15所示：
表15.式I化合物硫酸盐晶型B的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物硫酸盐晶型B的X射线粉末衍射图谱基本如图52所示。
在一实施方案中，所述式I化合物硫酸盐晶型B的热重分析曲线(TGA)显示在33.57℃±3℃加热至120.18℃±3℃过程中，有2.144％±0.5％的失重；在120.18℃±3℃加热至209.36℃±3℃过程中，有6.564％±0.5％的失重。
在一实施方案中，所述式I化合物硫酸盐晶型B的热重分析曲线显示在33.57℃加热至120.18℃过程中，有2.144％的失重；在120.18℃加热至209.36℃过程中，有6.564％的失重。
在一实施方案中，所述式I化合物硫酸盐晶型B的热重分析曲线基本如图53所示。
在一实施方案中，所述式I化合物硫酸盐晶型B的差示扫描量热曲线(DSC)具有起始温度为168.85℃±3℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐晶型B的差示扫描量热曲线具有起始温度为168.85℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐晶型B的差示扫描量热曲线具有峰值温度为174.37℃±3℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐晶型B的差示扫描量热曲线具有峰值温度为174.37℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐晶型B的差示扫描量热曲线基本如图54所示。
本发明还提供了一种式I化合物硫酸盐晶型B的制备方法，优选包括以下步骤：式I化合物、四氢呋喃和硫酸混合搅拌以析出固体，经分离、干燥后得到式I化合物硫酸盐晶型B；所述搅拌在20～30℃温度下进行；所述搅拌的时间优选为3～5小时；所述式I化合物与所述硫酸的物质的量之比为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比为(30mg～70mg)∶1mL。
在一实施方案中，所述式I化合物硫酸盐晶型B的制备方法中，所述式I化合物优选为式I化合物晶型A。所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为4小时。所述式I化合物与所述 硫酸的物质的量之比为1.2∶1。所述式I化合物与所述四氢呋喃的质量体积比优选为43.14mg∶1mL。
本发明提供了一种式I化合物硫酸盐晶型C，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个特征峰：5.818°±0.2°、6.576°±0.2°和15.904°±0.2°；
在一实施方案中，所述式I化合物硫酸盐晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.818°±0.2°、6.576°±0.2°、15.904°±0.2°、16.292°±0.2°和22.994°±0.2°。
在一实施方案中，所述式I化合物硫酸盐晶型C的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.818°±0.2°、6.576°±0.2°、8.996°±0.2°、9.976°±0.2°、10.578°±0.2°、11.55°±0.2°、15.239°±0.2°、15.904°±0.2°、16.292°±0.2°、16.55°±0.2°、17.599°±0.2°、18.818°±0.2°、20.641°±0.2°、21.538°±0.2°、22.14°±0.2°、22.994°±0.2°、23.815°±0.2°、24.237°±0.2°、24.468°±0.2°、26.105°±0.2°、29.566°±0.2°和30.089°±0.2°。
在一实施方案中，所述式I化合物硫酸盐晶型C的X射线粉末衍射图谱解析数据基本如表16所示：
表16.式I化合物硫酸盐晶型C的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物硫酸盐晶型C的X射线粉末衍射图谱基本如图55所示。
本发明还提供了一种式I化合物硫酸盐晶型C的制备方法，优选包括以下步骤：式I化合物、四氢呋喃和硫酸混合并搅拌，加入正庚烷以析出固体，经分离、干燥后得到式I化合物硫酸盐晶型C；所述搅拌在20～35℃温度下进行；所述搅拌的时间优选为3～5小时；所述式I化合物与所述硫酸的物质的量之比为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比为(40mg～50mg)∶1mL；所述式I化合物与所述正庚烷的质量体积比为(15mg～35mg)∶1mL。
在一实施方案中，所述式I化合物硫酸盐晶型C的制备方法中，所述式I化合物优选为式I化合物晶型A。所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为4小时。所述式I化合物与所述硫酸的物质的量之比优选为1.1∶1。所述式I化合物与所述四氢呋喃的质量体积比优选为45.45mg∶1mL。所述式I化合物与所述正庚烷的质量体积比优选为27.32mg∶1mL。
本发明提供了一种式I化合物硫酸盐甲苯溶剂合物的晶型，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个、至少四个、至少五个、至少六个或至少七个特征峰：5.351°±0.2°、5.819°±0.2°、10.347°±0.2°、19.48°±0.2°、19.792°±0.2°、24.086°±0.2°和24.826°±0.2°；
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.351°±0.2°、5.819°±0.2°和24.086°±0.2°。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.351°±0.2°、5.819°±0.2°、10.347°±0.2°和24.086°±0.2°。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.351°±0.2°、5.819°±0.2°、10.347°±0.2°、19.48°±0.2°和24.086°±0.2°。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.351°±0.2°、5.819°±0.2°、10.347°±0.2°、19.48°±0.2°、19.792°±0.2°和24.086°±0.2°。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.351°±0.2°、5.819°±0.2°、10.347°±0.2°、19.48°±0.2°、19.792°±0.2°、24.086°±0.2°和24.826°±0.2°。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.351°±0.2°、5.819°±0.2°、9.765°±0.2°、10.347°±0.2°、11.744°±0.2°、12.154°±0.2°、12.834°±0.2°、13.962°±0.2°、16.933°±0.2°、17.439°±0.2°、18.407°±0.2°、19.48°±0.2°、19.792°±0.2°、20.941°±0.2°、22.066°±0.2°、22.966°±0.2°、23.38°±0.2°、24.086°±0.2°、24.826°±0.2°、25.154°±0.2°、26.167°±0.2°和28.344°±0.2°。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.351°±0.2°、5.819°±0.2°、7.684°±0.2°、8.615°±0.2°、9.765°±0.2°、10.347°±0.2°、11.744°±0.2°、12.154°±0.2°、12.834°±0.2°、13.962°±0.2°、16.414°±0.2°、16.933°±0.2°、17.439°±0.2°、18.407°±0.2°、19.48°±0.2°、19.792°±0.2°、20.941°±0.2°、22.066°±0.2°、22.966°±0.2°、23.38°±0.2°、24.086°±0.2°、24.826°±0.2°、25.154°±0.2°、26.167°±0.2°、27.172°±0.2°、28.344°±0.2°、29.901°±0.2°和32.168°±0.2°。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱解析数据基本如表17所示：
表17.式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的X射线粉末衍射图谱基本如图56所示。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的热重分析曲线(TGA)显示在34.88℃±3℃加热至109.33℃±3℃过程中，有0.5679％±0.2％的失重；在109.33℃±3℃加热至192.37℃±3℃过程中，有3.645％±0.5％的失重；在192.37℃±3℃加热至222.48℃±3℃过程中，有1.535％±0.5％的失重。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的热重分析曲线显示在34.88℃加热至109.33℃过程中，有0.5679％的失重；在109.33℃加热至192.37℃过程中，有3.645％的失重；在192.37℃加热至222.48℃过程中，有1.535％的失重。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的热重分析曲线基本如图57所示。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的差示扫描量热曲线(DSC)具有起始温度为181.87℃±3℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的差示扫描量热曲线具有起始温度为181.87℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的差示扫描量热曲线具有峰值温度为199.71℃±3℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的差示扫描量热曲线具有峰值温度为199.71℃的吸热峰。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的差示扫描量热曲线基本如图58所示。
本发明还提供了一种式I化合物硫酸盐甲苯溶剂合物的晶型的制备方法，优选包括以下步骤：式I化合物硫酸盐晶型A和甲醇混合并过滤得滤液，加入甲苯以析出固体，经分离、干燥后得到式I化合物硫酸盐甲苯溶剂合物的晶型；所述式I化合物硫酸盐晶型A与所述甲醇的质量体积比优选为(30mg～40mg)∶1mL；所述式I化合物硫酸盐晶型A与所述甲苯的质量体积比优选为(35mg～45mg)∶1mL。
在一实施方案中，所述式I化合物硫酸盐甲苯溶剂合物的晶型的制备方法中，所述过滤优选使用0.22μm尼龙滤膜过滤。所述式I化合物硫酸盐晶型A与所述甲醇的质量体积比优选为35.71mg∶1mL。所述式I化合物硫酸盐晶型A与所述甲苯的质量体积比优选为41.67mg∶1mL。
本发明提供了一种式I化合物对甲苯磺酸盐晶型A，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个特征峰：4.788°±0.2°、5.839°±0.2°和17.48°±0.2°；
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：4.788°±0.2°、5.839°±0.2°、16.624°±0.2°、17.48°±0.2°、18.354°±0.2°、20.295°±0.2°和20.954°±0.2°。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：4.788°±0.2°、5.839°±0.2°、7.235°±0.2°、9.529°±0.2°、10.656°±0.2°、11.646°±0.2°、12.275°±0.2°、12.931°±0.2°、13.878°±0.2°、14.307°±0.2°、14.598°±0.2°、15.309°±0.2°、15.57°±0.2°、16.136°±0.2°、16.624°±0.2°、17.48°±0.2°、18.354°±0.2°、18.649°±0.2°、19.348°±0.2°、19.655°±0.2°、20.295°±0.2°、20.954°±0.2°、21.385°±0.2°、21.771°±0.2°、21.988°±0.2°、22.397°±0.2°、23.019°±0.2°、23.505°±0.2°、23.911°±0.2°、25.758°±0.2°、26.126°±0.2°、26.573°±0.2°、27.78°±0.2°、29.412°±0.2°、29.76°±0.2°、 30.614°±0.2°、30.827°±0.2°、32.215°±0.2°、32.517°±0.2°、33.632°±0.2°、35.063°±0.2°和37.779°±0.2°。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的X射线粉末衍射图谱解析数据基本如表18所示：
表18.式I化合物对甲苯磺酸盐晶型A的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的X射线粉末衍射图谱基本如图59所示。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的热重分析曲线(TGA)显示在30.7℃±3℃加热至130℃±3℃过程中，有0.9963％±0.2％的失重。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的热重分析曲线显示在30.7℃加热至130℃过程中，有0.9963％的失重。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的热重分析曲线基本如图60所示。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的差示扫描量热曲线(DSC)具有起始温度分别为85.28℃±3℃、193.65℃±3℃和223.74℃±3℃的吸热峰。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的差示扫描量热曲线具有起始温度分别为85.28℃、193.65℃和223.74℃的吸热峰。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的差示扫描量热曲线具有峰值温度分别为105.14℃±3℃、204.26℃±3℃和235.34℃±3℃的吸热峰。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的差示扫描量热曲线具有峰值温度分别为105.14℃、204.26℃和235.34℃的吸热峰。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的差示扫描量热曲线基本如图61所示。
本发明还提供了一种式I化合物对甲苯磺酸盐晶型A的制备方法，优选包括以下步骤：式I化合物、四氢呋喃和对甲苯磺酸混合并搅拌，加入正庚烷以析出固体，经分离、干燥后得到式I化合物对甲苯磺酸盐晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.2～0.8小时；所 述式I化合物与所述对甲苯磺酸的物质的量之比优选为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比优选为(40mg～60mg)∶1mL；所述式I化合物与所述正庚烷的质量体积比优选为(70mg～90mg)∶1mL。
在一实施方案中，所述式I化合物对甲苯磺酸盐晶型A的制备方法中，所述式I化合物优选为式I化合物晶型A。所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为0.5小时；所述式I化合物与所述对甲苯磺酸的物质的量之比优选为1.1∶1。所述式I化合物与所述四氢呋喃的质量体积比优选为50.7∶1mL。所述式I化合物与所述正庚烷的质量体积比优选为84.5mg∶1mL。
本发明提供了一种式I化合物苯磺酸盐晶型A，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个或至少四个特征峰：13.477°±0.2°、15.787°±0.2°、17.362°±0.2°和25.371°±0.2°；
在一实施方案中，所述式I化合物苯磺酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：13.477°±0.2°、15.787°±0.2°和17.362°±0.2°。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：13.477°±0.2°、15.787°±0.2°、17.362°±0.2°和25.371°±0.2°。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.519°±0.2°、8.866°±0.2°、13.477°±0.2°、13.842°±0.2°、15.787°±0.2°、17.362°±0.2°、18.971°±0.2°、20.452°±0.2°、20.802°±0.2°、21.48°±0.2°、21.735°±0.2°、22.067°±0.2°、22.668°±0.2°、23.175°±0.2°、25.077°±0.2°、25.371°±0.2°、25.973°±0.2°、26.206°±0.2°和32.971°±0.2°。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：6.519°±0.2°、8.866°±0.2°、10.437°±0.2°、11.044°±0.2°、13.059°±0.2°、13.477°±0.2°、13.842°±0.2°、14.814°±0.2°、15.787°±0.2°、16.036°±0.2°、16.488°±0.2°、17.362°±0.2°、18.971°±0.2°、20.452°±0.2°、20.802°±0.2°、21.246°±0.2°、21.48°±0.2°、21.735°±0.2°、22.067°±0.2°、22.668°±0.2°、23.175°±0.2°、23.717°±0.2°、25.077°±0.2°、25.371°±0.2°、25.973°±0.2°、26.206°±0.2°、26.453°±0.2°、28.4°±0.2°、28.851°±0.2°、30.269°±0.2°、30.538°±0.2°、31.026°±0.2°、31.864°±0.2°、32.359°±0.2°、32.971°±0.2°、33.356°±0.2°、33.652°±0.2°和38.822°±0.2°。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的X射线粉末衍射图谱解析数据基本如表19所示：
表19.式I化合物苯磺酸盐晶型A的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物苯磺酸盐晶型A的X射线粉末衍射图谱基本如图62所示。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的热重分析曲线(TGA)显示在30.43℃±3℃加热至149.29℃±3℃过程中，有0.02869％±0.0005％的失重。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的热重分析曲线显示在30.43℃加热至149.29℃过程中，有0.02869％的失重。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的热重分析曲线基本如图63所示。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的差示扫描量热曲线(DSC)具有起始温度为235.01℃±3℃的吸热峰。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的差示扫描量热曲线具有起始温度为235.01℃的吸热峰。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的差示扫描量热曲线具有峰值温度为245.52℃±3℃的吸热峰。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的差示扫描量热曲线具有峰值温度为245.52℃的吸热峰。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的差示扫描量热曲线基本如图64所示。
本发明还提供了一种式I化合物苯磺酸盐晶型A的制备方法，优选包括以下步骤：式I化合物、四氢呋喃和苯磺酸混合并搅拌，加入正庚烷以析出固体，经分离、干燥后得到式I化合物苯磺酸盐晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.2～0.8小时；所述式I化合物与所述苯磺酸的物质的量之比为优选(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比优选为(40mg～60mg)∶1mL；所述式I化合物与所述正庚烷的质量体积比优选为(55mg～75mg)∶1mL。
在一实施方案中，所述式I化合物苯磺酸盐晶型A的制备方法中，所述式I化合物优选为式I化合物晶型A。所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为0.5小时；所述式I化合物与所述苯磺酸的物质的量之比优选为1.1∶1。所述式I化合物与所述四氢呋喃的质量体积比优选为52.8mg∶1mL。所述式I化合物与所述正庚烷的质量体积比优选为66mg∶1mL。
本发明提供了一种式I化合物甲磺酸盐晶型A，其X射线粉末衍射图谱(XRPD)在如下2θ角处 具有至少三个特征峰：7.548°±0.2°、15.087°±0.2°和15.554°±0.2°；
在一实施方案中，所述式I化合物甲磺酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：7.548°±0.2°、9.084°±0.2°、10.268°±0.2°、12.268°±0.2°、13.505°±0.2°、15.087°±0.2°、15.554°±0.2°、16.917°±0.2°、18.994°±0.2°、19.853°±0.2°、20.515°±0.2°、22.185°±0.2°、22.785°±0.2°、23.075°±0.2°、24.146°±0.2°、25.038°±0.2°、26.533°±0.2°、27.082°±0.2°、28.572°±0.2°、29.68°±0.2°和30.167°±0.2°。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的X射线粉末衍射图谱解析数据基本如表20所示：
表20.式I化合物甲磺酸盐晶型A的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物甲磺酸盐晶型A的X射线粉末衍射图谱基本如图65所示。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的热重分析曲线(TGA)显示在30.96℃±3℃加热至148.39℃±3℃的过程中，有0.03112％±0.0005％的失重。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的热重分析曲线显示在30.96℃加热至148.39℃的过程中，有0.03112％的失重。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的热重分析曲线基本如图66所示。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线(DSC)具有起始温度为250.75℃±3℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线具有起始温度为250.75℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线具有峰值温度为262.7℃±3℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线具有峰值温度为262.7℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线基本如图67所示。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的动态蒸汽吸附曲线(DVS)显示在25℃和80％RH下吸湿增重为0.84％±0.005％。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.84％。
在一实施方案中，所述式I化合物甲磺酸盐晶型A的动态蒸汽吸附曲线如图68所示。
本发明还提供了一种式I化合物甲磺酸盐晶型A的制备方法，优选下列任一方法：
方法一：式I化合物、四氢呋喃和甲磺酸混合搅拌以析出固体，经分离、干燥后得到式I化合物甲磺酸盐晶型A；所述搅拌在20～30℃温度下进行；所述搅拌的时间优选为0.2～0.8小时；所述式I化合物与所述甲磺酸的物质的量之比优选为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比优选为(20mg～30mg)∶1mL；
方法二：式I化合物甲磺酸盐的无定型在有机溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物甲磺酸盐晶型A，所述有机溶剂选自二氯甲烷、甲基异丁基酮、庚烷、丙酮、乙腈、乙酸乙酯、 四氢呋喃和甲苯中的一种或多种；所述搅拌优选在20～60℃下进行；所述搅拌的时间优选为(4～8)天；所述式I化合物的晶型A与有机溶剂的质量体积比优选为(150mg∶1mL～250mg)∶1mL；
在一实施方案中，所述方法一中，所述式I化合物优选为式I化合物晶型A。所述搅拌优选在25℃温度下进行。所述搅拌的时间优选为0.5小时；所述式I化合物与所述甲磺酸的物质的量之比优选为1.1∶1。所述式I化合物与所述四氢呋喃的质量体积比优选为25.05mg∶1mL。
在一实施方案中，所述方法二中，所述搅拌优选在25℃或50℃下进行。所述搅拌的时间优选为6天；所述式I化合物的晶型A与有机溶剂的质量体积比优选为200mg∶1mL。
本发明提供了一种式I化合物甲磺酸盐无定型，其X射线粉末衍射图谱基本如图70所示；
在一实施方案中，所述式I化合物甲磺酸盐无定型的热重分析曲线(TGA)显示在41.74℃±3℃加热至107.12℃±3℃的过程中，有0.8804％±0.005％的失重。
在一实施方案中，所述式I化合物甲磺酸盐无定型的热重分析曲线显示在41.74℃加热至107.12℃的过程中，有0.8804％的失重。
在一实施方案中，所述式I化合物甲磺酸盐无定型的热重分析曲线基本如图71所示。
在一实施方案中，所述式I化合物甲磺酸盐无定型的调制差示扫描量热曲线(mDSC)显示其玻璃化转化温度为139.32℃±3℃。
在一实施方案中，所述式I化合物甲磺酸盐无定型的调制差示扫描量热曲线显示其玻璃化转化温度为139.32℃。
在一实施方案中，所述式I化合物甲磺酸盐无定型的调制差示扫描量热曲线如图72所示。
本发明还提供了一种式I化合物甲磺酸盐无定形的制备方法，其包括以下步骤：式I化合物甲磺酸盐晶型A与二氯甲烷和甲醇的混合溶剂混合，喷雾干燥后真空干燥，即得所述式I化合物甲磺酸盐无定形；所述二氯甲烷和甲醇的体积比优选为(1.5～2.5)∶1；所述喷雾干燥的温度优选为80～100℃；所述真空干燥的温度优选为40～60℃；所述式I化合物甲磺酸盐晶型A与混合溶剂的质量体积比优选为(1.5～2.5)∶1。
某一实施例中，所述式I化合物甲磺酸盐无定形的制备方法中，所述所述二氯甲烷和甲醇的体积比优选为2∶1。所述喷雾干燥的温度优选为90℃；所述真空干燥的温度优选为50℃。所述式I化合物甲磺酸盐晶型A与混合溶剂的质量体积比优选为2∶1。
本发明提供了一种式I化合物甲磺酸盐甲醇溶剂合物的晶型，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有至少三个特征峰：7.467°±0.2°、21.736°±0.2°和23.056°±0.2°；
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：7.467°±0.2°、8.749°±0.2°、10.402°±0.2°、12.311°±0.2°、13.029°±0.2°、14.797°±0.2°、15.301°±0.2°、16.972°±0.2°、17.749°±0.2°、18.506°±0.2°、19.113°±0.2°、19.731°±0.2°、20.376°±0.2°、20.765°±0.2°、21.736°±0.2°、22.341°±0.2°、23.056°±0.2°、24.415°±0.2°、25.173°±0.2°、25.485°±0.2°、25.855°±0.2°、26.711°±0.2°、27.292°±0.2°、28.226°±0.2°、28.516°±0.2°、29.02°±0.2°、29.745°±0.2°、30.886°±0.2°、31.318°±0.2°、32.755°±0.2°、33.111°±0.2°、33.972°±0.2°、34.666°±0.2°、35.143°±0.2°、36.057°±0.2°、37.334°±0.2°和39.149°±0.2°。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的X射线粉末衍射图谱解析数据基本如表21所示：
表21.式I化合物甲磺酸盐甲醇溶剂合物的晶型的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的X射线粉末衍射图谱基本如图73所示。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的热重分析曲线(TGA)显示在34.15℃±3℃加热至201.2℃±3℃的过程中，有3.339％±0.5％的失重。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的热重分析曲线显示在34.15℃加热至201.2℃的过程中，有3.339％的失重。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的热重分析曲线基本如图74所 示。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的差示扫描量热曲线(DSC)具有起始温度分别为162.9℃±3℃和248.02℃±3℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的差示扫描量热曲线具有起始温度分别为162.9℃和248.02℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为176.43℃±3℃和260.81℃±3℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为176.43℃和260.81℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的差示扫描量热曲线基本如图75所示。
本发明还提供了一种式I化合物甲磺酸盐甲醇溶剂合物的晶型的制备方法，优选包括以下步骤：式I化合物甲磺酸盐无定形在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物甲磺酸盐甲醇溶剂合物的晶型；所述溶剂为甲醇或甲醇和有机溶剂的混合溶剂；所述有机溶剂选自四氢呋喃、乙酸乙酯和乙腈中的中的一种或多种；所述搅拌优选在20～60℃下进行；所述搅拌的时间优选为4～8天；所述式I化合物甲磺酸盐无定形与溶剂的质量体积比优选为(150mg∶1mL～250mg)∶1mL；所述甲醇与有机溶剂的体积比优选为(0.5～1.5)∶1。
在一实施方案中，所述式I化合物甲磺酸盐甲醇溶剂合物的晶型的制备方法中，所述搅拌优选在25℃、40℃或50℃下进行。所述搅拌的时间优选为6天。所述式I化合物甲磺酸盐无定形与溶剂的质量体积比优选为200mg∶1mL。所述甲醇与有机溶剂的体积比优选为1∶1。
本发明提供了一种式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型，其X射线粉末衍射图谱(XRPD)在如下2θ角处具有三个或至少四个特征峰：7.1°±0.2°、17.283°±0.2°、20.608°±0.2°和23.6°±0.2°；
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：7.1°±0.2°、20.608°±0.2°和23.6°±0.2°。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：7.1°±0.2°、17.283°±0.2°、20.608°±0.2°和23.6°±0.2°。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：7.1°±0.2°、13.26°±0.2°、13.923°±0.2°、17.283°±0.2°、17.596°±0.2°、18.121°±0.2°、18.547°±0.2°、19.424°±0.2°、20.608°±0.2°、22.628°±0.2°、23.116°±0.2°、23.6°±0.2°、23.913°±0.2°和26.322°±0.2°。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的X射线粉末衍射图谱在如下2θ角处具有特征峰：7.1°±0.2°、11.029°±0.2°、12.504°±0.2°、13.26°±0.2°、13.923°±0.2°、14.389°±0.2°、15.55°±0.2°、17.283°±0.2°、17.596°±0.2°、18.121°±0.2°、18.547°±0.2°、19.424°±0.2°、20.608°±0.2°、21.428°±0.2°、21.718°±0.2°、22.628°±0.2°、23.116°±0.2°、23.6°±0.2°、23.913°±0.2°、24.958°±0.2°、25.384°±0.2°、26.322°±0.2°、26.843°±0.2°、27.274°±0.2°、28.05°±0.2°、28.732°±0.2°、29.064°±0.2°、29.412°±0.2°、30.056°±0.2°、30.85°±0.2°、31.763°±0.2°、32.444°±0.2°、34.933°±0.2°、36.254°±0.2°、36.489°±0.2°和37.421°±0.2°。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的X射线粉末衍射图谱解析数据基本如表22所示：
表22.式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的X射线粉末衍射图谱解析数据

在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的X射线粉末衍射图谱基本如图76所示。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的热重分析曲线(TGA)显示在33.54℃±3℃加热至117.32℃±3℃的过程中，有1.573％±0.5％的失重；在117.32℃±3℃加热至200℃±3℃的过程中，有5.341％±0.5％的失重。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的热重分析曲线显示在33.54℃加热至117.32℃的过程中，有1.573％的失重；在117.32℃加热至200℃的过程中，有5.341％的失重。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的热重分析曲线基本如图77所示。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的差示扫描量热曲线(DSC)具有起始温度分别为115.31℃±3℃、156.68℃±3℃和256.2℃±3℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的差示扫描量热曲线具有起始温度分别为115.31℃、156.68℃和256.2℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的差示扫描量热曲线具 有峰值温度分别为120.45℃±3℃、170.41℃±3℃和261.15℃±3℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的差示扫描量热曲线具有峰值温度分别为120.45℃、170.41℃和261.15℃的吸热峰。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的差示扫描量热曲线基本如图78所示。
本发明还提供了一种式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的制备方法，优选包括以下步骤：式I化合物甲磺酸盐无定形在1，4二氧六环中搅拌以析出固体，经分离、干燥后得到式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型；所述搅拌优选在20～60℃下进行；所述搅拌的时间优选为4～8天；所述式I化合物甲磺酸盐无定形与1，4二氧六环的质量体积比优选为(150mg∶1mL～250mg)∶1mL。
在一实施方案中，所述式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型的制备方法中，所述搅拌优选在25℃、40℃或50℃下进行。所述搅拌的时间优选为6天。所述式I化合物甲磺酸盐无定形与1，4二氧六环的质量体积比优选为200mg∶1mL。
本发明还提供了一种药物组合物，所述药物组合物包括本发明中的大环类化合物或其盐、溶剂合物的结晶形式或无定形形式。
本发明还提供了一种治疗或预防抑制EED提供益处的疾病或病况的方法，其包括给予有需要的受试者本发明的大环类化合物或其盐、溶剂合物的结晶形式或无定型形式。
所述的抑制EED提供益处的疾病或病况优选癌症或增生性疾病。
在一实施方案中，所述癌症优选EED介导的癌症。所述EED介导的癌症为本领域已知的癌症。
具体地，EED介导的癌症可参见WO2021011713A1，其全文通过引用并入本文。
本发明的大环类化合物或其盐、溶剂合物的结晶形式或无定型形式包括但不限于本发明的式I化合物的晶型A、式I化合物的晶型B、式I化合物的晶型C、式I化合物甲苯溶剂合物的晶型、式I化合物的晶型E、式I化合物的晶型F、式I化合物的晶型G、式I化合物N-甲基吡咯烷酮溶剂合物的晶型、式I化合物DMF溶剂合物的晶型、式I化合物的晶型K、式I化合物盐酸盐晶型A、式I化合物盐酸盐乙醇溶剂合物的晶型、式I化合物盐酸盐异丙醇溶剂合物的晶型、式I化合物硫酸盐晶型A、式I化合物硫酸盐晶型B、式I化合物硫酸盐晶型C、式I化合物硫酸盐甲苯溶剂合物的晶型、式I化合物对甲苯磺酸盐晶型A、式I化合物苯磺酸盐晶型A、式I化合物甲磺酸盐晶型A、式I化合物甲磺酸盐无定型、式I化合物甲磺酸盐甲醇溶剂合物的晶型、式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型。
本发明中，所述X射线粉末衍射图谱是在Cu-Kα射线源的条件下检测得到。
本发明中，所述差示扫描量热曲线(DSC)是在升温速率为10℃/min的条件下测得。
本发明中，所述热重分析曲线(TGA)是在升温速率为10℃/min的条件下测得。
本发明中，所述调制差示扫描量热曲线(mDSC)是在升温速率为3℃/min的条件下测得。
本发明中，所述核磁共振氢谱(1H-NMR)是以氘代DMSO作为溶剂测得。
在不违背本领域常识的基础上，上述各优选条件，可任意组合，即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于：本发明的大环类化合物或其盐、溶剂合物的结晶形式或无定形形式具有结晶度高、稳定性好、引湿性低、易形成溶剂合物和较难制备中的一个或多个优点。
附图说明
图1为式I化合物无定型XRPD图谱；
图2为式I化合物无定型TGA图谱；
图3为式I化合物无定型mDSC图谱；
图4为式I化合物晶型A的XRPD图谱；
图5为式I化合物晶型A的TGA图谱；
图6为式I化合物晶型A的DSC图谱；
图7为式I化合物晶型A的DVS图谱；
图8为式I化合物晶型B的XRPD图谱；
图9为式I化合物晶型B的TGA图谱；
图10为式I化合物晶型B的DSC图谱；
图11为式I化合物晶型B的DVS图谱；
图12为式I化合物晶型C的XRPD图谱；
图13为式I化合物甲苯溶剂合物的XRPD图谱；
图14为式I化合物甲苯溶剂合物的TGA图谱；
图15为式I化合物甲苯溶剂合物的DSC图谱；
图16为式I化合物甲苯溶剂合物的1H-NMR图谱；
图17为式I化合物晶型E的XRPD图谱；
图18为式I化合物晶型E的TGA图谱；
图19为式I化合物晶型E的DSC图谱；
图20为式I化合物晶型F的XRPD图谱；
图21为式I化合物晶型F的TGA图谱；
图22为式I化合物晶型F的DSC图谱；
图23为式I化合物晶型G的XRPD图谱；
图24为式I化合物晶型G的TGA图谱；
图25为式I化合物晶型G的DSC图谱；
图26为式I化合物N-甲基吡咯烷酮溶剂合物的XRPD图谱；
图27为式I化合物N-甲基吡咯烷酮溶剂合物的TGA图谱；
图28为式I化合物N-甲基吡咯烷酮溶剂合物的DSC图谱；
图29为式I化合物N-甲基吡咯烷酮溶剂合物的1H-NMR图谱；
图30为式I化合物DMF溶剂合物的XRPD图谱；
图31为式I化合物DMF溶剂合物的TGA图谱；
图32为式I化合物DMF溶剂合物的DSC图谱；
图33为式I化合物DMF溶剂合物的1H-NMR图谱；
图34为式I化合物晶型K的XRPD图谱；
图35为式I化合物晶型K的DSC图谱；
图36为式I化合物盐酸盐晶型A的XPRD图谱；
图37为式I化合物盐酸盐晶型A的TGA图谱；
图38为式I化合物盐酸盐晶型A的DSC图谱；
图39为式I化合物盐酸盐晶型A的DVS图谱；；
图40为式I化合物盐酸盐晶型A样品DVS后的XPRD图谱
图41为式I化合物盐酸盐乙醇溶剂合物的XRPD图谱；
图42为式I化合物盐酸盐乙醇溶剂合物的TGA图谱；
图43为式I化合物盐酸盐乙醇溶剂合物的DSC图谱；
图44为式I化合物盐酸盐异丙醇溶剂合物的XRPD图谱；
图45为式I化合物盐酸盐异丙醇溶剂合物的TGA图谱；
图46为式I化合物盐酸盐异丙醇溶剂合物的DSC图谱；
图47为式I化合物硫酸盐晶型A的XPRD图谱；
图48为式I化合物硫酸盐晶型A的TGA图谱；
图49为式I化合物硫酸盐晶型A的DSC图谱；
图50为式I化合物硫酸盐晶型A的DVS图谱；
图51为式I化合物硫酸盐晶型A样品DVS后的XPRD图谱；
图52为式I化合物硫酸盐晶型B的XRPD图谱；
图53为式I化合物硫酸盐晶型B的TGA图谱；
图54为式I化合物硫酸盐晶型B的DSC图谱；
图55为式I化合物硫酸盐晶型C的XRPD图谱；
图56为式I化合物硫酸盐甲苯溶剂合物的XRPD图谱；
图57为式I化合物硫酸盐甲苯溶剂合物的TGA图谱；；
图58为式I化合物硫酸盐甲苯溶剂合物的DSC图谱；
图59为式I化合物对甲苯磺酸盐晶型A的XRPD图谱；
图60为式I化合物对甲苯磺酸盐晶型A的TGA图谱；
图61为式I化合物对甲苯磺酸盐晶型A的DSC图谱；
图62为式I化合物苯磺酸盐晶型A的XRD图谱；
图63为式I化合物苯磺酸盐晶型A的TGA图谱；
图64为式I化合物苯磺酸盐晶型A的DSC图谱；
图65为式I化合物甲磺酸盐晶型A的XRPD图谱；
图66为式I化合物甲磺酸盐晶型A的TGA图谱；
图67为式I化合物甲磺酸盐晶型A的DSC图谱；
图68为式I化合物甲磺酸盐晶型A的DVS图谱；
图69为式I化合物甲磺酸盐晶型A样品DVS后XRPD图谱；
图70为式I化合物甲磺酸盐无定型的XRPD图谱；
图71为式I化合物甲磺酸盐无定型的TGA图谱；
图72为式I化合物甲磺酸盐无定型的mDSC图谱；
图73为式I化合物甲磺酸盐甲醇溶剂合物的XRPD图谱；
图74为式I化合物甲磺酸盐甲醇溶剂合物的TGA图谱；
图75为式I化合物甲磺酸盐甲醇溶剂合物的DSC图谱；
图76为式I化合物甲磺酸盐1，4二氧六环溶剂合物的XRPD图谱；
图77为式I化合物甲磺酸盐1，4二氧六环溶剂合物的TGA图谱；
图78为式I化合物甲磺酸盐1，4二氧六环溶剂合物的DSC图谱。
具体实施方式
下列实施例中，所述的实验方法为按照常规条件或常规测试条件完成，实施例所用的化合物通过市售或自制的方法获得。其中式I化合物的制备可参照WO2021011713A1所述。
本发明所使用的所有溶剂是市售的，无需进一步纯化即可使用。
如无特殊说明，本发明中，所述88％丙酮为丙酮和水体积比为4∶1的丙酮和水的混合溶剂。
如无特殊说明，本发明中，各实施例均在室温下操作，所述室温一般为20～30℃，优选为25℃。
如无特殊说明，本发明中，所述过夜搅拌的时间一般为12～16小时，优选为14小时。
本发明中选用溶剂英文缩写的中文对照如下：
表38
本发明中，XRPD测试的参数设置如下：
表39
本发明中，DVS测试的参数设置如下：
表40
TGA和DSC图谱分别在TA Q5000/5500热重分析仪和TA Q2000/2500差示扫描量热仪上采集，参数设置如下：
表41.DSC和TGA测试参数
本发明中，mDSC测试的参数设置为：振幅±1℃，调制周期60s，升温速率3℃/min，温度范围：25-350℃。
本发明中，1H-NMR使用Qone-WNMR-I-AS400测试，参数设置为：溶剂氘代DMSO，扫描次数18，温度293.4K，磁场强度400MHz。
本发明中，HPLC(高效液相色谱)测试的参数设置如下：
表42
实施例1：
式I化合物无定型的制备：
5g式I化合物晶型B溶于500mL二氯甲烷/甲醇(2/1v/v)的，800rpm搅拌完全溶解，配置成10mg/mL的溶液，然后进行喷雾干燥，进气温度85℃，出口温度55℃，得到3.7g的粉末，50℃真空干燥4小时得最终产品。
式I化合物无定型的表征：
1)其XRPD表征结果如图1所示；
2)其TGA表征结果如图2所示；
3)其DSC表征结果如图3所示，所述式I化合物无定型玻璃化转化温度为178.67℃。
实施例2：
式I化合物晶型A的制备：
50mg式I化合物无定型样品，加入0.2mL的甲醇或乙腈等溶剂，室温或50℃下混悬搅拌2天后，得到的样品快速离心去除上清液，所得固体在室温下进行真空干燥。
式I化合物晶型A的表征：
1)其XRPD表征结果如图4和表1所示；
2)其TGA表征结果如图5所示；
3)其DSC表征结果如图6所示；
4)其DVS表征结果如图7所示，在80％RH下吸湿增重0.44％，略有引湿性。
实施例3：
式I化合物晶型B的制备：
60mg式I化合物晶型A，加入0.6mL的乙酸乙酯或丙酮等溶剂，室温或50℃下混悬搅拌2天后，得到的样品快速离心去除上清液，所得固体在室温下进行真空干燥。
式I化合物晶型B的表征：
1)其XRPD表征结果如图8和表2所示；
2)其TGA表征结果如图9所示；
3)其DSC表征结果如图10所示；
4)其DVS表征结果如图11所示，在80％RH下吸湿增重0.84％，略有引湿性。
实施例4：
式I化合物晶型C的制备：
100mg式I化合物晶型A，加入3mL的四氢呋喃，室温下混悬搅拌1天后，得到的样品快速离心去除上清液，所得固体直接进行检测，晶型C样品为湿品，未进行TGA-DSC检测。
式I化合物晶型C的表征：其XRPD表征结果如图12和表3所示。
实施例5：
式I化合物甲苯溶剂合物的制备：
60mg式I化合物晶型B，加入0.6mL的甲苯，室温下混悬搅拌2天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物甲苯溶剂合物的表征：
1)其XRPD表征结果如图13和表4所示；
2)其TGA表征结果如图14所示；
3)其DSC表征结果如图15所示；
4)其1H-NMR表征结果如图16所示，显示有3.27％重量的甲苯残留。
实施例6：
式I化合物晶型E的制备：
60mg式I化合物晶型B，加入0.6mL的叔丁基甲醚，室温下混悬搅拌2天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物晶型E的表征：
1)其XRPD表征结果如图17和表5所示；
2)其TGA表征结果如图18所示；
3)其DSC表征结果如图19所示。
实施例7：
式I化合物晶型F的制备：
60mg式I化合物晶型B，加入0.6mL的MeOH/H2O(1∶1，v/v)，室温下混悬搅拌2天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物晶型F的表征：
1)其XRPD表征结果如图20和表6所示；
2)其TGA表征结果如图21所示；
3)其DSC表征结果如图22所示。
实施例8：式I化合物晶型G的制备：
40mg式I化合物晶型A，加入0.2mL的甲苯，室温下混悬搅拌2天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物晶型G的表征：
1)其XRPD表征结果如图23和表7所示；
2)其TGA表征结果如图24所示；
3)其DSC表征结果如图25所示。
实施例9：
式I化合物N-甲基吡咯烷酮溶剂合物的制备：
50mg式I化合物无定型样品，加入0.2mL的NMP，室温下混悬搅拌2天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物N-甲基吡咯烷酮溶剂合物的表征：
1)其XRPD表征结果如图26和表8所示；
2)其TGA表征结果如图27所示，在114℃之前没有失重，在114.32-209.84℃之间失重15.56％，为NMP残留；
3)其DSC表征结果如图28所示；
4)其1H-NMR表征结果如图29所示，显示有溶剂NMP残留，与式I化合物的摩尔比为1∶0.96，重量百分比为15.3％。
实施例10：式I化合物DMF溶剂合物的制备：
50mg式I化合物无定型样品，加入0.2mL的DMF，室温下混悬搅拌2天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物DMF溶剂合物的表征：
1)其XRPD表征结果如图30和表9所示；
2)其TGA表征结果如图31所示，在196.62℃之前失重3.381％，为DMF残留；
3)其DSC表征结果如图32所示；
4)其1H-NMR表征结果如图33所示，显示有溶剂DMF残留，与式I化合物的摩尔比为1∶0.83，重量百分比为10.3％。
实施例11：
式I化合物晶型K的制备：
将10mg式I化合物晶型B放到TGA铂金盘中，升温至280℃，维持2分钟后，冷却至室 温，得到的样品即为晶型K。
式I化合物晶型K的表征：
1)其XRPD表征结果如图34和表10所示；
2)其DSC表征结果如图35所示。
实施例12：
式I化合物盐酸盐晶型A的制备：
称量50.2mg的式I化合物晶型A到4mL玻璃瓶中，加入2mL的四氢呋喃得到混悬溶液，加入1.1当量(105μL，1M的HCl-THF溶液)的盐酸，加入后即得到澄清溶液，室温下搅拌半小时后有固体析出，过夜搅拌后，快速离心，所得固体沉淀在40℃真空下干燥后得到白色固体。
式I化合物盐酸盐晶型A的表征：
1)其XRPD表征结果如图36和表11所示；
2)其TGA表征结果如图37所示，在加热至108.66℃之前有1.03％失重，推测为四氢呋喃溶剂残留。从108℃加热到209.57℃有6.68％失重，推测为盐酸失去(1eq盐酸占比约6.34％)；
3)其DSC表征结果如图38所示；
4)其DVS表征结果如图39所示，在80％RH下吸湿增重0.31％，略有引湿性；
5)吸湿前后晶型未发生变化，其XRPD表征如图40所示。
实施例13：
式I化合物盐酸盐乙醇溶剂合物的制备：
40mg式I化合物盐酸盐晶型A，加入0.4mL的乙醇，30℃下混悬搅拌4天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物盐酸盐乙醇溶剂合物的表征：
1)其XRPD表征结果如图41和表12所示；
2)其TGA表征结果如图42所示；
3)其DSC表征结果如图43所示。
实施例14：
式I化合物盐酸盐异丙醇溶剂合物的制备：
40mg式I化合物盐酸盐晶型A，加入0.3mL的异丙醇，30℃下混悬搅拌4天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物盐酸盐异丙醇溶剂合物的表征：
1)其XRPD表征结果如图44和表13所示；
2)其TGA表征结果如图45所示；
3)其DSC表征结果如图46所示。
实施例15：
式I化合物硫酸盐晶型A的制备：
称量49.4mg的式I化合物晶型A到4mL玻璃瓶中，加入1mL的四氢呋喃得到混悬溶液，加入1.1当量(105μL，1M的H2SO4-THF溶液)的硫酸，加入后即得到澄清溶液，室温下搅拌半小时后加入0.6mL反溶剂正庚烷有固体析出，过夜搅拌后，快速离心，所得固体沉淀在真空下干燥后得到白色固体。
式I化合物硫酸盐晶型A的表征：
1)其XRPD表征结果如图47和表14所示；
2)其TGA表征结果如图48所示；
3)其DSC表征结果如图49所示，显示在210.46℃的吸热峰推测为硫酸盐熔融并伴随降解；
4)其DVS表征结果如图50所示，在25℃和80％RH下吸湿增重1.43％，略有引湿性；
5)吸湿前后晶型未发生变化，其XRPD表征如图51所示。
实施例16：
式I化合物硫酸盐晶型B的制备：
称量1.51g式I化合物晶型A到40mL玻璃瓶中，加入30mL的四氢呋喃得到混悬溶液，加入1.2当量(342.9mg，5mLTHF稀释)的硫酸，加入后即得到澄清溶液，室温下搅拌4小时后析出少量的固体，过夜搅拌后，快速离心，所得固体沉淀在真空下干燥后得到白色固体。
式I化合物硫酸盐晶型B的表征：
1)其XRPD表征结果如图52和表15所示；
2)其TGA表征结果如图53所示；
3)其DSC表征结果如图54所示。
实施例17：
式I化合物硫酸盐晶型C的制备：
称量0.5g式I化合物晶型A到40mL玻璃瓶中，加入10mL的四氢呋喃得到混悬溶液，加入1.2当量(107mg，1mL的THF稀释)的硫酸，加入后即得到澄清溶液，室温下搅拌4小时后析出少量的固体，加入正庚烷过夜搅拌。过滤，用正庚烷洗涤，所得固体沉淀在真空下干燥后得到白色固体。
式I化合物硫酸盐晶型C的表征：其XRPD表征结果如图55和表16所示。
实施例18：
式I化合物硫酸盐甲苯溶剂合物的制备：
250mg式I化合物硫酸盐晶型A，加入7mL的甲醇，室温下超声得到澄清溶液，用0.22μm尼龙滤膜过滤得到溶液，取1mL滤液加入到40mL玻璃瓶中，然后加入6mL甲苯溶剂后，析出沉淀后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物硫酸盐甲苯溶剂合物的表征：
1)其XRPD表征结果如图56和表17所示；
2)其TGA表征结果如图57所示；
3)其DSC表征结果如图58所示。
实施例19：
式I化合物对甲苯磺酸盐晶型A的制备：
称量50.7mg的式I化合物晶型A到4mL玻璃瓶中，加入1mL的四氢呋喃得到混悬溶液，加入1.1当量(23.8mg)的对甲苯磺酸，加入后即得到澄清溶液，室温下搅拌半小时后加入0.6mL反溶剂正庚烷有固体析出，过夜搅拌后，快速离心，所得固体沉淀在真空下干燥后得到的黄色固体。
式I化合物对甲苯磺酸盐晶型A的表征：
1)其XRPD表征结果如图59和表18所示；
2)其TGA表征结果如图60所示；
3)其DSC表征结果如图61所示。
实施例20：
式I化合物苯磺酸盐晶型A的制备：
称量52.8mg的式I化合物晶型A到4mL玻璃瓶中，加入1mL的四氢呋喃得到混悬溶液，加入1.1当量(18.1mg)的苯磺酸，加入后即得到澄清溶液，室温下搅拌半小时后加入0.8mL反溶剂正庚烷有固体析出，过夜搅拌后，快速离心，所得固体沉淀在真空下干燥后，得到的黄色固体。
式I化合物苯磺酸盐晶型A的表征：
1)其XRPD表征结果如图62和表19所示；
2)其TGA表征结果如图63所示；
3)其DSC表征结果如图64所示。
实施例21：
式I化合物甲磺酸盐晶型A的制备：
称量50.1mg的式I化合物晶型A到4mL玻璃瓶中，加入2mL的四氢呋喃得到混悬溶液，加入1.1当量(10.8mg)的甲磺酸，加入后即得到澄清溶液，室温下搅拌半小时后有固体析出，过夜搅拌后，快速离心，所得固体沉淀在真空下干燥后得到淡黄色固体。
式I化合物甲磺酸盐晶型A的制备：
1)其XRPD表征结果如图65和表20所示；
2)其TGA表征结果如图66所示；
3)其DSC表征结果如图67所示，显示在250.75℃出现的吸热峰推测为甲磺酸盐熔融并伴随降解；
4)其DVS表征结果如图68所示，在80％RH下吸湿增重0.84％，略有引湿性；
5)吸湿前后晶型未发生变化，其XRPD表征如图69所示。
实施例22：
式I化合物甲磺酸盐无定型的制备：
将5g式I化合物甲磺酸盐晶型A加入到250mL的DCM/MeOH＝2-1(v/v)溶液中，超声2分钟后，原料全部溶解，得到淡黄色澄清溶液，进行喷雾干燥，进气温度为90℃，得到的固体粉末50℃下真空干燥2小时后，最终得到3.92g的淡黄色粉末。
式I化合物甲磺酸盐无定型的表征：
1)其XRPD表征结果如图70所示；
2)其TGA表征结果如图71所示；
3)其mDSC表征结果如图72所示，式I化合物无定型玻璃化转化温度为139.32℃。
实施例23：
式I化合物甲磺酸盐甲醇溶剂合物的制备：
40mg式I化合物甲磺酸盐无定型样品，加入0.2mL的甲醇，40℃下混悬搅拌6天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物甲磺酸盐甲醇溶剂合物的表征：
1)其XRPD表征结果如图73和表21所示；
2)其TGA表征结果如图74所示；
3)其DSC表征结果如图75所示。
实施例24：
式I化合物甲磺酸盐1，4二氧六环溶剂合物的制备：
40mg式I化合物甲磺酸盐无定型样品，加入0.2mL的1，4二氧六环，40℃下混悬搅拌6天后，得到的样品快速离心去除上清液，所得固体室温下真空干燥后直接进行检测。
式I化合物甲磺酸盐1，4二氧六环溶剂合物的表征：
1)其XRPD表征结果如图76和表22所示；
2)其TGA表征结果如图77所示；
3)其DSC表征结果如图78所示。
实施例25-式I化合物晶型A为起始物料的多晶筛选试验(悬浮液法)
称取30～40mg式I化合物晶型A置于2mL的玻璃瓶中，分别加入200μL的溶剂得到混悬溶液，置于40℃下搅拌2天后，将样品快速离心(6000rpm，5min)，去除上清液后，所得沉淀在真空下干燥(40℃，-0.1MPa)20小时后进行物理表征，其结果参见表23所示。
表23以晶型A为起始物料的多晶型筛选结果

实施例26-式I化合物晶型B为起始物料的多晶型筛选试验(悬浮液法)
称取60mg的式I化合物晶型B置于2mL的玻璃瓶中，分别加入200μL的溶剂得到混悬溶液，置于25℃或50℃下搅拌2天后，快速离心(6000rpm，5min)去除上清液后，所得沉淀在40℃真空下干燥20小时后进行物理表征。
表24以晶型B为起始物料的多晶型筛选结果

实施例27-式I化合物为起始物料的多晶型筛选试验(悬浮液法)
称取50mg式I化合物晶型B置于4mL的玻璃瓶中，分别加入500μL的溶剂(DMF和NMP)后，未得到澄清溶液，继续补加1mL溶剂后仍不溶解，于是分别加入500μL的不良溶剂(丙酮，ACN，MeOH，EtOAc，THF，H2O)，且补加了40mg的样品，改为混悬液法进行实验。所有混悬液样品置于50℃下搅拌，悬浮液样品搅拌2天后，快速离心(6000rpm，5min)去除上清液后，所得固体在40℃真空下干燥20小时后进行物理表征。
DCM做良溶剂，MeOH，EtOH，THF，EA做反溶剂对式I化合物进行多晶筛选，其在DCM，MeOH体系中均溶解，悬浮液样品搅拌2天后，快速离心。去除上清液后，所得沉淀在25℃下真空下干燥20小时后进行物理表征。
表25式I化合物在NMP和DMF混合溶剂的多晶型筛选结果(50℃，悬浮液法)
实施例28：式I化合物无定型为起始物料的多晶型筛选-(悬浮液法)
称取60mg的式I化合物无定型样品置于2mL的玻璃瓶中，分别加入200μL的溶剂得到混悬溶液，置于25℃和50℃下搅拌2天后，快速离心(6000rpm，5min)去除上清液后，所得沉淀在真空下室温干燥20小时后进行物理表征。
表26以无定型样品为起始物料的多晶型筛选结果(悬浮液法)

实施例29-式I化合物盐酸盐的多晶型筛选研究(混悬液法)
称取30mg式I化合物的盐酸盐晶型A置于2mL玻璃瓶中，分别加入200μL的溶剂得到混悬液，置于40℃下搅拌3天后，快速离心(6000rpm，6min)，去除上清液后，所得沉淀在真空下干燥20小时。
表27式I化合物盐酸盐的多晶型筛选结果

实施例30：式I化合物硫酸盐的多晶型筛选研究(混悬液法，40℃)
称取30mg的式I化合物硫酸盐晶型A置于2mL玻璃瓶中，分别加入200μL的溶剂得到混悬液，置于40℃下搅拌3天后，快速离心(6000rpm，6min)，去除上清液后，所得沉淀在真空下干燥20小时。
表28式I化合物硫酸盐的多晶型筛选试验结果
实施例31：式I化合物硫酸盐的多晶型筛选研究(反溶剂法)
称量250mg的式I化合物硫酸盐晶型A到40mL的玻璃瓶中，然后加入7mL的甲醇，超声1min后得到澄清溶液，溶液用0.22μm的滤膜过滤后，平均分到7个8mL的玻璃瓶中，然后加入反溶剂至有沉淀析出，样品在室温下搅拌1天后，快速离心，所得固体沉淀在真空下干燥过夜。
表29式I化合物硫酸盐的多晶型筛选试验结果

实施例32：式I化合物甲磺酸盐的多晶型筛选研究(混悬液法)
称取30mg的甲磺酸盐化合物晶型A置于2mL玻璃瓶中，分别加入200μL的溶剂得到混悬液，置于40℃下搅拌3天后，快速离心(6000rpm，6min)，去除上清液后，所得沉淀在真空下干燥20小时。
表30式I化合物甲磺酸盐的多晶型筛选结果
实施例33：式I化合物甲磺酸盐的多晶型筛选研究(反溶剂法)
称取一定量的式I化合物甲磺酸盐化合物晶型A置于8mL玻璃瓶，加入如下溶剂，配置成一定浓度的澄清溶液，分成6份，每份0.5mL，然后加入反溶剂至有沉淀析出，室温下搅拌过夜后快速离心(6000rpm，6min)，去除上清液后，所得沉淀在真空下干燥20小时。
表31式I化合物甲磺酸盐的多晶型筛选结果

实施例34：式I化合物甲磺酸盐的多晶型筛选研究(气液扩散法)
称取一定量的式I化合物甲磺酸盐化合物晶型A置于8mL玻璃瓶，加入如下溶剂，配置成一定浓度的澄清溶液，分成6份，每份0.5mL在1.5mL的玻璃瓶中，然后放入20mL的玻璃瓶中，瓶内装有2mL反溶剂(如下表)，然后室温下盖紧瓶盖后置于通风橱中静置扩散，若有沉淀析出，则取出小瓶，所得沉淀在真空下干燥20小时。
表32式I化合物甲磺酸盐的多晶型筛选结果

实施例35：式I化合物甲磺酸盐的多晶型筛选研究(缓慢挥发法)
称取一定量的式I化合物甲磺酸盐化合物晶型A置于8mL玻璃瓶，分别加入如下溶剂，配置成一定浓度的澄清溶液，室温下置于通风橱中静置扩散，若有沉淀析出，则取出小瓶，所得沉淀在真空下干燥20小时。
表33式I化合物甲磺酸盐的多晶型筛选结果
实施例36：式I化合物甲磺酸盐无定型筛选研究(混悬液法)
称取40mg的甲磺酸盐无定型样品置于2mL玻璃瓶中，分别加入200μL的溶剂，分别置于50℃与室温下下搅拌6天后，快速离心(6000rpm，6min)，去除上清液后，所得沉淀在真空下干燥20小时。
表34式I化合物甲磺酸盐的无定型筛选结果

实施例37：式I化合物，盐酸盐，甲磺酸盐，硫酸盐稳定性研究
分别称取适量的相应化合物(式I化合物晶型A、式I化合物晶型B、式I化合物盐酸盐晶型A、式I化合物甲磺酸盐晶型A和式I化合物硫酸盐晶型A)到20mL的玻璃瓶中，均匀平摊在瓶底。然后将样品瓶敞口(铝箔纸封口，扎有小孔)置于高温(60℃)、室温高湿(RT/92.5％RH)、RT/75％RH以及40℃/75％RH恒温恒湿箱中放置30天，分别于第5、10、30天取样进行XRPD以及HPLC检测。
XRPD结果显示：式I化合物晶型A、式I化合物晶型B、式I化合物盐酸盐晶型A、式I化合物甲磺酸盐晶型A和式I化合物硫酸盐晶型A在放置30天后晶型均未发生变化，显示有良好的物理稳定性。
HPLC结果(表35，TRS为总杂质含量)显示式I化合物晶型A、式I化合物晶型B和式I化合物盐酸盐晶型A均有良好的化学稳定性。
表35式I化合物稳定性试验含量和有关物质结果

表36式I化合物晶型汇总
表37式I化合物盐型汇总

虽然以上描述了本发明的具体实施方式，但是本领域的技术人员应当理解，这些仅是举例说明，在不背离本发明的原理和实质的前提下，可以对这些实施方式做出多种变更或修改。因此，本发明的保护范围由所附权利要求书限定。

Claims (26)

  1. 一种式I化合物的晶型A，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有至少三个、至少四个、至少五个、至少六个或至少七个特征峰：5.181°±0.2°、6.254°±0.2°、8.708°±0.2°、11.496°±0.2°、11.743°±0.2°、16.538°±0.2°和20.361°±0.2°；
  2. 如权利要求1所述的式I化合物的晶型A，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、16.538°±0.2°和20.361°±0.2°；
    或者，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、11.743°±0.2°、16.538°±0.2°和20.361°±0.2°；
    或者，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、11.743°±0.2°、16.538°±0.2°和20.361°±0.2°；
    或者，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、11.496°±0.2°、11.743°±0.2°和16.538°±0.2°、20.361°±0.2°；
    或者，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、8.708°±0.2°、11.496°±0.2°、11.743°±0.2°、16.538°±0.2°和20.361°±0.2°；
    或者，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、8.708°±0.2°、10.304°±0.2°、11.496°±0.2°、11.743°±0.2°、16.538°±0.2°、18.275°±0.2°、18.58°±0.2°、20.361°±0.2°、21.113°±0.2°、23.495°±0.2°、24.232°±0.2°、26.337°±0.2°和26.767°±0.2°；
    或者，所述式I化合物的晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.181°±0.2°、6.254°±0.2°、7.052°±0.2°、8.708°±0.2°、10.304°±0.2°、10.633°±0.2°、11.496°±0.2°、11.743°±0.2°、12.466°±0.2°、12.849°±0.2°、13.224°±0.2°、14.047°±0.2°、14.784°±0.2°、15.004°±0.2°、15.917°±0.2°、16.538°±0.2°、17.529°±0.2°、17.726°±0.2°、18.275°±0.2°、18.58°±0.2°、19.083°±0.2°、19.291°±0.2°、19.848°±0.2°、20.361°±0.2°、21.113°±0.2°、22.221°±0.2°、22.458°±0.2°、23.066°±0.2°、23.495°±0.2°、23.743°±0.2°、24.232°±0.2°、25.19°±0.2°、25.885°±0.2°、26.337°±0.2°、26.767°±0.2°、27.119°±0.2°、27.832°±0.2°、28.188°±0.2°、29.263°±0.2°和30.363°±0.2°；
    或者，所述式I化合物的晶型A的X射线粉末衍射图谱解析数据如下表所示：

    或者，所述式I化合物的晶型A的X射线粉末衍射图谱基本如图4所示。
  3. 如权利要求1所述的晶型A，其特征在于，所述式I化合物的晶型A的热重分析曲线显示在29.6℃±3℃加热至150.14℃±3℃过程中，有0.1264％±0.05％的失重；例如，所述式I化合物的晶型A的热重分析曲线显示在29.6℃加热至150.14℃过程中，有0.1264％的失重；又例如，所述式I化合物的晶型A的热重分析曲线基本如图5所示；
    和/或，所述式I化合物的晶型A的差示扫描量热曲线具有起始温度分别为327.1℃±3℃和334.5℃±3℃的吸热峰；例如，所述式I化合物的晶型A的差示扫描量热曲线具有起始温度分别为327.1℃和334.5℃的吸热峰；
    和/或，所述式I化合物的晶型A的差示扫描量热曲线具有峰值温度分别为330.45℃±3℃和336.58℃±3℃的吸热峰；例如，所述式I化合物的晶型A的差示扫描量热曲线具有峰值温度分别为330.45℃和336.58℃的吸热峰；又例如，所述式I化合物的晶型A的差示扫描量热曲线基本如图6所示；
    和/或，所述式I化合物的晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.44％±0.05％；例如，所述式I化合物的晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.44％；又例如，所述晶型A的动态蒸汽吸附曲线基本如图7所示。
  4. 一种如权利要求1-3任一项所述式I化合物晶型A的制备方法，其特征在于，其选自下列任一方法：
    方法一包括以下步骤：式I化合物的晶型B在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述溶剂为有机溶剂或有机溶剂和水的混合溶剂；所述有机溶剂选自甲醇、乙醇、二氯甲烷和乙腈中的一种或多种；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；在所述式I化合物的晶型B与所述溶剂的质量体积比优选为(250mg～350mg)∶1mL；当所述溶剂为有机溶剂和水的混合溶剂时，所述有机溶剂和水的体积比优选为(0.5～3.5)∶1；其中，当所述有机溶剂为乙醇时，所述搅拌在40～60℃温度下进行；当所述溶剂为甲醇和水体积比为(2.5～3.5)∶1的混合溶剂时，所述搅拌在20～30℃温度下进行；当所述溶剂为甲醇和水的体积比为(0.5～1.5)∶1 的混合溶剂时，所述搅拌在40～60℃温度下进行；
    方法二包括以下步骤：式I化合物的晶型B在二氯甲烷中搅拌得到混合溶液，加入反溶剂并搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述反溶剂选自乙醇、四氢呋喃和乙酸乙酯中的一种或多种；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型B与所述二氯甲烷的质量体积比优选为(50mg～200mg)∶1mL；所述二氯甲烷与所述反溶剂的体积比优选为(0.5～2.5)∶1；
    方法三包括以下步骤：式I化合物的无定形在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述溶剂为有机溶剂或有机溶剂和水的混合溶剂；所述有机溶剂选自甲醇、乙醇、乙腈、异丙醇和二氯甲烷中的一种或多种；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定型与所述溶剂的质量体积比优选为(200mg～350mg)∶1mL；当所述溶剂为有机溶剂和水的混合溶剂时，所述有机溶剂和水的体积比优选为(0.5～3.5)∶1；其中，当所述溶剂为甲醇和水的混合溶剂时，所述甲醇和水的体积比为(2.5～3.5)∶1；当所述溶剂为乙醇或乙醇和水的体积比为1∶1的混合溶剂时，所述搅拌在40～60℃温度下进行；
    方法四包括以下步骤：式I化合物盐酸盐晶型A在有机溶剂和水的混合溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述有机溶剂选自甲醇和乙醇中的一种或两种；所述搅拌优选在35～45℃温度下进行；所述搅拌的时间优选为2.5～3.5天；所述式I化合物盐酸盐与所述混合溶剂的质量体积比优选为(100mg～200mg)∶1mL；所述有机溶剂和水的体积比优选为(2.5～3.5)∶1；
    方法五包括以下步骤：式I化合物硫酸盐晶型A在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述溶剂为甲醇、有机溶剂和水的混合溶剂或甲醇和二氯甲烷的混合溶剂；所述有机溶剂选自甲醇、乙醇和乙腈中的一种或多种；所述搅拌优选在35～45℃温度下进行；所述搅拌的时间优选为2.5～3.5天；所述式I化合物硫酸盐晶型A与所述溶剂的质量体积比优选为(100mg～200mg)∶1mL；所述有机溶剂和水的体积比优选为(0.5～3.5)∶1；
    方法六包括以下步骤：式I化合物硫酸盐晶型A和甲醇混合，加入庚烷至析出固体并搅拌，经分离、干燥后得到式I化合物的晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.5～1.5天；所述式I化合物硫酸盐晶型A与所述甲醇的质量体积比优选为(30mg～40mg)∶1mL；
    方法七包括以下步骤：式I化合物甲磺酸盐晶型A在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型A；所述溶剂为水或有机溶剂和水的混合溶剂；所述有机溶剂选自甲醇和乙腈中的一种或两种；所述搅拌优选在35～45℃温度下进行；所述搅拌的时间优选为2.5～3.5天；所述式I化合物甲磺酸盐晶型A与所述溶剂的质量体积比优选为(100mg～200mg)∶1mL；
    方法八包括以下步骤：式I化合物甲磺酸盐晶型A和DMF混合，加入乙腈至析出固体并搅拌，经分离、干燥后得到式I化合物的晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为12～16小时；所述式I化合物甲磺酸盐与所述DMF的质量体积比优选为(30mg～70mg)∶1mL；
    方法九包括以下步骤：式I化合物甲磺酸盐晶型A在溶剂中搅拌至澄清，经挥发、干燥后得到式 I化合物的晶型A；所述溶剂为甲醇，或乙醇和乙酸甲酯的混合溶剂；所述有机溶剂选自甲醇和乙腈中的一种或两种；所述挥发、干燥优选在20～30℃温度下进行；所述乙醇和乙酸甲酯的体积比优选为(1.5～2.5)∶1。
  5. 一种式I化合物的晶型B，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有至少三个、至少四个、至少五个、至少六个或至少七个特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°、18.116°±0.2°、19.987°±0.2°、22.225°±0.2°和26.884°±0.2°；
  6. 如权利要求5所述的式I化合物的晶型B，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°和16.575°±0.2°；
    或者，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°和18.116°±0.2°；
    或者，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°、18.116°±0.2°和26.884°±0.2°；
    或者，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°、18.116°±0.2°、19.987°±0.2°和26.884°±0.2°；
    或者，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、14.747°±0.2°、16.575°±0.2°、18.116°±0.2°、19.987°±0.2°、22.225°±0.2°和26.884°±0.2°；
    或者，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、13.263°±0.2°、14.747°±0.2°、16.575°±0.2°、17.259°±0.2°、18.116°±0.2°、19.558°±0.2°、19.987°±0.2°、21.566°±0.2°、22.225°±0.2°、23.456°±0.2°、23.999°±0.2°和26.884°±0.2°；
    或者，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、13.263°±0.2°、13.868°±0.2°、14.299°±0.2°、14.747°±0.2°、15.622°±0.2°、16.575°±0.2°、17.259°±0.2°、18.116°±0.2°、19.558°±0.2°、19.987°±0.2°、21.566°±0.2°、22.225°±0.2°、23.258°±0.2°、23.456°±0.2°、23.999°±0.2°、24.894°±0.2°、26.884°±0.2°、29.551°±0.2°、31.442°±0.2°和31.695°±0.2°；
    或者，所述式I化合物的晶型B的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.884°±0.2°、10.54°±0.2°、11.629°±0.2°、12.427°±0.2°、13.263°±0.2°、13.868°±0.2°、14.299°±0.2°、14.747°±0.2°、15.622°±0.2°、16.575°±0.2°、17.259°±0.2°、18.116°±0.2°、19.558°±0.2°、19.987°±0.2°、21.566°±0.2°、 22.225°±0.2°、23.258°±0.2°、23.456°±0.2°、23.999°±0.2°、24.894°±0.2°、25.501°±0.2°、26.884°±0.2°、27.328°±0.2°、27.7°±0.2°、28.048°±0.2°、28.557°±0.2°、29.551°±0.2°、30.497°±0.2°、30.859°±0.2°、31.442°±0.2°、31.695°±0.2°、32.436°±0.2°、33.328°±0.2°、34.071°±0.2°、34.715°±0.2°、35.553°±0.2°、35.842°±0.2°和36.347°±0.2°；
    或者，所述式I化合物的晶型B的X射线粉末衍射图谱解析数据如下表所示：

    ；或者，所述式I化合物的晶型B的X射线粉末衍射图谱基本如图8所示。
  7. 如权利要求5所述的式I化合物的晶型B，其特征在于，所述式I化合物的晶型B的热重分析曲线显示在28.73℃±3℃加热至149.63℃±3℃过程中，有0.1817％±0.05％的失重；例如，所述式I化合物的晶型B的热重分析曲线显示在28.73℃加热至149.63℃过程中，有0.1817％的失重；又例如，所述式I化合物的晶型B的热重分析曲线基本如图9所示；
    和/或，所述式I化合物的晶型B的差示扫描量热曲线具有起始温度分别为249.1℃±3℃和336.8℃±3℃的吸热峰；例如，所述式I化合物的晶型B的差示扫描量热曲线具有起始温度分别为249.1℃和336.8℃的吸热峰；
    和/或，所述式I化合物的晶型B的差示扫描量热曲线具有峰值温度分别为252.54℃±3℃和337.59℃±3℃的吸热峰；例如，所述式I化合物的晶型B的差示扫描量热曲线具有峰值温度分别为252.54℃和337.59℃的吸热峰；
    和/或，所述式I化合物的晶型B的差示扫描量热曲线具有峰值温度为255.28℃±3℃的放热峰；例如，所述式I化合物的晶型B的差示扫描量热曲线具有峰值温度为255.28℃的放热峰；
    和/或，所述式I化合物的晶型B的差示扫描量热曲线基本如图10所示；
    和/或，所述式I化合物的晶型B的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.84％±0.05％；例如，所述式I化合物的晶型B的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.84％；又例如，所述式I化合物的晶型B的动态蒸汽吸附曲线如图11所示。
  8. 一种如权利要求5-7任一项所述晶型B的制备方法，其特征在于，其选自下列任一方法：
    方法一包括以下步骤：式I化合物的晶型A在有机溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物晶型B，所述有机溶剂选自乙酸乙酯、丙酮、88％丙酮和四氢呋喃中的一种或多种；所述搅拌优选在20～60℃下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型A与有机溶剂的质量体积比优选为(80mg∶1mL～250mg)∶1mL；其中，当所述有机溶剂为四氢呋喃时，所述搅拌在35～45℃温度下进行；
    方法二包括以下步骤：式I化合物的无定形在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型B；所述溶剂为有机溶剂或丙酮和水的体积比为(0.25～0.75)∶1的混合溶剂；所述有机溶剂选自乙醇、乙酸乙酯、丙酮、甲基异丁基酮和甲基叔丁基醚中的一种或多种；所述搅拌优选在20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定型与所述溶剂的质量体积比优选为(250mg～350mg)∶1mL；其中，当所述有机溶剂为乙酸乙酯或甲基叔丁基醚时，所述搅拌在40～60℃温度下进行；当所述有机溶剂为乙醇或甲基异丁基酮时，所述搅拌在20～30℃温度下进行；
    方法三包括以下步骤：式I化合物盐酸盐晶型A或式I化合物硫酸盐晶型A在88％丙酮中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型B；所述搅拌优选在35～45℃温度下进行；所述搅拌的时间优选为2.5～3.5天；所述式I化合物盐酸盐晶型A或式I化合物硫酸盐晶型A与所述88％丙酮的质量体积比优选为(100mg～200mg)∶1mL；
    方法四包括以下步骤：式I化合物硫酸盐晶型A和甲醇混合，加入丙酮至析出固体并搅拌，经分离、干燥后得到式I化合物的晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.5～1.5天；所述式I化合物硫酸盐晶型A与所述甲醇的质量体积比优选为(30mg～40mg)∶1mL；
    方法五包括以下步骤：式I化合物甲磺酸盐晶型A在溶剂中搅拌至澄清，经挥发、干燥后得到式I化合物的晶型A；所述溶剂为乙醇，或甲醇和有机溶剂的混合溶剂；所述有机溶剂选自乙酸甲酯和二氯甲烷中的一种或两种；所述挥发、干燥优选在20～30℃温度下进行；所述乙醇和乙酸甲酯的体积比优选为(1.5～2.5)∶1。
  9. 一种式I化合物的晶型G，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有至少三个、至少四个、至少五个、至少六个、至少七个或至少八个特征峰：5.279°±0.2°、10.926°±0.2°、11.843°±0.2°、16.187°±0.2°、16.831°±0.2°、20.453°±0.2°、23.55°±0.2°和26.825°±0.2°；
  10. 如权利要求9所述的式I化合物的晶型G，其特征在于，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、20.453°±0.2°和23.55°±0.2°；
    或者，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、11.843°±0.2°、20.453°±0.2°和23.55°±0.2°；
    或者，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、 11.843°±0.2°、16.831°±0.2°、20.453°±0.2°和23.55°±0.2°；
    或者，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、11.843°±0.2°、16.187°±0.2°、16.831°±0.2°、20.453°±0.2°和23.55°±0.2°；
    或者，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、10.926°±0.2°、11.843°±0.2°、16.187°±0.2°、16.831°±0.2°、20.453°±0.2°和23.55°±0.2°；
    或者，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、10.926°±0.2°、11.843°±0.2°、16.187°±0.2°、16.831°±0.2°、20.453°±0.2°、23.55°±0.2°和26.825°±0.2°；
    或者，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、6.388°±0.2°、9.02°±0.2°、10.926°±0.2°、11.843°±0.2°、12.68°±0.2°、14.96°±0.2°、15.758°±0.2°、16.187°±0.2°、16.831°±0.2°、17.98°±0.2°、18.352°±0.2°、20.453°±0.2°、20.881°±0.2°、21.194°±0.2°、22.732°±0.2°、23.55°±0.2°、25.208°±0.2°、25.949°±0.2°和26.825°±0.2°；
    或者，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、6.388°±0.2°、9.02°±0.2°、10.926°±0.2°、11.843°±0.2°、12.68°±0.2°、13.44°±0.2°、14.162°±0.2°、14.96°±0.2°、15.758°±0.2°、16.187°±0.2°、16.831°±0.2°、17.98°±0.2°、18.352°±0.2°、19.423°±0.2°、20.453°±0.2°、20.881°±0.2°、21.194°±0.2°、21.755°±0.2°、22.732°±0.2°、23.55°±0.2°、24.217、24.772、25.208°±0.2°、25.949°±0.2°、26.825°±0.2°、28.694°±0.2°、29.143°±0.2°、30.154°±0.2°、30.774°±0.2°、31.537°±0.2°、32.318°±0.2°和33.834°±0.2°；
    或者，所述式I化合物的晶型G的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.279°±0.2°、6.388°±0.2°、7.147°±0.2°、9.02°±0.2°、10.926°±0.2°、11.843°±0.2°、12.68°±0.2°、13.44°±0.2°、14.162°±0.2°、14.96°±0.2°、15.758°±0.2°、16.187°±0.2°、16.831°±0.2°、17.98°±0.2°、18.352°±0.2°、19.423°±0.2°、20.453°±0.2°、20.881°±0.2°、21.194°±0.2°、21.755°±0.2°、22.732°±0.2°、23.55°±0.2°、24.217°±0.2°、24.772°±0.2°、25.208°±0.2°、25.949°±0.2°、26.825°±0.2°、27.64°±0.2°、28.694°±0.2°、29.143°±0.2°、30.154°±0.2°、30.774°±0.2°、31.537°±0.2°、32.318°±0.2°、33.834°±0.2°、35.49°±0.2°、36.347°±0.2°、37.793°±0.2°和38.493°±0.2°；
    或者，所述的式I化合物的晶型G的X射线粉末衍射图谱解析数据如下表所示：

    ；或者，所述晶型G的X射线粉末衍射图谱基本如图23所示。
  11. 如权利要求9所述的式I化合物晶型G，其特征在于，所述式I化合物晶型G的热重分析曲 线显示在36.93℃±3℃加热至150.57℃±3℃过程中，有0.1261％±0.05％的失重；例如，所述式I化合物晶型G的热重分析曲线显示在36.93℃加热至150.57℃过程中，有0.1261％的失重；又例如，所述式I化合物晶型G的热重分析曲线如图24所示；
    和/或，所述式I化合物晶型G的差示扫描量热曲线具有起始温度为334.21℃±3℃的吸热峰；例如，所述式I化合物晶型G的差示扫描量热曲线具有起始温度为334.21℃的吸热峰；又例如，所述式I化合物晶型G的差示扫描量热曲线如图25所示。
  12. 一种如权利要求9-11任一项所述式I化合物晶型G的制备方法，其特征在于，其选自下列任一方法：
    方法一包括以下步骤：式I化合物的晶型A在甲苯中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型G；所述搅拌优选在20～45℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型A与所述甲苯的质量体积比优选为(100mg～250mg)∶1mL；
    方法二包括以下步骤：式I化合物的晶型B在甲基叔丁基醚中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型G；所述搅拌在40～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的晶型B与所述甲基叔丁基醚的质量体积比优选为(250mg～350mg)∶1mL；
    方法三包括以下步骤：式I化合物的无定型在溶剂中搅拌以析出固体，经分离、干燥后得到式I化合物的晶型G；所述溶剂为水、庚烷、甲苯或甲醇与水的体积比为(0.5～1.5)∶1的混合溶剂；所述搅拌在优选20～60℃温度下进行；所述搅拌的时间优选为1.5～2.5天；所述式I化合物的无定型与所述溶剂的质量体积比优选为(250mg～350mg)∶1mL；其中，当所述溶剂为庚烷或混合溶剂时，所述搅拌在40～60℃温度下进行。
  13. 一种式I化合物盐酸盐晶型A，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有至少三个、至少四个、至少五个、至少六个、至少七个、至少八个特征峰：5.527°±0.2°、11.026°±0.2°、11.805°±0.2°、16.39°±0.2°、17.572°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°；
  14. 如权利要求13所述的式I化合物盐酸盐晶型A，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、16.39°±0.2°和23.853°±0.2°；
    或者，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、16.39°±0.2°、23.853°±0.2°和24.398°±0.2°；
    或者，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、16.39°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°；
    或者，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、11.805°±0.2°、16.39°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°；
    或者，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、11.026°±0.2°、11.805°±0.2°、16.39°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°；
    或者，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、11.026°±0.2°、11.805°±0.2°、16.39°±0.2°、17.572°±0.2°、23.853°±0.2°、24.398°±0.2°和27.683°±0.2°；
    或者，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、11.026°±0.2°、11.805°±0.2°、12.655°±0.2°、13.027°±0.2°、16.39°±0.2°、17.572°±0.2°、20.57°±0.2°、21.819°±0.2°、22.358°±0.2°、22.685°±0.2°、23.853°±0.2°、24.398°±0.2°、27.037°±0.2°、27.683°±0.2°和28.304°±0.2°；
    或者，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.527°±0.2°、5.911°±0.2°、8.228°±0.2°、11.026°±0.2°、11.805°±0.2°、12.655°±0.2°、13.027°±0.2°、16.39°±0.2°、17.572°±0.2°、18.876°±0.2°、20.57°±0.2°、21.819°±0.2°、22.358°±0.2°、22.685°±0.2°、23.284°±0.2°、23.853°±0.2°、24.398°±0.2°、27.037°±0.2°、27.683°±0.2°、28.304°±0.2°、29.471°±0.2°、30.051°±0.2°、33.574°±0.2°、36.726°±0.2°和38.297°±0.2°；
    或者，所述式I化合物盐酸盐晶型A的X射线粉末衍射图谱解析数据如下表所示：

    ；或者，所述盐酸盐晶型A的X射线粉末衍射图谱基本如图36所示。
  15. 如权利要求13所述的式I化合物盐酸盐晶型A，其特征在于，所述式I化合物盐酸盐晶型A的热重分析曲线显示在25.19℃±3℃加热至108.66℃±3℃过程中，有1.033％±0.05％的失重，在108.66℃±3℃加热至209.57℃±3℃过程中，有6.683％±0.05％的失重；例如，所述式I化合物盐酸盐晶型A的热重分析曲线显示在25.19℃加热至108.66℃过程中，有1.033％的失重，在108.66℃加热至209.57℃过程中，有6.683％的失重；又例如，所述式I化合物盐酸盐晶型A的热重分析曲线基本如图37所示；
    和/或，所述式I化合物盐酸盐晶型A的差示扫描量热曲线具有起始温度分别为55.55℃±3℃和190.92℃±3℃的吸热峰；例如，所述式I化合物盐酸盐晶型A的差示扫描量热曲线具有起始温度分别为55.55℃和190.92℃的吸热峰；
    和/或，所述式I化合物盐酸盐晶型A的差示扫描量热曲线具有峰值温度分别为97.51℃±3℃和208.18℃±3℃的吸热峰；例如，所述式I化合物盐酸盐晶型A的差示扫描量热曲线具有峰值温度分别为97.51℃和208.18℃的吸热峰；
    和/或，所述式I化合物盐酸盐晶型A的差示扫描量热曲线基本如图38所示；
    和/或，所述式I化合物盐酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.31％±0.005％；例如，所述盐酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.31％；又例如，所述式I化合物盐酸盐晶型A的动态蒸汽吸附曲线基本如图39所示。
  16. 一种如权利要求13-15任一项所述式I化合物盐酸盐晶型A的制备方法，其特征在于，其包括以下步骤：式I化合物、盐酸和四氢呋喃混合搅拌以析出固体，经分离、干燥后得到式I化合物盐酸盐晶型A；所述搅拌在20～45℃温度下进行；所述搅拌的时间优选为0.2～0.8小时；所述式I化合物与所述盐酸的物质的量之比优选为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比优选为(20mg～30mg)∶1mL。
  17. 一种式I化合物甲磺酸盐晶型A，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有 至少三个特征峰：7.548°±0.2°、15.087°±0.2°和15.554°±0.2°；
  18. 如权利要求17所述的式I化合物甲磺酸盐晶型A，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有特征峰：7.548°±0.2°、9.084°±0.2°、10.268°±0.2°、12.268°±0.2°、13.505°±0.2°、15.087°±0.2°、15.554°±0.2°、16.917°±0.2°、18.994°±0.2°、19.853°±0.2°、20.515°±0.2°、22.185°±0.2°、22.785°±0.2°、23.075°±0.2°、24.146°±0.2°、25.038°±0.2°、26.533°±0.2°、27.082°±0.2°、28.572°±0.2°、29.68°±0.2°和30.167°±0.2°；
    或者，所述的式I化合物甲磺酸盐晶型A的X射线粉末衍射图谱解析数据如下表所示；

    ；或者，所述式I化合物甲磺酸盐晶型A的X射线粉末衍射图谱基本如图65所示。
  19. 如权利要求17所述的式I化合物甲磺酸盐晶型A，其特征在于，所述式I化合物甲磺酸盐晶型A的热重分析曲线显示在30.96℃±3℃加热至148.39℃±3℃的过程中，有0.03112％±0.0005％的失重；例如，所述式I化合物甲磺酸盐晶型A的热重分析曲线显示在30.96℃加热至148.39℃的过程中，有0.03112％的失重；又例如，所述式I化合物甲磺酸盐晶型A的热重分析曲线如图66所示；
    和/或，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线具有起始温度为250.75℃±3℃的吸热峰；例如，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线具有起始温度为250.75℃的吸热峰；
    和/或，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线具有峰值温度为262.7℃±3℃的吸热峰；例如，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线具有峰值温度为262.7℃的吸热峰；
    和/或，所述式I化合物甲磺酸盐晶型A的差示扫描量热曲线如图67所示；
    和/或，所述式I化合物甲磺酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.84％±0.005％；例如，所述甲磺酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为0.84％；又例如，所述式I化合物甲磺酸盐晶型A的动态蒸汽吸附曲线如图68所示。
  20. 一种如权利要求17-19任一项所述式I化合物甲磺酸盐晶型A的制备方法，其特征在于，其包括以下步骤：式I化合物、四氢呋喃和对甲苯磺酸混合并搅拌，加入正庚烷以析出固体，经分离、干燥后得到式I化合物对甲苯磺酸盐晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.2～0.8小时；所述式I化合物与所述对甲苯磺酸的物质的量之比优选为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比优选为(40mg～60mg)∶1mL；所述式I化合物与所述正庚烷的质量体积比优选为(70mg～90mg)∶1mL。
  21. 一种式I化合物硫酸盐晶型A，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有至少三个特征峰：7.645°±0.2°、15.146°±0.2°和17.17°±0.2°；
  22. 如权利要求21所述的式I化合物硫酸盐晶型A，其特征在于，其X射线粉末衍射图谱在如下2θ角处具有特征峰：5.468°±0.2°、7.645°±0.2°、15.146°±0.2°、17.17°±0.2°、19.25°±0.2°、19.813°±0.2°和24.106°±0.2°；
    或者，所述式I化合物硫酸盐晶型A的X射线粉末衍射图谱在如下2θ角处具有特征峰：5.119°±0.2°、5.468°±0.2°、7.645°±0.2°、8.424°±0.2°、11.303°±0.2°、15.146°±0.2°、16.289°±0.2°、16.701°±0.2°、17.17°±0.2°、18.176°±0.2°、19.25°±0.2°、19.813°±0.2°、20.826°±0.2°、21.138°±0.2°、21.522°±0.2°、22.476°±0.2°、23.152°±0.2°、24.106°±0.2°、24.456°±0.2°、25.351°±0.2°、26.613°±0.2°、27.41°±0.2°、27.816°±0.2°、28.324°±0.2°和29.084°±0.2°；
    或者，所述的式I化合物硫酸盐晶型A的X射线粉末衍射图谱解析数据如下表所示：

    ；或者，所述式I化合物硫酸盐晶型A的X射线粉末衍射图谱基本如图47所示。
  23. 如权利要求21所述的式I化合物硫酸盐晶型A，其特征在于，所述式I化合物硫酸盐晶型A的热重分析曲线显示在32.19℃±3℃加热至159.29℃±3℃过程中，有0.2336％±0.005％的失重，在159.29℃±3℃加热至252.51℃±3℃过程中，有4.029％±0.005％的失重；例如，所述式I化合物硫酸盐晶型A的热重分析曲线显示在32.19℃加热至159.29℃过程中，有0.2336％的失重，在159.29℃加热至252.51℃过程中，有4.029％的失重；又例如，所述式I化合物硫酸盐晶型A的热重分析曲线如图48所示；
    和/或，所述式I化合物硫酸盐晶型A的差示扫描量热曲线具有起始温度为210.46℃±3℃的吸热峰；例如，所述式I化合物硫酸盐晶型A的差示扫描量热曲线具有起始温度为210.46℃的吸热峰；
    和/或，所述式I化合物硫酸盐晶型A的差示扫描量热曲线具有峰值温度为224.37℃±3℃的吸热峰；例如，所述式I化合物硫酸盐晶型A的差示扫描量热曲线具有峰值温度为224.37℃的吸热峰；
    和/或，所述式I化合物硫酸盐晶型A的差示扫描量热曲线如图49所示；
    和/或，所述式I化合物硫酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为1.43％±0.05％；例如，所述式I化合物硫酸盐晶型A的动态蒸汽吸附曲线显示在25℃和80％RH下吸湿增重为1.43％；例如，所述式I化合物硫酸盐晶型A的动态蒸汽吸附曲线如图50所示。
  24. 一种如权利要求22-23任一项所述硫酸盐晶型A的制备方法，其特征在于，其包括下列步骤：式I化合物、硫酸和四氢呋喃混合并搅拌，加入正庚烷以析出固体，经分离、干燥后得到式I化合物硫酸盐晶型A；所述搅拌优选在20～30℃温度下进行；所述搅拌的时间优选为0.2～0.8天；所述式I化合物与所述硫酸的物质的量之比优选为(1～1.5)∶1；所述式I化合物与所述四氢呋喃的质量体积比优选为(40mg～50mg)∶1mL；所述式I化合物与所述正庚烷的质量体积比为(70mg～90mg)∶1mL。
  25. 一种药物组合物，所述药物组合物包括式I化合物的晶型A、式I化合物的晶型B、式I化合物的晶型C、式I化合物甲苯溶剂合物的晶型、式I化合物的晶型E、式I化合物的晶型F、式I化合物的晶型G、式I化合物N-甲基吡咯烷酮溶剂合物的晶型、式I化合物DMF溶剂合物的晶型、式I 化合物的晶型K、式I化合物盐酸盐晶型A、式I化合物盐酸盐乙醇溶剂合物的晶型、式I化合物盐酸盐异丙醇溶剂合物的晶型、式I化合物硫酸盐晶型A、式I化合物硫酸盐晶型B、式I化合物硫酸盐晶型C、式I化合物硫酸盐甲苯溶剂合物的晶型、式I化合物对甲苯磺酸盐晶型A、式I化合物苯磺酸盐晶型A、式I化合物甲磺酸盐晶型A、式I化合物甲磺酸盐无定型、式I化合物甲磺酸盐甲醇溶剂合物的晶型、式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型。
  26. 一种治疗或预防抑制EED提供益处的疾病或病况的方法，其包括给予有需要的受试者式I化合物的晶型A、式I化合物的晶型B、式I化合物的晶型C、式I化合物甲苯溶剂合物的晶型、式I化合物的晶型E、式I化合物的晶型F、式I化合物的晶型G、式I化合物N-甲基吡咯烷酮溶剂合物的晶型、式I化合物DMF溶剂合物的晶型、式I化合物的晶型K、式I化合物盐酸盐晶型A、式I化合物盐酸盐乙醇溶剂合物的晶型、式I化合物盐酸盐异丙醇溶剂合物的晶型、式I化合物硫酸盐晶型A、式I化合物硫酸盐晶型B、式I化合物硫酸盐晶型C、式I化合物硫酸盐甲苯溶剂合物的晶型、式I化合物对甲苯磺酸盐晶型A、式I化合物苯磺酸盐晶型A、式I化合物甲磺酸盐晶型A、式I化合物甲磺酸盐无定型、式I化合物甲磺酸盐甲醇溶剂合物的晶型、式I化合物甲磺酸盐1，4二氧六环溶剂合物的晶型。
PCT/CN2023/073719 2022-01-30 2023-01-29 一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式 WO2023143576A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022075258 2022-01-30
CNPCT/CN2022/075258 2022-01-30

Publications (1)

Publication Number Publication Date
WO2023143576A1 true WO2023143576A1 (zh) 2023-08-03

Family

ID=87407011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/073719 WO2023143576A1 (zh) 2022-01-30 2023-01-29 一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式

Country Status (2)

Country Link
CN (1) CN116514814A (zh)
WO (1) WO2023143576A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790166A (zh) * 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
CN109906224A (zh) * 2016-06-20 2019-06-18 诺华股份有限公司 ***吡啶化合物及其应用
WO2021011713A1 (en) * 2019-07-16 2021-01-21 The Regents Of The University Of Michigan Imidazopyrimidines as eed inhibitors and the use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790166A (zh) * 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
CN109906224A (zh) * 2016-06-20 2019-06-18 诺华股份有限公司 ***吡啶化合物及其应用
WO2021011713A1 (en) * 2019-07-16 2021-01-21 The Regents Of The University Of Michigan Imidazopyrimidines as eed inhibitors and the use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROHAN KALYAN REJ, CHANGWEI WANG, JIANFENG LU, MI WANG, ELYSE PETRUNAK, KAITLIN P. ZAWACKI, DONNA MCEACHERN, ESTER FERNANDEZ-SALAS,: "EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 63, no. 13, 9 July 2020 (2020-07-09), US , pages 7252 - 7267, XP055722737, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c00479 *

Also Published As

Publication number Publication date
CN116514814A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
US20220024967A1 (en) Salts and crystal forms of gaba-a positive allosteric modulator
TW201725200A (zh) 奧拉帕尼之結晶形式及其製備方法
JP5899214B2 (ja) ４−［−２−［［５−メチル−１−（２−ナフタレニル）−１ｈ−ピラゾール−３−イル］オキシ］エチル］モルホリン塩酸塩の固体形態
WO2017193914A1 (zh) 克立硼罗游离形式的晶型及其制备方法和用途
WO2017107972A1 (zh) 一种选择性s1p1受体激动剂的新晶型及其制备方法
WO2023040513A1 (zh) Amg510化合物的晶型及其制备方法和用途
WO2023143576A1 (zh) 一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
WO2022258060A1 (zh) 一种lanifibranor的晶型及其制备方法
WO2016157136A1 (en) Crystalline forms of idelalisib
WO2016110243A1 (zh) 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法
US10544129B2 (en) Crystalline forms of AP26113, and preparation method thereof
WO2017016512A1 (zh) 马赛替尼甲磺酸盐的新晶型及其制备方法
WO2013013594A1 (zh) 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的无定形物及其制备方法
WO2018233591A1 (zh) 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
WO2019019851A1 (zh) 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2021147982A1 (en) Amorphous form or crystalline form of 2-indolinolinololylspironone compounds or their salts, solvent complexes
AU2019388805B2 (en) Solid form, crystalline form, and crystal form A of FXR agonist, and preparation method therefor and application thereof
CN117736176A (zh) 雄激素受体拮抗剂的可药用盐及其多晶型物、制备方法和用途
WO2023231996A1 (zh) 羟肟酸酯化合物及其盐的结晶形式与制备方法
WO2021233296A1 (zh) 大环化合物的固体形式及其制备和用途
US20240140985A1 (en) Salts and crystal forms of gaba-a positive allosteric modulator
WO2019105217A1 (zh) Galunisertib的晶型及其制备方法和用途
TW202408494A (zh) 異噁唑衍生物及其鹽的新晶型以及包括其之醫藥組合物
WO2019086008A1 (zh) 一种苯并三氮唑衍生物的晶型及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23746453

Country of ref document: EP

Kind code of ref document: A1